document incorporate reference portion proxy statement registrant annual meeting stockholder hold incorporate reference iii annual report item business general bristolmyers squibb company refer bristolmyer squibb bms company incorporate law state delaware august bristolmyer company successor new york business start bristolmyer company change bristolmyer squibb company result merger company division subsidiary engage discovery development licensing manufacturing marketing distribution sale pharmaceutical health care relate product acquisition divestiture january company complete sale inventory trademark patent intellectual property right relate dovonex treatment psoriasis united states warner chilcott company inc million cash addition company receive royalty base net sale dovonex end result transaction company expect recognize pretax gain approximately million million net tax quarter subject certain postclosing adjustment company complete sale canadian consumer medicine business relate asset consumer medicine novartis ag novartis term agreement novartis acquire trademark patent intellectual property right canadian consumer medicine business right consumer medicine brand latin america europe middle east africa result operation consumer medicine include company consolidated statement earning date disposal result transaction company record pretax gain million million net tax quarter subject certain postclosing adjustment company complete sale oncology therapeutic network otn equity partner llc cash proceed million include impact work capital adjustment company record pretax gain million million net tax present gain sale discontinue operation consolidated statement earning otn previously present separate segment bristolmyer squibb website company internet website address wwwbmscom company make available free charge website annual quarterly current report include amendment report soon reasonably practicable company electronically file material furnish material united states securities exchange commission sec information relate corporate governance bristolmyer squibb include company standard business conduct ethic code ethic senior financial officer code business conduct ethic director collectively code corporate governance guideline information concern company executive committee board director include board committee committee charter transaction bristolmyers squibb security director executive officer available company website wwwbmscom investorscorporate governance caption print stockholder request waiver code director executive officer material amendment code business conduct ethic director code ethic senior financial officer post promptly company website information relate stockholder service include company dividend reinvestment plan direct deposit dividend available company website wwwbmscom investorsstockholder service caption company incorporate reference certain information part proxy statement annual meeting stockholder sec allow company disclose important information refer manner refer information company proxy statement annual meeting stockholder annual report available company website wwwbmscom investorssec filing caption business segment company reportable segmentspharmaceutical nutritional health care pharmaceutical segment global pharmaceutical international consumer medicine business nutritional segment consist mead johnson nutritionals mead johnson primarily infant formula children nutritional business health care segment consist convatec medical imaging consumer medicine canada businesse additional information segment item financial statementsnote segment information pharmaceutical segment pharmaceutical segment compete worldwide researchbase drug company small research company generic drug manufacturer company near end transition pharmaceutical portfolio away product lose expect lose exclusivity growth driver new product result company focus area significant unmet medical need company experience substantial revenue loss year expiration market exclusivity certain product company estimate reduction net sale range billion billion level product lose lose exclusivity period primarily glucophage xr extend release glucovance united states taxol paclitaxel europe pravachol united states europe cefzil united states revenue reduction exclusivity loss anticipate begin moderate level major new exclusivity loss expect timing amount sale reduction exclusivity loss realization particular period eventual level remain sale revenue uncertain dependent level sale time exclusivity end time degree development generic competition speed approval market entry impact factor anticipate decrease revenue continued exclusivity loss expect offset growth net sale company growth driver potential new product period product include plavix avaproavalide abilify reyataz erbitux baraclude orencia emsam company compound late stage development include dasatinib adult chronic mylogenous leukemia ixabepilone metastatic breast cancer belatacept solid organ transplantation rejection vinflunine cancer ipilimumab cancer saxagliptin diabete expectation continue sale growth subject competitive factor outcome plavix patent litigation discuss risk inherent product development regulatory approval gross margin expect stabilize relatively high margin realize sale growth driver certain new recently launch product offset low margin product lose expect lose exclusivity earning adversely affect company investment support introduction new product development launch additional new compound base management current estimate growth company growth driver new product launch expect realization productivity saving company expect begin enter period sustained growth company expectation future sale growth include substantial expect increase sale plavix net sale billion currently company large product rank net sale composition matter patent plavix expire currently subject litigation united states trial schedule begin june similar proceeding involve plavix ongoing canada patent enforcement proceeding outside canada company continue believe patent valid infringe alliance partner patentholder sanofiaventis sanofi vigorously pursue case possible time reasonably assess outcome litigation adverse determination litigation time potential generic competition plavix apotex inc apotex corporation apotex announce january receive final approval anda clopidogrel bisulfate food drug administration fda accordingly apotex decide launch generic product risk time generic competition likely result substantial decrease sale plavix united states loss market exclusivity plavix subsequent development generic competition material company result operation material financial condition liquidity company subsidiary subject number significant pende lawsuit claim proceeding investigation possible time reasonably assess final outcome investigation litigation management continue believe previously disclose year aggregate impact current reserve legal matter affect company favorably resolve reasonably likely material company result operation cash flow material financial condition liquidity company expectation described reflect potential impact litigation company result operation information matter product competition research development item management discussion analysis financial condition result operationsoutlook item financial statementsnote legal proceeding contingency product company pharmaceutical revenue come product follow therapeutic class cardiovascular virology include human immunodeficiency virus hiv infectious disease oncology affective psychiatric disorder metabolic pharmaceutical industry majority innovative product commercial value usually realize period product market exclusivity market exclusivity base patent right andor certain regulatory form exclusivity country patent right form exclusivity expire generic version medicine approve market substantial rapid decline sale original innovative product company business focus innovative pharmaceutical product company rely patent right form protection maintain market exclusivity product discussion patent right regulatory form exclusivity intellectual property product exclusivity discussion impact generic competition company business generic competition chart show net sale key product pharmaceutical segment year basic exclusivity loss patent right datum exclusivity occur currently estimate occur united states european union eu japan company sell pharmaceutical product country datum provide countrybycountry basis individual country sale significant outside united states eu japan instance basic exclusivity loss date list expiration date patent claim active ingredient drug method drug approve indication instance basic exclusivity loss date list chart expiration date datum exclusivity period situation datum exclusivity patent protection competitor seek regulatory approval submit clinical trial datum obtain marketing approval prior expiration datum exclusivity company estimate market exclusivity period product casebycase basis purpose business planning length market exclusivity company product impossible predict certainty complex interaction patent regulatory form exclusivity inherent uncertainty patent litigation company provide estimate business planning purpose intend indication company patent fare particular patent litigation bring potential infringer assurance particular product enjoy market exclusivity period time appear estimate exclusivity limited estimate past currently past currently past currently estimate estimate estimate year year year basic eu basic japanese basic pharmaceutical product exclusivity loss exclusivity loss exclusivity loss dollar million cardiovascular plavix pravachol avaproavalide coumadin b monopril virology reyataz sustiva zerit videxvidex ec baraclude infectious disease cefzil oncology taxol paclitaxel c erbitux paraplatin affective psychiatric disorder abilify total revenue metabolic glucophage franchise immunology orencia note currently estimate year basic exclusivity loss include statutory extension exclusivity earn speculative instance laterexpire patent cover particular form compositions drug method manufacture method drug patent result favorable market position company product product exclusivity predict assure indicate brand name product register trademark own company subsidiary specific trademark ownership information find company currently market product jurisdiction indicate reference eu include follow current member state austria belgium cyprus czech republic denmark estonia finland france germany greece hungary ireland italy latvia lithuania luxembourg malta netherlands poland portugal slovakia slovenia spain sweden united kingdom instance date basic exclusivity loss different eu member states instance early late date basic exclusivity loss list eu country basic patent obtain datum protection available b eu basic exclusivity expire bms acquire product c year datum exclusivity expire bms patent japan preclude generic entry japan later summary indication intellectual property position license arrangement thirdparty manufacturing arrangement product united states applicable eu japan cardiovascular plavix clopidogrel bisulfate platelet aggregation inhibitor approve protection fatal nonfatal heart attack stroke patient history heart attack stroke peripheral arterial disease acute coronary syndrome clopidogrel bisulfate codevelope jointly market sanofi worldwide alliance operate framework geographic territory americas australia bmss primary territory europe asia sanofis primary territory composition matter patent united states expire include statutory patent term extension patent currently subject litigation company continue believe patent valid infringe alliance partner patentholder sanofi vigorously pursue litigation possible time reasonably assess outcome litigation adverse determination litigation time potential generic competition plavix apotex announce january receive final approval anda clopidogrel bisulfate fda accordingly apotex decide launch generic product risk time generic competition likely result substantial decrease sale plavix united states information litigation item financial statementsnote legal proceeding contingency information potential effect generic competition plavix item management discussion analysis financial condition result operationsoutlook eu regulatory datum exclusivity extend key composition matter patent expire bulk requirement clopidogrel supply territory sanofi produce bulk clopidogrel facility obtain portion bulk clopidogrel requirement party arrangement include royalty payment base product sale territory produce finish product sale information company arrangement sanofi strategic alliance item financial statementsnote alliance investment pravachol pravastatin sodium hmg coa reductase inhibitor indicate adjunct diet exercise patient primary hypercholesterolemia lower risk heart attack people clinically evident coronary heart disease elevate cholesterol reduce risk heart attack stroke patient clinically evident coronary heart disease company license patent cover pravastatin market company pravachol sankyo company ltd sankyo japan agreement expiring exclusivity expire marketbymarket basis company enter distribution agreement watson pharmaceutical watson authorize watson distribute pravastatin sodium tablet exclusivity patent include pediatric extension last april term license company market sell pravastatin world exclude japan korea taiwan thailand market sankyo retain exclusive patent right sankyo copromote comarket pravastatin certain european latin american country composition matter patent schedule expire united states october extend month april law provide exclusivity extension pediatric research eu composition matter patent obtain greece luxembourg portugal expire spain composition matter patent expire austria belgium denmark finland germany ireland netherlands united kingdom france sweden expiration occur august march respectively italy expiration occur january company bulk requirement pravastatin supply sankyo company finish product facility avaproavalide irbesartanirbesartanhydrochlorothiazide angiotensin ii receptor antagonist indicate treatment hypertension diabetic nephropathy irbesartan codevelope jointly market sanofi worldwide alliance operate framework geographic territory americas australia bmss primary territory europe asia sanofis primary territory basic composition matter patent united states expire eu data exclusivity eu expire irbesartan manufacture company sanofi bulk irbesartan sell territory joint venture fix price kilogram intellectual property license arrangement sanofi collect royalty base percentage net sale information company arrangement sanofi strategic alliance item financial statementsnote alliance investment coumadin warfarin sodium oral anticoagulant predominantly patient atrial fibrillation deep venous thrombosispulmonary embolism market exclusivity expire united states basic patent protection regulatory datum protection expire company acquire coumadin company obtain bulk requirement warfarin party produce majority finish good facility monopril fosinopril sodium secondgeneration angiotensin convert enzyme ace inhibitor onceaday dosing indicate treatment hypertension monopril develop internally basic composition matter patent united states expire june basic composition matter patent expire denmark greece portugal spain october composition matter patent obtain finland rest eu composition matter patent expire countrybycountry basis virology reyataz atazanavir sulfate protease inhibitor treatment hiv reyataz launch united states july company develop atazanavir worldwide license novartis ag novartis pay royalty base percentage net sale market exclusivity reyataz expected expire country eu japan sustiva efavirenz antiretroviral drug treatment hiv right market efavirenz united states canada united kingdom france germany ireland italy spain license merck co inc merck royalty base percentage net sale basic composition matter patent expire united states separate method use patent expire basic composition matter patent united kingdom ireland france germany italy spain expire datum exclusivity eu expire company obtain bulk requirement efavirenz party produce finished good facility zerit stavudine treatment hiv company hold exclusive patent license zerit yale university pursuant pay royalty base product sale japan company exclusive license zerit yamasa corporation pursuant pay royalty base net sale japan use patent expire united states december use patent series expire eu patent application pende denmark finland japan december videxvidex ec didanosine antiretroviral drug treatment adult pediatric patient hiv didanosine market company different formulation use oral solution second reduce mass tablet enteric coat capsule formulation videx ec company license government patent series claim method didanosine treat hiv patent series cover approve use aforementioned formulation company license nonexclusive october company obtain license government marketing didanosine government method use patent expire united states includes earn pediatric extension japan europe government grant use patent austria belgium france germany italy luxembourg netherlands sweden united kingdom patent pende ireland expiration use patent eu occur countrybycountry basis method use patent obtain government denmark finland greece portugal spain videx reduce mass formulation company patent cover reduce mass formulation videx united states eu japan expire company attempt develop reduce mass formulation didanosine infringe patent videx ec enteric coat capsule company pende patent application cover videx ec formulation united states eu japan patents issue expiration data exclusivity videx ec expire japanese datum exclusivity videx ec expire march company obtain material necessary bulk manufacture didanosine party produce finished product facility baraclude entecavir potent selective inhibitor hepatitis b virus approve fda march treatment chronic hepatitis b infection approve china markets asiapacific region company composition matter patent expire united states baraclude develop internally infectious disease cefzil cefprozil semisynthetic broadspectrum cephalosporin antibiotic treatment mild moderately severe bacterial infection throat ear sinuse respiratory tract skin cefprozil discover develop internally basic composition matter patent protect cefprozil united states include patent term extension expire december european country include austria finland italy switzerland united kingdom composition matter patent expire include term extension spain patent expire february european countries japan patent expire oncology taxol paclitaxel paclitaxel treatment refractory ovarian cancer firstline treatment ovarian cancer combination cisplatin secondline treatment aid relate kaposis sarcoma treatment metastatic breast cancer failure combination chemotherapy adjuvant treatment node positive breast cancer treatment nonsmall cell lung carcinoma cisplatin paclitaxel develop collaborative research development agreement government agreement company obtain right government taxol paclitaxel data active ingredient taxol paclitaxel patent protection united states eu japan regulatory protection form datum exclusivity datum exclusivity united states expire initial approval generic version grant revoke fda reinstate datum exclusivity eu expire data exclusivity taxol paclitaxel japan expire patent claim approve dose administration schedule expire japan nullity action file japanese patent office invalidate patent company appeal decision numerous factor impossible predict loss market exclusivity japan actually occur company supply bulk requirement paclitaxel party produce finished good facility erbitux erbitux cetuximab igg monoclonal antibody design exclusively target block epidermal growth factor receptor egfr express surface certain cancer cell multiple tumor type normal cell erbitux approve treatment combination irinotecan patient egfrexpresse metastatic colorectal cancer fail irinotecanbase regimen monotherapy patient intolerant irinotecan march fda approve erbitux use treatment squamous cell carcinoma head neck erbitux market north america company distribution copromotion agreement imclone system incorporate imclone company imclone share distribution right erbitux merck kgaa japan description companys alliance imclone strategic alliance item financial statementsnote alliance investment composition matter patent specifically claim erbitux erbitux approve monotherapy use patent use erbitux combination antineoplastic agent approve fda combination use claim grant patent expire information biologic patent intellectual property product exclusivity inventorship use patent challenge scientist weizmann institute claim name coinventor information litigation item financial statementsnote legal proceeding contingency european equivalent use patent oppose company purchase bulk requirement erbitux imclone imclone party produce finished good facility description company supply agreement imclone manufacture quality assurance paraplatin carboplatin chemotherapeutic agent treatment ovarian cancer patent carboplatin expire prior expiration patent company hold exclusive patent license carboplatin research corporation technologies university michigan company right market paraplatin worldwide pay royalty base percentage product sale eu basic patent cover carboplatin obtain france germany netherlands sweden united kingdom patent expire country france japan basic patent expire company enter agreement teva pharmaceuticals usa inc teva allow tevas authorize affiliate sicor pharmaceuticals sales inc distribute unbranded version carboplatin supply bms commencing agreement expire june company obtain bulk requirement carboplatin party produce finish good facility affective psychiatric disorder abilify aripiprazole atypical antipsychotic agent patient schizophrenia acute bipolar mania bipolar disorder abilify introduce united states november approve marketing eu switzerland application pende country aripiprazole copromote united states company otsuka bmss rights commercialize aripiprazole united states terminate otsuka sole right commercialize aripiprazole united states company right distribute andor copromote abilify european country united kingdom france germany italy spain act exclusive distributor product rest eu company exclusive licensee product rest world exclude japan certain country company record alliance revenue contractual share net sale copromotion country exclude united kingdom record expense relate product alliance revenue record company net sale base otsukas net sale copromotion country company recognize alliance revenue abilify ship risk reward ownership transfer otsukas customer uk company record net sale relate cost product sell country company exclusive right sell abilify company record net sale relate cost product sell information company arrangement otsuka strategic alliance item financial statementsnote alliance investment basic composition matter patent abilify expire include grant patent term extension otsuka file united states patent trademark office uspto request reexamination composition matter patent patent number patent cover abilify aripiprazole uspto grant request reexamination otsuka determine original patent application mistakenly identify prior art reference wrong patent number addition otsuka take opportunity bring citation attention uspto reexamination allow uspto consider patentability patent claim light correctly identify patent reference newly cite document uspto expect final decision reexamination company otsuka believe subject matter claim patent patentable prior art expect uspto reconfirm reexamination guarantee outcome patentability patent reconfirm follow reexamination loss market exclusivity abilify soon expect subsequent development generic competition material company composition matter patent austria belgium finland greece ireland luxembourg portugal latvia hungary cyprus czech republic slovenia slovakia poland malta lithuania eu member states composition matter patent expire country supplemental protection certificate grant case composition matter patent expire otsuka supply bulk requirement aripiprazole otsuka company produce finished product facility metabolic glucophage franchise metformin hydrochlorideglyburide metformin hydrochloride oral antidiabetic agent type diabete metformin develop merck sante sas term arrangement company market sell metformin united states company purchase bulk metformin price include royalty base percentage net sale datum exclusivity glucophage ir expire regulatory exclusivity expire glucophage xr glucovance company obtain bulk requirement metformin merck sante sas produce finished product facility immunology orencia abatacept biological product fusion protein novel immunosuppressive activity target initially adult patient moderate severe rheumatoid arthritis inadequate response certain currently available treatment approve fda december commercially available february company series patent cover abatacept method use late composition matter patent expire united states litigation repligen corporation repligen concern inventorship abatacept conclude favor company repligen receive patent claim use abatacept treat specific autoimmune disease include rheumatoid arthritis january bring suit company eastern district texas allege patent infringement information litigation item financial statementsnote legal proceeding contingency abatacept develop internally addition pharmaceutical product discuss company pharmaceutical segment include company wholly own upsa consumer medicine business europe upsa brand acetaminophen efferalgan market pain relief european continent company market aspirine upsa dafalgan fervex europe overseas market strategic alliance arrangement company enter strategic alliance arrangement party company right develop manufacture market andor sell pharmaceutical product right own party company enter strategic alliance arrangement party party right develop manufacture market andor sell pharmaceutical product right own company alliance arrangement form include licensing arrangement codevelopment comarkete agreement copromotion arrangement joint venture alliance arrangement reduce risk incur research development expense lead revenuegenerate product gross margin alliance product generally low substantially gross margin company product profit alliance product share company alliance partner assurance new alliance form company actively pursue arrangement view alliance important complement discovery development activity companys significant current alliance arrangement company inline product sanofi plavix avaproavalide otsuka abilify imclone erbitux sankyo pravachol company significant alliance arrangement product development subject approval regulatory authority pierre fabre medicament sa pierre fabre vinflunine right own pierre fabre medarex inc medarex ipilimumab right own medarex gilead sciences inc gilead fix dose combination company product sustiva gilead truvada somerset pharmaceuticals inc somerset emsam right own somerset significant alliance arrangement discuss detail additionally company licensing arrangement yale zerit government videx novartis reyataz general company strategic alliance arrangement periods coextensive period market exclusivity protection countrybycountry basis base company current expectation respect expiration market exclusivity company significant market license arrangement yale zerit expect expire eu japan government videx term nonexclusive expect expire include earn pediatric extension japan eu country novartis reyataz expect expire eu japan discussion market exclusivity protection include chart show net sale key product year basic exclusivity loss occur expect occur eu japan product intellectual property product exclusivity company strategic alliance arrangement party right manufacture market andor sell pharmaceutical product contain customary early termination provision typically find agreement kind generally base party material breach bankruptcy voluntary involuntary product safety concern notice require early termination generally range immediately notice day receipt notice termination immediately notice generally available party file voluntary bankruptcy petition termination day notice generally available involuntary bankruptcy petition file dismiss material breach party occurred cure early termination product safety concern typically arise product determine create significant risk harm patient concern product efficacy level toxicity company strategic alliance arrangement typically contain provision provide party right terminate alliance short notice general party company strategic alliance arrangement continue exclusivity protection expiration termination alliance company retain right product party intellectual property loss right product market sell company pursuant strategic alliance arrangement party country territory material company result operation cash flow case plavix material financial condition liquidity customary pharmaceutical industry term company strategic alliance arrangement generally coextensive exclusivity period discuss vary countrybycountry basis discuss company strategic alliance otsuka expire november united states puerto rico prior expiration market exclusivity protection abilify expect expire include grant patent term extension growth driver sanofi company agreement codevelopment cocommercialization avaproavalide irbesartan angiotensin ii receptor antagonist indicate treatment hypertension diabetic nephropathy copromote certain country outside tradename aprovelcoaprovel comarkete certain country outside company tradename karveakarvezide plavix clopidogrel platelet aggregation inhibitor copromote certain country outside tradename plavix comarkete certain country outside company tradename iscover worldwide alliance operate framework geographic region cover certain european asian country define territory cover puerto rico canada australia certain latin american country territory b region cover puerto rico canada australia certain latin american country manage separate territory agreement puerto rico avaproavalide second agreement puerto rico plavix plus canada australia mexico brazil colombia argentina product territory b territory partnership exist supply product country territory manage certain central expense market research development royalty country territory b structure company local affiliate sanofi comarket affiliate operate independently sell compete brand copromote single brand territory comarketing country include germany spain italy irbesartan greece china company sell iscover karveakarvezide sanofi sell plavix aprovelcoaprovel country company sanofi copromote plavix aprovelcoaprovel france united kingdom ireland belgium sweden denmark finland norway netherlands switzerland portugal addition company sanofi copromote plavix austria italy turkey taiwan korea singapore malaysia hong kong aprovelcoaprovel certain french export country sanofi act operating partner territory own majority financial control interest territory company ownership interest territory company account investment partnership entity territory equity method record share result equity net income affiliate consolidate statement earning company share net income partnership entity tax million million million territory b company sanofi copromote plavix canada puerto rico avaproavalide canada territory b countries australia mexico brazil colombia clopidogrel argentina comarketing country company sanofi modify previous exclusive license company avaproavalide puerto rico form copromotion joint venture company contribute avaproavalide intellectual property sanofi agree pay company million million company account payment sale interest license defer amortize total million income expect life license approximately year date formation copromotion joint venture company act operating partner territory b uspuerto rico avaproavalide territory own majority control interest territory company consolidate partnership result territory record sanofis share result minority interest expense net taxis million million million company record sale territory b uspuerto rico avaproavalide territory comarkete country germany italy spain greece million million million company optedout comarkete copromotion arrangement sanofi number country company receive royalty payment sanofi sanofis net sale country royalty payment record company income million million million territory partnership govern series committee enumerate function power responsibilitie territory senior committee senior committee final decision make authority respect territory enumerate function power responsibility jurisdiction agreement sanofi expire later respect plavix respect avaproavalide americas australia europe asia ii expiration patent exclusivity right applicable territory alliance arrangement terminate company sanofi affected country territory depend circumstance event voluntary involuntary bankruptcy insolvency case involuntary bankruptcy continue day order decree approving continue unstayed effect day ii material breach obligation major alliance agreement remain uncured day follow notice breach commencement diligent prosecution cure occur day notice iii deadlock senior committee render continue commercialization product impossible give country territory case avaproavalide respect advertising promotion spending level sale force commitment iv increase combine cost good royalty exceed specify percentage net selling price product v good faith determination terminate party commercialization product terminate reason patient safety case termination right agreement include provision termination relevant alliance respect applicable product applicable country territory case termination bankruptcy insolvency material breach product applicable territory termination procedure slightly different event company lose right product applicable relevant country territory case bankruptcy insolvency material breach company default party information item financial statementsnote alliance investment otsuka company enter worldwide commercialization agreement otsuka codevelop copromote abilify aripiprazole treatment schizophrenia relate psychiatric disorder japan china taiwan north korea south korea philippines thailand indonesia pakistan egypt company begin copromote product otsuka puerto rico november june company receive marketing approval european commission product currently copromote otsuka united kingdom spain germany company otsuka right copromote france abilify currently distribute exclusively company france temporary basis copromotion otsuka commence company record alliance revenue contractual share otsukas net sale copromotion country exclude united kingdom record expense relate product alliance revenue record company net sale base otsukas net sale copromotion country company recognize alliance revenue abilify ship risk reward ownership transfer otsukas customer uk france copromotion otsuka commence company record net sale relate cost product sell company exclusive right sell abilify number country europe americas asia countries company record net sale relate cost product sell term agreement company purchase product otsuka perform finish manufacture sale company customer agreement expire november puerto rico european union agreement expire june later tenth anniversary commercial sale country expiration applicable patent country early termination available base party voluntary involuntary bankruptcy failure minimum payment failure commence commercial sale month receipt necessary approval material breach notice require early termination strategic alliance immediately notice case voluntary bankruptcy ii minimum payment otsuka iii commercial sale occur month receipt necessary approval day material breach occur cure commencement cure occur day notice material breach day case involuntary bankruptcy petition file dismiss addition termination available otsuka day notice event company challenge otsuka patent right marketbymarket basis company market product direct competition abilify termination expiration alliance company retain right abilify company record total revenue abilify million million million total milestone payment otsuka million million expense acquire inprocess research development remain million capitalize intangible asset amortize cost product sell remain life agreement range year company amortize cost product sell million million unamortized capitalize payment balance million million december respectively information item financial statementsnote alliance investments imclone company purchase million share imclone share million represent approximately imclone share outstanding prior company commencement public tender offer imclone share imclone biopharmaceutical company focus develop targeted cancer treatment include growth factor blocker cancer vaccine antiangiogenesis therapeutic equity investment imclone strategic agreement company imclone include arrangement expire september codevelop copromote cancer drug erbitux series payment originally total billion company pay imclone milestone payment million expense agreement imclone revise reduce total payment million billion accordance agreement company pay imclone million million million approval fda biologics license application bla erbitux use combination irinotecan treatment patient egfrexpresse metastatic colorectal cancer refractory irinotecan base chemotherapy use single agent treatment patient egfrexpresse metastatic colorectal cancer intolerant irinotecan base chemotherapy fda approve imclone chemistry manufacture control supplemental biologic license application sbla licensure bb manufacturing facility march fda approve erbitux use treatment squamous cell carcinoma head neck result fda approval company million milestone payment imclone march company codevelopment copromotion right canada japan extent product commercialize country japan company imclone share distribution right erbitux merck kgaa agreement imclone receive distribution fee base flat rate product revenue north america company purchase commercial requirement bulk erbitux imclone price equal manufacturing cost plus payment subsequent approval capitalize amortize cost product sell remain term agreement respect million milestone payment company pay imclone million expense acquire process research development million record additional equity investment eliminate income statement effect portion milestone payment company economic claim ownership interest imclone company account million approval milestone pay additional million milestone expect pay march license acquisition amortize payment cost product sell expect useful life license approximately year company amortize cost product sell million million respectively unamortized portion million payment record intangible asset net consolidated balance sheet million million december respectively company determine equity share imclone net income loss eliminate imclone result milestone revenue imclone recognize preapproval milestone payment record company additional equity investment company record net loss million net income million net loss million share imclone net incomelosse company record share result equity net income affiliate consolidate statement earning company record net sale erbitux million million company record investment market value holding imclone common stock december million approximately million respectively share basis carry value imclone investment closing market price imclone share december respectively early termination available base material breach effective day notice material breach material breach cure commencement cure occur month notice company exist significant concern regulatory patient safety issue seriously impact longterm viability product termination expiration alliance company retain right erbitux help maintain product quality erbitux product ship enduser intermediary wholesaler hold later sale mckesson corporation mckesson company wholesaler provide warehousing packing shipping service erbitux mckesson hold erbitux inventory consignment company recognize revenue mckesson ship inventory enduser mckesson hold inventory erbitux account divestiture oncology therapeutic network otn company discontinue consignment arrangement mckesson company sell erbitux intermediary specialty oncology distributor ship erbitux directly enduser product customer intermediary company recognize revenue shipment enduser discussion company strategic alliance imclone item financial statementsnote alliance investment line product sankyo company license patent cover pravastatin market company pravachol sankyo agreement expiring exclusivity expire marketbymarket basis exclusivity patent include pediatric extension last april term license company market sell pravastatin world exclude japan korea taiwan thailand market sankyo retain exclusive patent right sankyo copromote comarket pravastatin certain european latin american country early termination available base party voluntary involuntary bankruptcy material breach notice require early termination strategic alliance immediately notice case voluntary involuntary bankruptcy day notice case material breach occur cure commencement cure occur termination expiration alliance company retain patent exclusivity right relation pravastatin potential new product medarex company enter worldwide collaboration share purchase agreement medarex codevelop copromote ipilimumab fully human antibody currently phase iii development treatment metastatic melanoma agreement effective january company receive certain governmental clearance approval receipt consent public health service sublicense company medarexs right mdx gp vaccine develop combination ipilimumab fda grant fast track status ipilimumab combination mdx treatment patient late stage unresectable metastatic melanoma fail intolerant line therapy january term agreement company cash payment million medarex expense research development additional million equity investment medarex milestone payment expect successful achievement regulatory sale relate stage company medarex share future development commercialization cost medarex receive million regulatory milestone meet million salesrelated milestone medarex option copromote receive profit company united states company receive exclusive license outside pay royalty medarex agreement medarex expire follow event occur company voluntarily terminate agreement entirety countrybycountry basis provide medarex month prior write notice company voluntarily terminate agreement productbyproduct basis second product glp toxicology study later countrybycountry basis provide medarex month prior write notice depend circumstance company terminate medarexs copromotion option right united states day write notice end second calendar year event medarex provide percent certain performance obligation consecutive calendar year termination right exercise respect indication medarex fail meet performance obligation termination company scenario medarex long right share profit loss product terminate indication instead company pay medarex royalty net sale product medarex terminate agreement respect product day write notice company provide percent certain performance obligation consecutive calendar year generally termination company assign right product medarex receive royalty intellectual property license company medarex medarex elect copromote product indication united states event receive royalty sale product indication material breach manufacturing party party shall limit termination party manufacturing right pierre fabre company pierre fabre enter relate agreement patent knowhow license agreement trademark license agreement supply agreement develop commercialize vinflunine novel investigational anticancer agent vinflunine currently phase iii clinical trial metastatic bladder cancer investigation breast lung cancer term agreement company receive exclusive license vinflunine united states canada japan korea select southeast asian market pierre fabre responsible development marketing vinflunine country include europe supply company requirement product term agreement company expensed upfront milestone payment million million potential additional million milestone payment time patent knowhow license agreement company license right market vinflunine expire countrybycountry product formbyproduct form basis date later expiration applicable patent datum exclusivity give product form country ii tenth anniversary commercial sale product form country time company exercise royaltyfree nonexclusive right market product agreement terminate soon follow party terminate agreement voluntary involuntary bankruptcy insolvency party dismiss certain period time party terminate material breach cure specify period termination shall relate country product form relate material breach product form iv form case form terminate breach pertains united states case country terminate pierre fabre pierre fabre terminate supply agreement material breach company party day notice justifiable demonstrable safety efficacy technical regulatory reason preclude development iv form indication determine joint steering committee pierre fabre company fail file process registrational filing require file agreement justifiable demonstrable safety efficacy technical regulatory reason b company launch iv product form country time period require agreement generally ninety day follow receipt regulatory applicable pricing approval c company challenge contest pierre fabre patent right company make improper contract assignment e company fail meet certain minimum sale level agreement company cause countryby country basis give pierre fabre ninety day prior write notice notice give prior regulatory approval approve indication united states ii eighty day prior write notice regulatory approval approve indication united states generally termination pierre fabre termination company cause company shall retain right product right shall revert pierre fabre gilead company gilead enter joint venture develop commercialize fixeddose combination company sustiva efavirenz gileads truvada emtricitabine tenofovir disoproxil fumarate united states february fda approve treatment complete highly active antiretroviral therapy haart treatment product hiv available united states fixeddose combination take daily fixeddose combination contain multiple medicine formulate help simplify hiv therapy patient provider guideline issue department health human service list combination emtricitabine tenofovir disoproxil fumarate efavirenz preferred non nucleoside reverse transcriptase inhibitor nnrtibase treatment use appropriate patient take antihiv medicine joint venture company gilead work partnership complete development regulatory filing fixeddose combination regimen subject receive marketing approval fixeddose combination regimen company share responsibility commercialize product united states company provide fund fieldbased sale representative support promotional effort combination product company gilead receive revenue future net sale percentage relative contribution represent individual product comprise fixeddose combination joint venture company gilead continue terminate mutual agreement party describe new drug application nda combination product file december nda approve fda december party terminate joint venture event material breach party nonbreache party terminate joint venture party agree desirable practicable withdraw combination product market united states time generic version sustiva appear market united states gilead right terminate joint venture acquire right combination product company continue year receive percentage net sale base contribution sustiva combination product somerset company somerset joint venture mylan laboratories inc watson pharmaceuticals inc enter agreement commercialization distribution somerset emsam selegiline transdermal system investigational monoamine oxidase inhibitor administer transdermal patch treatment patient major depressive disorder somerset receive approvable letter fda emsam approve fda emsam transdermal treatment major depressive disorder october fda advisory committee recommend emsam safely administer dietary modification mg hour dose february fda approve emsam use dietary modification low dose mg hour term agreement company receive exclusive distribution right commercialize emsam approve canada company expense million upfront payment december payment follow regulatory approval addition upfront payment somerset receive milestone payment base achievement certain sale level reimbursement certain development cost incur term agreement somerset supply product company receive royalty company sale emsam early terminate extended accordance term agreement terminate fifth anniversary date commercial sale emsam agreement early terminate party event material breach agreement bankruptcy party addition general right termination company right terminate agreement prior date commercial sale emsam imposition certain regulatory requirement restriction relate emsam failure party agree respect allocation specify excess development cost failure somerset deliver launch inventory ii time follow launch generic product occurrence material safety issue relate emsam date month date commercial sale emsam day prior notice somerset right terminate agreement prior date commercial sale emsam failure party agree respect allocation specify excess development cost time follow occurrence material safety issue relate emsam failure company meet specify detail requirement information alliance relate drug discovery research development health care group health care group consist segment nutritional health care consist convatec medical imaging consumer medicine canada health care group sale account company sale company sale health care group sale account total health care group sale respectively international health care group sale account total health care group sale respectively nutritional segment nutritional segment mead johnson manufacture market distribute sell infant formula nutritional product include entire line enfamil product company commence sale enfamil lipil infant formula united states contain nutrient dha docosahexaenoic acid ara arachidonic acid naturally find breast milk dha ara believe support infant brain eye development company obtain nutrients sole provider pursuant nonexclusive worldwide licensing supply arrangement guaranty supply pricing subject change agreement expire begin countrybycountry basis year company commence sale country company nutritional product generally sell wholesaler retailer promote primarily health care professional company promote nutritional product directly consumer worldwide advertising company manufacture products united states foreign country nutritional sale account company sale company sale company sale nutritional sale account total nutritional sale respectively international nutritional sale account total nutritional sale respectively approximately onehalf gross sale infant formula subject rebate issue woman infant child wic program sale subject wic rebate low margin nonwic program sale net sale select product product category nutritional segment follow dollar million infant formula enfamil toddlerchildren nutritional february company complete divestiture adult nutritional business novartis million include million payment contingent achievement contractual requirement satisfy million upfront payment supply agreement adult nutritional product record sale million health care segment health care segment consist convatec medical imaging consumer medicine canada health care sale account company sale respectively health care sale account total health care sale respectively international health care sale account total health care sale respectively convatec convatec manufacture distribute sell ostomy modern wound skin care product principal brand convatec include natura surfit esteem aquacel duoderm product market worldwide primarily hospital medical profession medical supplier company mainly rely internal sale force sale distributor world company manufacture products united states united kingdom dominican republic contract manufacturing agreement party convatec sale account approximately company sale company sale convatec sale account total convatec sale respectively international convatec sale account total convatec sale respectively medical imaging medical imaging manufacture distribute sell medical imaging product principal brand include cardiolite kit preparation technetium tcm sestamibi injection cardiac perfusion image agent definity vial perflutren lipid microsphere injectable suspension ultrasound contrast agent product manufacture company market internal sale force cardiolite radiopharmaceutical product primarily sell distribute thirdparty radiopharmacie endcustomer eg healthcare provider definity distribute directly endus customer company currently supplier technetium tcm generator widely radioisotope require compound unitdose cardiolite injection company rely single source supply key ingredient molybdenum connection company international business medical imaging own certain radiopharmacie outside united states cardiolite cover series patent claim component patent coverage differ somewhat countrybycountry basis patent expiry timeline span december company currently expect year basic exclusivity loss eu patent expiry timeline span december japan patent expiry timeline span august medical imaging sale account company sale medical imaging sale account total medical imaging sale international medical imaging sale account total medical imaging sale company maintain license supply agreement radiopharmacie include cardinal health nuclear pharmacy service independent radiopharmacie provide right sell cardiolite consumer medicine quarter company complete sale canadian consumer medicine business relate asset novartis ag novartis company consumer medicine business japan consumer medicine product asia pacific latin america europe middle east africa include pharmaceutical segment include divestiture consumer medicine sale account company sale company sale source availability raw material general company purchase raw material medical device supply require production company product open market product company purchase raw material medical device supply single source certain circumstance specify company product registration require company obtain raw material supply particular source company attempt possible mitigate raw material supply risk company inventory management alternative source strategy discussion source manufacture quality assurance discussion particular product manufacture quality assurance company seek design operate manufacturing facility manage thirdparty manufacturer maintain inventory way allow meet expect product demand maintain flexibility reallocate manufacturing capacity improve efficiency respond change supply demand pharmaceutical production process complex highly regulate vary widely product product shift add manufacturing capacity lengthy process require significant capital expenditure regulatory approval discussion regulatory impact company manufacturing government regulation price constraint pharmaceutical manufacturing facility require significant ongoing capital investment maintenance compliance increase regulatory requirement addition company add product line realign focus year company expect modify exist manufacturing network devote substantial resource excess historical level meet heighten processing standard require sterile newly introduce product include biologic biologic manufacturing involve complex process traditional pharmaceutical operation company capacity manufacture biologic clinical trial commercial launch capacity manufacture large commercial volume limited biologic important company product portfolio company continue arrangement party manufacturer addition expect substantial investment increase internal capacity produce biologic commercial scale march board director approve capital expenditure million construction expandable largescale multiproduct bulk biologic manufacturing facility facility modular design order accommodate future expansion construction facility expect complete assume require regulatory approval obtain company expect begin commercial distribution material manufacture facility approximately year company rely party manufacture supply active ingredient necessary manufacture certain product include pravachol plavix abilify erbitux coumadin paraplatin sustiva taxol paclitaxel videxvidex ec maintain stable supply product company take variety action design provide reasonable level ingredient hold thirdparty supplier company company manufacture operation interrupt additional protection case company take step maintain approve backup source available company file receive approval fda manufacture orencia company syracuse new york manufacturing facility orencia give company limit capacity commercial volume company file sbla fda approve lonza biologic plcs lonza manufacturing facility manufacture orencia expect rely celltrion inc celltrion provide additional capacity orencia commercial scale production pende submission sbla fda approval sbla company rely initially party manufacturer manufacture belatacept ipilimumab commercial scale product commercialize belatacept ipilimumab investigational biologic compound late stage development company filing fda seek approval lonza celltrion manufacture belatacept ipilimumab company seek approval fda market sell belatacept ipilimumab assurance regulatory approval product obtain company enter agreement lonza celltrion thing reserve portion respective biologic manufacturing capacity company future requirement orencia ii contain certain right negotiate lonza celltrion additional biologic manufacturing capacity biologic product company commence certain discussion party manufacturer relate biologic manufacturing capacity belatacept ipilimumab regulatory approval obtain information orencia product additional information belatacept ipilimumab research development company thirdparty manufacturer company rely exist future product unable maintain stable supply product operate sufficient capacity meet order requirement comply government regulation manufacturing pharmaceutical meet heighten processing requirement biologic company business performance prospect negatively impact additionally company thirdparty supplier experience extend plant shutdown substantial unplanned increase demand suspension manufacture regulatory reason company experience interruption supply certain product product shortage production resume expand connection divestiture license arrangement distribution agreement certain company pharmaceutical certain circumstance company enter agreement company agree supply product party addition liability arise company failure supply product agreement arrangement require company invest facility production nonstrategic product result additional regulatory filing obligation cause interruption manufacturing product company success depend great measure customer confidence quality product integrity datum support safety effectiveness product quality arise total commitment quality part company operation include research development purchasing facility planning manufacturing distribution company maintain qualityassurance procedure relate quality integrity scientific information production process control production process involve rigid specification ingredient equipment facility manufacturing method process packaging material label company perform test stage production process final product assure product meet regulatory requirement company standard test involve chemical physical chemical analyse microbiological testing combination analyse quality control provide business unitsite quality assurance group monitor exist manufacturing procedure system company subsidiary thirdparty supplier intellectual property product exclusivity company own license intellectual property number patent united states foreign country primarily cover pharmaceutical product company develop brand name trademark product area company consider overall protection patent trademark license intellectual property right material value act protect right infringement pharmaceutical industry majority innovative product commercial value usually realize period product market exclusivity country market exclusivity expire generic version product approve market substantial rapid decline product sale rate decline vary country therapeutic category discussion generic version product impact product sale generic competition product market exclusivity generally determine form intellectual property patent right hold innovator company regulatory form exclusivity innovative drug entitle patent key determinant market exclusivity brand pharmaceutical patent provide innovator right exclude practice invention relate medicine patent cover thing active ingredient use drug product pharmaceutical formulation drug delivery mechanism process intermediate useful manufacture product protection individual product extend vary period accordance expiration date patent country protection afford vary country country depend type patent scope coverage availability meaningful legal remedy country market exclusivity influence regulatory intellectual property right develop country provide certain nonpatent incentive development medicine example united states eu japan provide minimum period time approval new drug regulatory agency rely innovators data approve competitor generic copy regulatory intellectual property right available certain market incentives research new indication orphan drug medicine useful treat pediatric patient regulatory intellectual property right independent patent right company possess particularly important drug lack broad patent protection regulatory form exclusivity prevent competitor gain regulatory approval prior expiration regulatory data exclusivity basis competitor safety efficacy datum drug drug identical market innovator company estimate likely market exclusivity period product casebycase basis possible predict length market exclusivity company product certainty complex interaction patent regulatory form exclusivity inherent uncertainty concern patent litigation assurance particular product enjoy market exclusivity period time company currently estimate exclusivity limited estimate company expect continue exclusivity challenge year discussion exclusivity challenge pharmaceutical segment item management discussion analysis financial condition result operationsoutlook addition patent regulatory form exclusivity company hold intellectual property form trademark product enfamil trademark effect market exclusivity product consider marketing value worldwide company important product sell trademark consider aggregate material importance trademark protection continue country long country long register registration fix term renew indefinitely specific aspect law govern market exclusivity pharmaceutical vary country country follow summarize key exclusivity rule market represent significant company sale united states company seek market innovative pharmaceutical united states file complete set safety efficacy datum fda type application file depend drug chemical small molecule biological product large molecule innovative pharmaceutical chemical company file nda medicine biological product bla file type application file affect regulatory exclusivity right competitor seek launch generic substitute chemical innovative drug united states file abbreviate new drug application anda fda anda generic manufacturer need demonstrate bioequivalence generic substitute approve nda drug anda rely safety efficacy datum previously file innovator nda medicine approve nda receive type regulatory data protection innovative chemical pharmaceutical know new chemical entity entitle year regulatory data protection anda file fda innovators patent challenge describe generic manufacturer file anda fourth year fiveyear datum protection period pharmaceutical drug product contain active ingredient previously approve nda approve new formulation new indication basis new clinical trial receive year datum protection finally nda designate orphan drug drug gain indication treatment condition occur rarely unite state receive seven year exclusivity orphan indication time period nda andas drug product approve orphan use significant portion patent life lose time take obtain regulatory approval innovator extend patent compensate innovator lose patent term specifically innovator identify patent claim product approve method use depend number factor extend expiration date patent limit extension maximum term patent extend year second extension cause patent effect year date nda approval company earn month additional exclusivity drug specific clinical trial conduct write request fda study use medicine treat pediatric patient submission fda prior loss basic exclusivity sixmonth period extend form exclusivity patent regulatory list fda time study complete submit fda currently generic version biological product approve law law change future absence new legislation fda take step allow generic version certain biologic competitor seek approval biological product file safety efficacy datum address challenge biologic manufacturing involve complex process costly traditional pharmaceutical operation minimum period regulatory exclusivity provide law innovative drug cover patent hold nda sponsor innovator company require list certain patent cover medicine fda commonly know orange book absent successful patent challenge fda approve anda innovators list patent expire innovator market product year generic manufacturer file anda allege patent list orange book innovators nda invalid infringe allegation commonly know paragraph iv certification innovator decide file patent infringement suit generic manufacturer ndaliste patent successfully challenge innovator chooses sue filer paragraph iv certification filer generic qualifie entitle day period market exclusivity generic manufacturer time time anda include paragraph iv certification file respect certain company product company evaluate andas casebycase basis warrant file suit generic manufacturer protect patent right recent development united states increase likelihood generic challenge innovators intellectual property increase risk loss innovator market exclusivity generic company increasingly seek challenge innovator basic patent cover major pharmaceutical product discussion litigation relate patent challenge generic company item financial statementsnote legal proceeding contingenciesplavix litigation second recent statutory regulatory provision united states limit ability innovator company prevent generic drug approve launch patent litigation ongoing fda actively consider way expand use regulatory mechanism allow regulatory approval drug similar generic copy innovative drug basis extensive datum require nda result development possible predict length market exclusivity particular company product certainty base solely expiration relevant patent current form regulatory exclusivity information new legislation government regulation price constraint european union eu innovative pharmaceutical entitle year regulatory data protection marketing approval obtain centralized procedure product receive approval centralized procedure automatically receive approval member state eu company obtain pricing reimbursement pharmaceutical product typically subject member state law pricing reimbursement procedure month year obtain consequently regardless innovative medicine cover patent generic copy rely innovator datum usually approve minimum year approval additional year protection available certain circumstance innovator drug receive substantial new indication approval innovative pharmaceutical gain marketing approval noncentralized mutual recognition procedure period year depend individual eu member state regardless regulatory exclusivity competitor obtain approval identical product basis safety efficacy datum time information regulation pharmaceutical product eu government regulation price constraint recent pharmaceutical legislation eu impact procedure authorization pharmaceutical product eu centralize mutual recognition procedure particular legislation contain new data protection provision product regardless approve centralized mutual recognition procedure subject regime year innovator receive community authorization medicinal product generic company file marketing authorization application product health authority generic company commercialize product year elapse initial marketing authorization grant innovator possible year extension available innovator year marketing authorization obtain additional indication significant clinical benefit comparison exist treatment transitional provision new datum protection requirement provision apply new marketing authorization application submit new legislation patent pharmaceutical product generally enforceable eu contrast united states patent list regulatory authority generic copy approve data protection expire regardless innovator hold patent cover drug possible innovator seek enforce patent generic competitor market product european patent system opposition procedure generic manufacturer challenge validity patent cover innovator product month grant united states patent eu extended compensate patent term lose regulatory review process extension grant countrybycountry basis general eu law treat chemically synthesize drug biologically derive drug respect intellectual property market exclusivity generic biological product receive regulatory marketing authorization eu japan japan medicines new chemical entity generally afford year protection approve indication dosage patent pharmaceutical product enforceable generic copy receive regulatory approval datum protection patent expirations united states patent japan extended compensate patent term lose regulatory review process general japanese law treat chemically synthesize biologically derive drug respect intellectual property market exclusivity rest world country outside united states eu japan wide variety legal system respect intellectual property market exclusivity pharmaceutical develop country utilize system similar united states eg canada eu eg switzerland develop country adopt patent law andor regulatory exclusivity law develop nation formally adopt law order comply world trade organization wto commitment take step implement law meaningful way enforcement wto obligation long process assurance outcome assess likely future market exclusivity company innovative drug develop country company take account formal legal right political factor marketing distribution customer company promote product medical journal directly health care provider doctor nurse practitioner physician assistant pharmacist technologist hospital pharmacy benefit manager pbms manage care organization mcos government agency company market directly consumer united states directtoconsumer print radio television advertising addition company sponsor general advertising educate public innovative medical research discussion regulation promotion marketing pharmaceutical government regulation price constraint company sale marketing organization company explain approve use advantage product medical professional company work gain access health authority pbm mco formulary list recommend approve medicine product include medicare plan reimbursement list demonstrate quality treatment benefit product marketing prescription pharmaceutical limit approve use particular product company continue develop information product provide information response unsolicite inquiry doctor medical professional drug complete clinical trial require regulatory authority safe effective treat medical problem manufacturer choose undertake additional study include comparative clinical trial competitive product demonstrate additional advantage compound study costly year complete result uncertain balancing consideration make difficult decide undertake additional study successful study major impact approve marketing claim strategy company operation include pharmaceutical marketing sale organization organization market distinct group product support sale force typically base particular therapeutic area physician group sale force focus sell new product introduce promotion physician increasingly target specialist high value primary care physician addition ventiv pharma services llc ventiv division ventiv health inc provide company sale force focus cefzil december tequin january company provide notice ventiv terminate agreement relate sale force tequin effective quarter company prescription pharmaceutical product sell principally wholesaler company sell directly retailer hospital clinic government agency pharmacie sale pharmaceutical wholesaler united states mckesson cardinal health inc cardinal amerisourcebergen corporation amerisourcebergen account approximately respectively company total net sale sale mckesson cardinal amerisourcebergen account approximately respectively company total net sale sale mckesson cardinal amerisourcebergen account approximately respectively company total net sale sale wholesaler concentrated pharmaceutical segment company pharmaceutical business inventory management agreement ima arrangement substantially direct wholesaler customer allow company monitor wholesaler inventory level require wholesaler maintain inventory level approximately month demand second quarter company negotiate amendment ima large wholesaler amendment extend original agreement december establish low limit original agreement inventory level company pharmaceutical product hold wholesaler december company reach year agreement principle large wholesaler provide low limit wholesaler inventory level m extension previously negotiate help maintain product quality erbitux product ship enduser intermediary wholesaler hold later sale mckesson company wholesaler provide warehousing packing shipping service erbitux mckesson hold erbitux inventory consignment company recognize revenue mckesson ship inventory enduser mckesson hold inventory erbitux account divestiture otn company discontinue consignment arrangement mckesson company sell erbitux intermediary specialty oncology distributor ship erbitux directly enduser product customer intermediary company recognize revenue shipment enduser information sale marketing nutritional nutritional segment competition market company compete generally broadbase highly competitive principal mean competition vary product category business group company pharmaceutical segment compete worldwide researchbase drug company small research company limit therapeutic focus generic drug manufacturer important competitive factor include product efficacy safety ease use price demonstrate cost effectiveness marketing effectiveness product label service research development new product process sale company product impact new study indicate competitor product great efficacy treat disease particular form disease company product company sale impact additional labeling requirement relate safety convenience impose product fda similar regulatory agency different country competitor introduce new product process therapeutic cost advantage companys product subject progressive price reduction decrease volume sale example grow market statin reduce cholesterol pravachol company second large product rank net sale billion experience increase competition establish brand new entrant prescription pravachol decline compare pravachol begin lose exclusivity europe anticipate loss exclusivity april expect rate decline sale share statin segment accelerated increase competition successfully compete business manage care pharmacy benefit management organization company demonstrate product offer medical benefit cost advantage compare form care new product company introduce compete product market product later develop competitor manufacturer generic pharmaceutical typically invest far research development researchbase pharmaceutical company price product significantly lower brand product accordingly brand product lose market exclusivity normally face intense price competition generic form product certain country outside united states patent protection weak nonexistent company compete generic version shortly launch innovative product company large small manufacture sell product similar market company nutritional health care segment source competitive advantage include product quality efficacy brand identity advertising promotion product innovation broad distribution capability customer satisfaction price significant expenditure advertising promotion marketing generally require achieve consumer trade acceptance product company believe longterm competitive position depend success discover develop innovative costeffective product serve unmet medical need ability manufacture product efficiently market effectively highly competitive environment assurance company research development effort result commercially successful product product process outmoded time time result product process develop competitor manage care organization growth mcos united states major factor competitive makeup health care marketplace half population participate version manage care size patient population cover mcos marketing prescription drug pbms serve organization important company business mco include medical insurance company medical plan administrator healthmaintenance organization medicare formulary alliance hospital physicians physician organization organization consolidate few large entity enhance purchasing strength importance company major objective mco contain possible reduce health care expenditure typically use formulary volume purchase longterm contract negotiate discount pharmaceutical provider mcos pbms typically develop formulary reduce cost medication formulary base price therapeutic benefit available product generally low cost generic medicine favor breadth product cover formulary vary considerably mco formulary include alternative competitive product treatment particular medical problem mcos use variety mean encourage patient use product list formulary exclusion product formulary lead sharply reduce usage mco patient population consequently pharmaceutical company compete aggressively product include possible company compete inclusion base unique feature product great efficacy well patient ease use few effect low overall cost therapy important factor product demonstrate few therapeutic advantage compete inclusion base primarily price company generally universally successful major product include mco formulary generic competition big competitive challenge company face united states less extent internationally generic pharmaceutical manufacturer expiration loss market exclusivity product company lose major portion sale product short period time united states fda approval process exempt generic costly timeconsuming clinical trial demonstrate safety efficacy allow generic manufacturer rely safety efficacy pioneer product generic competitor operate company large research development expense cost convey medical information product medical community information market exclusivity intellectual property product exclusivity rate sale decline product expiration exclusivity vary country general decline market rapid develop country decline develop country tend rapid develop country rate sale decline expiration exclusivity historically influence product characteristic example drug large patient population eg prescribe primary care physician tend experience rapid decline drug specialized area medicine eg oncology drug complex manufacture eg sterile injectable product usually experience slow decline simple manufacture note mco focus primarily immediate cost drug favor generic brandname drug government encourage use generic alternative brandname drugs health care program laws united states generally allow case require pharmacist substitute generic drug rate government procedure therapeutically equivalent brandname drug substitution prescribe physician expressly forbid law policy provide add incentive generic manufacturer seek marketing approval automatic substitution remove need generic manufacturer incur sale marketing cost innovator incur research development company invest heavily research development believe critical longterm competitiveness pharmaceutical research development carry bristolmyers squibb pharmaceutical research institute major facilities princeton hopewell new brunswick new jersey wallingford connecticut pharmaceutical research development carry facility united states belgium canada united kingdom management continue emphasize leadership innovation productivity quality strategy success pharmaceutical research institute company spend million million million company sponsor research development activity company sponsor pharmaceutical research development spending include certain payment thirdparty collaboration contract percentage pharmaceutical sale compare end company employ approximately people research development company include pharmaceutical research institute include substantial number physician scientist hold graduate postgraduate degree higher skilled technical personnel company concentrate pharmaceutical research development effort follow disease area significant unmet medical need affective psychiatric disorder alzheimersdementia atherosclerosisthrombosis diabete hepatitis human immunodeficiency virusacquire immune deficiency syndrome hivaid obesity oncology rheumatoid arthritis relate disease solid organ transplant company continue analyze selectively pursue promising lead area addition discover develop new molecular entity company look way expand value exist product new use formulation provide additional benefit patient supplement company internal effort company collaborate independent research organization include educational institution researchbase pharmaceutical biotechnology company contract performance research facility company use service physician hospital medical school research organization worldwide conduct clinical trial establish safety effectiveness new product company actively seek investment external research technology hold promise complement strengthen research effort investment form include licensing arrangement codevelopment comarkete agreement copromotion arrangement joint ventures drug development timeconsume expensive risky development human health product industry practice government regulation united states foreign country provide determination effectiveness safety new molecular entity preclinical test control clinical evaluation new drug market united states record datum preclinical clinical experience include nda bla fda require approval development certain product subject government regulation cover safety efficacy united states foreign country assurance compound develop result program obtain regulatory approval necessary market particular disease indication average thousand chemical compound discover pharmaceutical industry researcher prove medically effective safe approve medicine process discovery regulatory approval typically take year long drug candidate fail stage process latestage product candidate fail receive regulatory approval company believe investment research internally collaboration reward number new pharmaceutical compound indication stage development company drug discovery program include alliance collaborative agreement agreement bring new product pipeline help company remain cut edge technology search novel medicine list investigational compound company later stage development compound phase iii clinical trial regulatory review investigational compound ultimately company market product depend result preclinical clinical study competitive landscape potential product market manufacturing process necessary produce potential product commercial scale factor note assurance company seek regulatory approval compound approval sought obtain stage development company determine intellectual property issue patent protection available investigational compound patent coverage highlight include potential patent term extension emsam emsam investigational monoamine oxidase inhibitor administer transdermal patch treatment patient major depressive disorder codevelope somerset receive approvable letter fda february october fda advisory committee recommend emsam safely administer dietary modification mg hour dose february fda approve emsam use dietary modification low dose mg hour ixabepilone ixabepilone epothilone b analog develop internally novel tubulin inhibitor multiple tumor type develop internally currently phase iii clinical trial treatment metastatic breast cancer phase ii clinical trial treatment prostate cancer company composition matter patent united states expire vinflunine vinflunine codevelope pierre fabre currently phase iii clinical trial novel investigational anticancer agent pierre fabre composition matter patent expire ipilimumab ipilimumab codevelope medarex currently phase iii clinical trial monoclonal antibody investigate anticancer treatment novel class agent intend potentiate element immunologic response company own composition matter patent expire right method use patent own medarex expire company right medarex composition matter patent expire pende medarex patent application cover composition matter method use ipilimumab belatacept belatacept biological product develop internally phase iii clinical trial fusion protein novel immunosuppressive activity target prevention solid organ transplant rejection company pende patent application united states japan grant patent application eu cover belatacept saxagliptin saxagliptin develop internally currently phase iii clinical trial oral compound potential treatment diabetes patent application cover composition matter issue expire dasatinib dasatinib develop internally investigational multitargeted kinase inhibitor treat adult chronic myelogenous leukemia chronic accelerate blast phase december company submit nda fda march nda accept grant priority review accelerate approval company submit maa emea january company composition matter patent expire muraglitazar dual ppar agonist treatment type diabete metabolic disorder october fda issue approvable letter muraglitazar request additional information ongoing clinical trial fully address cardiovascular safety profile product company continue discussion fda determine likely initiate additional new trial gain regulatory approval consider range option include conduct additional study terminate development muraglitazar additional study approximately year complete december company merck co inc terminate collaboration agreement muraglitazar right muraglitazar return company december result termination agreement company recognize million defer income fourth quarter record expense net company composition matter patent expire united states company competitor devote substantial fund resource research development addition consolidation occur pharmaceutical industry create company substantial research development resource extent company competitor successful research result erosion sale product unanticipate product obsolescence government regulation price constraint pharmaceutical industry subject extensive global regulation regional country state local agency federal food drug cosmetic act fdc act federal statute regulation state statute regulation law regulation foreign government govern vary degree test approval production labeling distribution postmarket surveillance advertising dissemination information promotion company product lengthy process laboratory clinical testing datum analysis manufacture development regulatory review necessary require governmental approval extremely costly significantly delay product introduction give market promotion marketing manufacturing distribution pharmaceutical product extensively regulate major world market addition company operation subject complex federal state local foreign environmental occupational safety law regulation company anticipate law regulation affect manufacture sale current product introduction new product continue require substantial scientific technical effort time expense significant capital investment particular importance fda united states jurisdiction virtually company business impose requirement cover testing safety effectiveness manufacturing labeling marketing advertising postmarkete surveillance company pharmaceutical product fda regulate company nutritional health care product case fda requirement increase time money necessary develop new product bring market united states company pharmaceutical product subject premarket approval requirement united states new drug approve subject fdc act relate regulation biological drug subject fdc act public health service act phs act relate regulation biological drug license phs act nutritional product regulate fda primarily infant formula act amendment ifa fda mandate drug manufacture package label conformity current good manufacturing practice cgmp establish fda comply cgmp regulation manufacturer continue expend time money effort production record keep quality control ensure product meet applicable specification requirement ensure product safety efficacy fda periodically inspect drug manufacturing facility ensure compliance applicable cgmp requirement failure comply statutory regulatory requirement subject manufacturer possible legal regulatory action suspension manufacturing seizure product voluntary recall product adverse experience use product report fda result imposition market restriction label change product removal product approval withdraw compliance regulatory requirement maintain problem concern safety efficacy product occur follow approval federal government extensive enforcement power activitie pharmaceutical manufacturer include authority withdraw product approval commence action seize prohibit sale unapproved noncomplye product halt manufacture operation compliance cgmp impose seek injunction voluntary recall civil monetary criminal penalty restriction prohibition sale withdrawal approval product market company materially adversely affect business financial condition result operation marketing authorization company product subject revocation applicable governmental agency addition modification enhancement approve product change manufacturing location circumstance subject additional fda approval receive subject lengthy application process distribution pharmaceutical product subject prescription drug marketing act know pdma fdc act regulate activity federal state level pdma implement regulation state permit require registration manufacturer distributor provide pharmaceutical manufacturer distributor place business state state permit adopt regulation limit distribution product sample license practitioner pdma impose extensive licensing personnel record keep packaging quantity label product handle facility storage security requirement intend prevent sale pharmaceutical product sample diversion marketing practice pharmaceutical manufacturer subject federal state health care law protect integrity government health care program office inspector general united states department health human service oig oversee compliance applicable federal law connection payment product government fund program primarily medicaid medicare law include federal antikickback statute criminalize offer value induce recommendation order purchase product service reimburse government health care program oig issue series guidances segment health care industry include compliance program guidance pharmaceutical manufacturer oig guidance include recommendation pharmaceutical manufacturer minimum adhere phrma code voluntary industry code marketing practice company subscribe phrma code implement compliance program address requirement set forth oig guidance company compliance health care law failure comply health care law subject company administrative legal proceeding include action state federal government agency action result imposition civil criminal sanction include fine penalty injunctive remedy impact materially adversely affect company business financial condition result operation company subject jurisdiction federal state regulatory enforcement department agency federal trade commission ftc department justice department health human services united states company license drug enforcement agency procure produce control substance company subject possible administrative legal proceeding action organization action result imposition civil criminal sanction include fine penalty injunctive administrative remedy federal state agency regulatory authority manufacture storage transportation disposal medical imaging product radioactive nature company activity outside united states subject regulatory requirement govern testing approval safety effectiveness manufacturing labeling marketing company product regulatory requirement vary country country eu way company obtain marketing authorization pharmaceutical product route centralized procedure procedure compulsory certain pharmaceutical product particular biotechnological process available certain new chemical compound product second route obtain marketing authorization eu mutual recognition procedure application single member state member state approve pharmaceutical product national procedure applicant submit approval mutual recognition procedure member state set forth pricing reimbursement product continue subject member state law fda approval approval european medicine evaluation agency obtain product approval product comparable regulatory authority country outside united states eu case obtain prior marketing product country approval process rigorous country country time require approval long shorter require united states approval country assure product approve country market outside united states company operate environment governmentmandate costcontainment program government place restriction physician prescription level patient reimbursement emphasize great use generic drug andor enact theboard price cut method cost control european country provide market price new medicine united kingdom germany pricing freedom limited united kingdom operation profit control plan germany operation reference price system company face significant delay mainly france spain italy belgium market access new product year elapse new medicine available national market additionally member states eu regularly impose new additional cost containment measure pharmaceutical recent year italy example impose mandatory price decrease existence price differential europe different national pricing reimbursement law lead significant parallel trade flow recent year congress state legislature consider number proposal enact law effect major change health care system nationally state level drive budget concern medicaid access reimbursement restriction implement state propose similar cost containment issue exist foreign country company business federal state government pursue direct method reduce cost drug pay company participate state governmentmanage medicaid program certain qualify federal state government program discount rebate provide participate state local government entity rebate medicaid relate state program reduce revenue million million million company participate prime vendor program government entity significant department defense department veterans affair entity receive minimum discount base define nonfederal average manufacturer price purchase prime vendor program company participate provide discount outpatient medicine purchase certain public health service entity disproportionate share hospital hospital meet certain criterion company record discount relate prime vendor program million million million united states governmental cost containment effort extend federally fund special supplemental nutrition program wic state participate wic program sought obtain rebate manufacturer infant formula product program state conduct competitive bidding infant formula contract require use specific infant formula product state wic program physician request noncontract formula wic customer state participate wic program require engage competitive bidding use cost containment measure yield saving equal great saving generate competitive bidding system mead johnson participate program approximately half gross sale subject rebate wic program rebate wic program reduce revenue million million million merger separate japanese pharmaceutical regulatory office lead gain efficiency timeliness drug registration japan pricing environment pharmaceutical japan remain challenge reference pricing biennial government mandate price reduction environmental regulation company facility operation subject extensive foreign law regulation relate environmental protection human health safety include govern discharge pollutant air water use management disposal hazardous radioactive biological material waste cleanup contamination pollution control permit require company operation permit subject modification renewal revocation issue authority environment health safety group company monitor operation world provide company overview regulatory requirement oversee implementation company standard compliance company incur operate capital cost matter ongoing basis company expend approximately million million million capital environmental project undertake specifically meet environmental requirement respectively expect spend approximately million company believe substantial compliance applicable environmental health safety requirement permit require operation company incur additional cost include civil criminal fine penalty cleanup cost thirdparty claim property damage personal injury violation liabilitie law company current facility operation year time company operator facility generate store dispose substance waste consider hazardous federal state foreign environmental law include comprehensive environmental response compensation liability act cercla result soil groundwater certain facility contaminated company require significant expenditure investigate control remediate contamination case provide compensation andor restoration damage natural resource currently company involve investigation remediation approximately current company facility company identify potentially responsible party prp applicable law environmental condition approximately waste disposal reprocess facility operate party investigation andor remediation activity ongoing company face liability cercla federal state foreign law entire cost investigation remediation contaminate site natural resource damage regardless fault ownership time disposal release addition certain site company bear remediation responsibility pursuant contract obligation generally thirdparty operator site involve multiple prps liability expect apportion base nature hazardous substance dispose party site number financially viable prps additional information matter item financial statementsnote legal proceeding contingency employee company employ approximately people december foreign operation company significant operation outside united states conduct company subsidiary distributor involve business segment company operation pharmaceutical nutritional health care revenue operation outside united states billion account company total revenue revenue exceed million france japan spain canada italy germany single country outside united states contribute company total revenue geographic breakdown net sale table caption geographic item financial statementsnote segment information discussion company sale geographic area item management discussion analysis financial condition result operation geographic area international operation subject certain risk inherent conduct business abroad include limited currency fluctuation possible nationalization expropriation price exchange control counterfeit limitation foreign participation local enterprise restrictive governmental action company international business subject governmentimpose constraint include law price reimbursement use product depend direction change relative dollar foreign currency value increase reduce report dollar value company net asset result operation change foreign exchange rate favorable impact growth rate revenue company predict certainty future change foreign exchange rate effect company attempt mitigate impact operational mean financial instrument discussion item financial statementsnote financial instrument item risk factor factor describe significantly negatively affect business prospect financial condition operating result credit rating cause trading price common stock decline additional risk uncertainty presently know company risk company currently consider immaterial impair company operation litigationplavix company predict outcome plavix litigation schedule trial june plaintiff intend vigorously pursue enforcement patent right plavix possible time reasonably assess outcome litigation company prevail litigation apotex inc apotex corp apotex final approval snda enter market generic product risk time potential generic competition plavix loss market exclusivity plavix subsequent development generic competition andor decision apotex launch generic clopidogrel risk material company sale plavix result operation cash flow material financial condition liquidity company record defer tax asset relate foreign tax credit research tax credit carryforward expire vary amount begin realization foreign tax credit research tax credit carryforward dependent generate sufficient taxable income prior expiration realization assure management believe likely defer tax asset realize foreign tax credit research tax credit carryforward consider realizable reduce near term outcome plavix litigation unfavorable andor time successful generic competition plavix accelerate event occur company need record significant additional valuation allowance defer tax asset additional information plavix litigation item financial statement note legal proceeding contingency competition competition manufacturer generic version product major challenge product mature patent expire product generic company increasingly seek challenge patent competitive factor company face include new product develop competitor low price superior performance feature competitive current product ii technological advance patent attain competitor iii result clinical study relate product competitor product iv problem licensor supplier distributor v business combination competitor major customer manufacture company experience difficulty delay inherent product development manufacturing sale product appear promise development fail reach market approve additional indication number reason include efficacy safety concern delay denial necessary regulatory approval difficulty excessive cost manufacture ii failure company product achieve maintain commercial viability iii seizure recall pharmaceutical product force closing manufacture plant iv failure obtain imposition limitation use loss patent intellectual property right v failure company vendor supplier comply current good manufacturing practice application regulation quality assurance guideline lead temporary manufacturing shutdown product shortage delay product manufacture vi manufacturing distribution problem include change manufacture production site limit manufacturing capacity regulatory requirement change type product produce biologic physical limitation impact continuous supply litigation company continue obligation defer prosecution agreement united states securities exchange commission sec consent order relate wholesaler inventory accounting matter pursuant company agree implement certain remedial measure include recommendation independent monitor defer prosecution agreement undertake corporate reform include additional disclosure periodic report file sec annual report shareholder company experience legal difficulty include lawsuit claim proceeding government investigation preclude delay commercialization product adversely affect operation profitability liquidity financial condition include intellectual property dispute ii sale marketing practice internationally iii adverse decision litigation include product liability commercial case iv company determination selfinsure product liability effective july v recall withdrawal pharmaceutical product force closing manufacture plant vi failure fulfill obligation supply contract government customer result liability vii product pricing promotion matter viii claim assert violation security antitrust federal state pricing law ix environmental health safety matter x tax liability assurance increase scope matter future lawsuit claim proceeding investigation material regulation company subject new government law regulation health care reform initiatives united states state federal level country ii change fda foreign regulatory approval process cause delay approve prevent approval new product iii tax change phase tax benefit heretofore available united states certain foreign country iv new law regulation judicial decision affect pricing marketing jurisdiction v change intellectual property law pricing pressure pharmaceutical product subject increase price pressure restriction united states worldwide include rule practice manage care group institutional governmental purchasers ii judicial decision governmental law regulation relate medicare medicaid healthcare reform include medicare prescription drug improvement modernization act iii potential impact importation restriction legislative pharmaceutical reimbursement medicare formularie product pricing general reliance party company rely vendor partner party meet contractual regulatory obligation relation arrangement company economic factor company expose change interest rate fluctuation foreign currency exchange rate economic factor company control execution company strategy company able fully execute strategic transformation business attain new period sustainable revenue earning growth company continue invest growth driver pipeline focus address area significant unmet medical need failure realize additional cost saving successfully transition product portfolio materially adversely affect company result operationschange company structure operation revenue cost staff efficiency result acquisition divestiture merger alliance restructuring strategic initiative result great expect cost difficulty include need regulatory approval appropriate spending change advertise promotional spend category spending affect sale information technology company increasingly dependent information technology system significant breakdown invasion destruction interruption system negatively impact operation company believe prudent plan assumption assurance give goal plan set forth forward look statement achieve reader caution place undue reliance statement speak date company undertake obligation release publicly revision forwardlooke statement result new information future event item b unresolved staff comment item property company world headquarter locate park avenue new york new york lease approximately square foot floor space approximately square foot sublet company manufacture product major worldwide location aggregate floor space approximately million square foot facility own company follow table illustrate geographic location company significant manufacturing facility business segment total company pharmaceutical nutritional health care united states europe middle east africa western hemisphere pacific total portion facility facility own lease company united states research administration storage distribution information company facility item businessmanufacture quality assurance item legal proceeding information pertain legal proceeding find item financial statementsnote legal proceeding contingency incorporate reference item submission matter vote security holder matter submit vote security holder fourth quarter year end december ia executive officer registrant list information executive officer company march executive officer elect board director initial term continue board meeting follow annual meeting stockholder elect oneyear term successor elect executive officer serve pleasure board director current position age employment history past year lamberto andreotti president europe worldwide medicine group division executive vice president president company worldwide pharmaceutical senior vice president president international worldwide member executive committee medicine group division company present executive vice president president worldwide pharmaceutical division company stephen e bear vice president marketing business development senior vice president human resources new york botanical gardens nonprofit organization corporate staff present senior vice president human resource corporate staff member executive committee company andrew g bodnar md vice president medical external affair corporate staff senior vice president strategy company medical external affair corporate staff senior vice president medical external affair member executive committee corporate staff company present senior vice president strategy medical external affair corporate staff company andrew r j bonfield executive director finance bg group plc chief financial officer present chief financial officer corporate staff company corporate staff member executive committee joseph c caldarella vice president finance pharmaceutical research institute vice president corporate controller division company corporate staff present vice president corporate controller corporate staff company john e celentano vice president general manager northern europe president health care group international medicine division company member executive committee senior vice president operation plan worldwide medicine group division company president canada mexico puerto rico worldwide medicine group division company president latin america canada worldwide medicine group division company present president health care group division company carlo de notaristefani cirm vice president io international aventis pharma president technical operations vice president io international latin america japan member executive committee aventis pharma senior vice president global finishing solid aventis pharma president pharmaceutical grouptechnical operation division company present president technical operation division company wendy l dixon phd vice president marketing merck co chief marketing officer president global marketing senior vice president merck co member executive committee present chief marketing officer president global marketing worldwide medicine group division company peter r dolan president director company chief executive officer chairman board chief executive officer member executive committee company present chief executive officer director company edward dwyer vice president treasurer att vice president treasurer corporate staff present vice president treasurer corporate staff company anthony c hooper president asiapacific middle east southern africa president pharmaceutical international medicine division company member executive committee president intercontinental international medicine division company president europe middle east africa worldwide medicine group division company present president pharmaceuticals worldwide medicine group division company tamar howson biotechnology consultant chief executive officer senior vice president corporate business development corporate staff business executive member executive committee present senior vice president corporate business development corporate staff company sandra leung corporate secretary corporate staff company vice president corporate secretary present vice president corporate secretary corporate staff corporate staff company john l mcgoldrick executive vice president general counsel corporate staff executive vice president corporate staff company president medical devices group division member executive committee company executive vice president general counsel corporate staff company present executive vice president corporate staff company elliott sigal md phd senior vice president early discovery apply chief scientific officer president technology pharmaceutical research institute division company pharmaceutical research institute senior vice president drug discovery exploratory member executive committee development pharmaceutical research institute division company senior vice president global clinical pharmaceutical development pharmaceutical research institute division company present chief scientific officer president pharmaceutical research institute division company richard k willard senior vice president general counsel gillette senior vice president general counsel company corporate staff present senior vice president general counsel corporate staff member executive committee company richard l wolgemuth phd vice president cedd global regulatory affair senior vice president global regulatory sciences glaxosmithkline member executive committee present senior vice president global regulatory science pharmaceutical research institute division company david l zabor vice president finance technical operation worldwide vice president strategic business initiative medicine group division company corporate staff vice president financial analysis corporate staff member executive committee company vice president acting controller corporate staff company vice president controller corporate staff company vice president operation controller corporate staff company vice president financial operation controller corporate staff company present vice president strategic business initiative corporate staff company robert zito executive vice president communications new york stock senior vice president corporate business exchange communication chief communication officer present senior vice president corporate affairs corporate staff member executive committee company ii item market registrant common stock stockholder matter market price bristolmyer squibb common preferred stock trade new york stock exchange pacific exchange inc symbol bmy bmypr quarterly summary high low market price present common high low high low quarter second quarter quarter fourth quarter prefer high low high low quarter second quarter quarter fourth quarter second quarter second fourth quarter trades companys prefer stock prefer stock pay quarterly dividend share holder common stock number record holder common stock december number record holder base actual number holder register book company date include holder share street name person partnership association corporation entity identify security position listing maintain depository trust company vote security principal holder reference proxy statement file march respect vote security principal holder incorporate reference hereof response information require item dividend dividend declare share common prefer quarter second quarter quarter fourth quarter december board director company declare quarterly dividend share common stock company pay february shareholders record january unregistere sale equity security use proceed follow table summarize surrender company equity security connection stock option restrict stock program twelvemonth period end december total number approximate dollar share purchase value share publicly purchase total number average price announce plan plan period share purchaseda pay sharea programsb programsb dollar million share datum january february march month end march april june month end june july august september month end september october november december month end december month end december reflect follow transaction month end december deem surrender company share common stock pay exercise price satisfy tax withholding obligation connection exercise employee stock option ii surrender company share common stock satisfy tax withholding obligation connection vest restricted stock issue employee b june company announce board director authorize purchase billion company common stock month end december share repurchase pursuant program purchase share program expect item select financial datum fiveyear financial summary amount million share datum income statement datum net sale earning continue operation minority interest income taxis earning continue operation earning continue operation common share basic diluted average common share outstanding basic dilute dividend pay common prefer stock dividend declare common share financial position datum december total asset cash cash equivalent marketable security longterm debt stockholder equity company record item affect comparability result set forth table item management discussion analysis financial condition result operationsexpense year discussion item item management discussion analysis financial condition result operationsexpense item financial statementsnote alliance investment note restructure item note acquisition divestiture note discontinued operation note legal proceeding contingency exclude discontinue operation otn year clairol zimmer include discontinue operation year item management discussion analysis financial condition result operation executive summary company bristolmyer squibb company bms company bristolmyer squibb worldwide pharmaceutical relate health care product company mission extend enhance human life provide high quality pharmaceutical relate health care product company engage discovery development licensing manufacturing marketing distribution sale pharmaceutical relate health care product company reportable segmentspharmaceutical nutritional health care pharmaceutical segment global pharmaceutical international consumer medicine business nutritional segment consist mead johnson nutritionals mead johnson primarily infant formula children nutritional business health care segment consist convatec medical imaging consumer medicine canada business quarter company complete sale consumer medicine business nutritional health care segment collectively know health care group additional information segment item financial statementsnote segment information business environment company conduct business primarily pharmaceutical industry highly competitive subject numerous government regulation competitive factor significantly affect company sale product include product efficacy safety price costeffectiveness marketing effectiveness product label quality control quality assurance manufacturing operation research development new product successfully compete business health care industry company demonstrate product offer medical benefit cost advantage currently company new product introduction compete product market therapeutic category company manufacture brand product price high generic product generic competition company lead challenge globally pharmaceutical industry majority innovative product commercial value usually realize period product market exclusivity product lose exclusivity long protect patent subject new compete product form generic brand exclusivity loss product company lose major portion product sale short period time discussion product exclusivity item businessintellectual property product exclusivity internationally health care industry subject governmentimposed regulation authorize price price control continue impact company sale congress state legislature consider number proposal enact law effect major change health care system nationally state level drive budget concern medicaid access reimbursement restriction implement state propose addition december medicare prescription drug improvement modernization act mma enact provide outpatient prescription drug coverage senior citizen united states mma effective january company predict potential impact legislation business negative impact company pharmaceutical business great federal involvement budget constraint increase likelihood pricing pressure control future market outside united states company operate environment governmentmandate costcontainment program regulatory regime exert downward pressure pricing pricing freedom limited united kingdom instance operation profit control plan germany operation reference price system company face significant delay market access new product year elapse new medicine available national market growth manage care organization mcos play large role competition surround health care industry mco seek reduce health care expenditure participant make volume purchase enter longterm contract negotiate discount pharmaceutical provider market potential create large pool participant marketing prescription drug mcos important company strategy company compete inclusion mco formulary company generally successful major product include company believe development manage care industry include continued consolidation continue generally downward pressure price pharmaceutical production process complex highly regulate vary widely product product shift add manufacturing capacity lengthy process require significant capital expenditure regulatory approval biologic manufacturing involve complex process traditional pharmaceutical operation biologic important company product portfolio company continue arrangement party manufacturer expect substantial investment increase internal capacity produce biologic commercial scale company maintain competitive position market strive uphold position dependent success discover develop innovative costeffective product serve unmet medical need company subsidiary subject number significant pende lawsuit claim proceeding investigation possible time reasonably assess final outcome investigation litigation management continue believe previously disclose year aggregate impact current reserve legal matter affect company reasonably likely material company result operation cash flow material financial condition liquidity additional discussion legal matter item financial statement supplementary datanote legal proceeding contingency strategy company continue execute strategy long term growth currently track complete strategic transition attain period sustainable sale earning growth start strategy consist increase investment growth driver focus company research development program product pharmaceutical pipeline disease area address significant unmet medical need align sale marketing emphasis specialist high value primary care prescriber implement initiative design achieve maintain efficient cost base company process transform pharmaceutical portfolio favor growth driver specialty product include plavix avaproavalide abilify reyataz erbitux baraclude net sale product account company worldwide pharmaceutical net sale compare worldwide net sale product account company worldwide net sale compare december food drug administration fda approve orencia abatacept commercially available february orencia target initially adult patient moderate severe rheumatoid arthritis inadequate response certain currently available treatment marketing authorization application maa submit product european medicine evaluation agency emea january supplemental biologics license application sbla file fda approval thirdparty manufacturing facility support increase production capacity orencia sbla company plan engage thirdparty manufacture arrangement meet future commercial demand expect generate approval commercialization variety biologic december company complete submission new drug application nda fda dasatinib kinase inhibitor potential treatment chronic myelogenous leukemia cml march nda accept grant priority review accelerate approval january company submit maa dasatinib emea october fda advisory committee recommend emsam transdermal patch treatment adult major despressive disorder safely administer dietary modification mg hour dose february fda approve emsam use dietary modification low dose mg hour keep strategy company invest billion research development represent growth rate research development dedicated pharmaceutical product include milestone payment inlicense development program billion pharmaceutical sale compare billion pharmaceutical sale major aspect company strategy relate business specifically market sale approach specialist play great role decision relate patient treatment care particularly critical disease area company focus effort company realign european sale force focus specialist primary care physician involve treat patient disease area strategy company reexamine operating cost achieve maintain efficient cost base end company launch initiative identify realize productivity saving initiative company reexamine operating model focus resource high value priority simplify streamline business process governance decision make build capability sustain cost reduction long term company goal realize minimum million productivity saving incremental million implement last change company productive efficient effective result operation follow discussion company result continue operation exclude result relate oncology therapeutic network otn business previously present separate segment segregate continue operation reflect discontinued operation period present discontinued operation change dollar million net sale earning continue operation minority interest income taxis net sale provision income taxis effective tax rate earning continue operation net sale net sale net sale continue operation decrease billion compare net sale decrease billion compare international net sale billion remain relatively constant compare include favorable foreign exchange impact net sale continue operation increase billion billion net sale remain relatively constant billion compare international net sale increase billion include favorable foreign exchange impact billion composition change sale follow analysis change foreign total change volume price exchange vs vs general company business seasonal information pharmaceutical prescriber demand reference table business segment pharmaceutical section set forth comparison change net sale estimate total prescription growth retail mail order customer certain company pharmaceutical product company operate reportable segmentspharmaceutical nutritional health care company complete sale otn previously present separate segment result operation otn present company result discontinue operation accordance statement financial standard sfas accounting impairment disposal longlive asset accordingly otn result operation prior period reclassify discontinued operation conform current year presentation percent company net sale segment follow net sale change dollar million pharmaceutical net sale nutritional net sale health care net sale total company recognize revenue net sale adjustment arrive net sale report consolidated statement earning adjustment refer grosstonet sale adjustment describe critical accounting policy follow table set forth reconciliation company gross sale net sale significant category grosstonet sale adjustment year end december dollar millions gross sale grosstonet sale adjustment prime vendor chargebacks woman infant child wic rebate manage health care rebate contract discount medicaid rebate cash discount sale return adjustment total grosstonet sale adjustment net sale decrease prime vendor chargeback manage health care rebate primarily low relative sale volume segment product mix decrease sale return primarily low return certain product include tequin pravachol sustiva decrease adjustment low sale discount government rebate international business increase prime vendor chargeback medicaid rebate primarily shift sale product high discount prime vendor medicaid program decrease sale return primarily attributable high sale return result discontinued product product conversion follow table set forth activity end balance significant category grosstonet sale adjustment manage woman health care prime infant rebate vendor child charge wic contract medicaid cash dollar million back rebate discount rebate discount sale return adjustment total balance december provision relate sale current period provision relate sale prior period return payment impact foreign currency translation balance december provision relate sale current period provision relate sale prior period return payment impact foreign currency translation balance december company record grosstonet sale adjust charge credit relate sale prior period significant item include charge million medicaid rebate primarily result higher expect medicaid utilization product credit million adjustment primarily result lower expect rebate foreign government credit million sale return result low return certain product include tequin avaproavalide plavix company record charge million medicaid rebate relate sale prior period charge include million rebate claim prior year certain state primarily relation medicaid utilization oncology product previously report company revision result availability additional information addition company record million adjustment result low expect rebate foreign government significant revision estimate grosstonet sale adjustment pharmaceutical composition change pharmaceutical sale follow analysis change foreign total change volume price exchange vs vs worldwide pharmaceutical sale decrease million pharmaceutical sale decrease million compare million primarily continued impact exclusivity loss paraplatin glucophage franchise increase competition pravachol partially offset increase sale growth driver include plavix abilify erbitux reyataz aggregate estimate wholesaler inventory level company key pharmaceutical product sell pharmaceutical business end end approximately threetenth month approximately half week decline inventory level negatively impact sale performance certain product international pharmaceutical sale decrease include favorable foreign exchange impact million primarily increase generic competition pravachol taxolpaclitaxel partially offset increase sale new product include reyataz ablilfy growth plavix worldwide pharmaceutical sale increase million pharmaceutical sale remain constant million compare million sale negatively affect increase competition pravachol exclusivity loss paraplatin glucophage franchise offset increase sale plavix new product include abilify reyataz erbitux international pharmaceutical sale increase million include favorable foreign exchange impact primarily generic competition pravachol taxolpaclitaxel partially offset launches abilify reyataz continue growth plavix avaproavalide key pharmaceutical product sale represent total pharmaceutical sale respectively follow change dollar millions cardiovascular plavix pravachol avaproavalide coumadin monopril virology reyataz sustiva zerit videxvidex ec baraclude infectious disease cefzil oncology taxol paclitaxel erbitux paraplatin affective psychiatric disorder abilify total revenue metabolic glucophage franchise pharmaceutical efferalgan change excess sale plavix platelet aggregation inhibitor sell company primarily increase include favorable foreign exchange impact million primarily prescription growth approximately market rate growth reflect deceleration growth rate plavix sale compare growth rate include favorable foreign exchange impact primarily prescription growth company seek enhance growth rate measure include expansion relate direct consumer dtc campaign recentlyfile snda result commit clarity trial assurance effort successful sale million sale million plavix cardiovascular product launch alliance company sanofiaventis sanofi market exclusivity plavix expect expire european union eu statement exclusivity subject adverse determination occur respect plavix patent litigation additional information plavix patent litigation item financial statementsnote legal proceeding contingency sale pravachol hmg coa reductase inhibitor decrease million sale decrease million primarily low demand result increase competition relate reduction wholesaler inventory level partially offset lower manage health care rebate estimate prescription decline approximately compare international sale decrease include favorable foreign exchange impact million reflect generic competition key european market sale pravachol decrease include favorable foreign exchange impact million million primarily decrease prescription demand approximately exclusivity loss select european market include germany uk company enter distribution agreement watson pharmaceutical watson authorize watson distribute pravastatin sodium tablet market exclusivity protection pravachol expected expire april market exclusivity eu expire exception france sweden expiration occur august march respectively italy expiration occur january sale avaproavalide angiotensin ii receptor blocker treatment hypertension sanofi alliance increase include favorable foreign exchange impact million sale increase million compare primarily increase demand partially offset reduction wholesaler inventory level estimate total prescription demand increase approximately compare international sale increase include favorable foreign exchange impact million million primarily increase sale canada france germany sale increase include favorable foreign exchange impact million million primarily increase sale europe strong prescription growth approximately sale increase million compare million international sale increase include favorable foreign exchange impact million million market exclusivity avaproavalide know eu aprovelkarvea expect expire country eu avaproavalide currently market japan sale coumadin oral anticoagulant predominantly patient atrial fibrillation deep venous thrombosispulmonary embolism decrease million compare sale continued competition estimate total prescription demand decrease approximately compare sale decrease million million increase generic competition market exclusivity coumadin expire sale monopril second generation angiotesin convert enzyme ace inhibitor treatment hypertension decrease include favorable foreign exchange impact million increase generic competition key european market sale million decrease include favorable foreign exchange impact million impact market exclusivity loss market exclusivity protection monopril expire expire expect expire country eu monopril currently market japan sale reyataz protease inhibitor treatment human immunodeficiency virus hiv launch quarter europe second quarter increase million primarily increase demand european sale increase million million reyataz achieve estimate monthly new prescription share protease inhibitor market approximately sale million compare million market exclusivity reyataz expect expire country eu japan sales sustiva nonnucleoside reverse transcriptase inhibitor treatment hiv increase million primarily estimate total prescription growth approximately high average selling price low sale return sustiva sale increase include favorable foreign exchange impact million million primarily increase demand high price market exclusivity protection sustiva expect expire country eu company market sustiva japan sales zerit antiretroviral agent treatment hiv decrease include favorable foreign exchange impact million primarily result decrease estimate total prescription approximately compare zerit sale decrease include favorable foreign exchange impact million million primarily result continue decrease demand potential adverse effect market exclusivity protection zerit expect expire country eu japan sales videxvidex ec antiretroviral agent treatment hiv decrease million primarily generic competition begin fourth quarter videxvidex ec sale increase include favorable foreign exchange impact million million increase sale europe partially offset sale decline company license arrangement government videxvidex ec term nonexclusive government intellectual property protection expire include earn pediatric extension japan countries eu license company nonexclusive allow company obtain license government receive approval marketing respect videxvidex ec company patent cover reduce mass formulation videxvidex ec expire eu japan patent apply type reduce mass formulation specify patent reduce mass formulation exist currently issue patent covering videx ec formulation baraclude company internally develop oral antiviral agent treatment chronic hepatitis b approve fda march generate sale million primarily launch april baraclude receive approval international authority include china mexico brazil indonesia argentina second half company believe primary market baraclude outside company composition matter patent expire sale cefzil antibiotic treatment mild moderately severe bacterial infection decrease include favorable foreign exchange impact million primarily low demand cefzil sale decrease include favorable foreign exchange impact million million primarily decreased demand partially offset high international sale market exclusivity expire december expect expire eu sales taxol paclitaxel anticancer agent sell exclusively nonus market million compare million sale taxol paclitaxel decrease include favorable foreign exchange impact primarily result increase generic competition europe generic competition taxol paclitaxel majority major european market begin second quarter increase second half taxol paclitaxel sale increase include favorable foreign exchange impact million million primarily generic competition europe market exclusivity protection taxol paclitaxel expire eu expect expire japan erbitux treat refractory metastatic colorectal cancer approve fda february sales erbitux sell exclusively increase million compare million erbitux market company distribution copromotion agreement imclone system incorporate imclone patent relate combination therapy erbitux expire company right market erbitux north america japan expire september company market erbitux country eu sales paraplatin anticancer agent decrease million generic competition begin mid increase entry multiple generic competitor fourth quarter sale paraplatin decrease million paraplatin sale decrease include favorable foreign exchange impact million million primarily generic competition market exclusivity protection paraplatin expire october eu japan total revenue abilify antipsychotic agent treatment schizophrenia acute bipolar mania bipolar disorder increase million primarily demand growth continued growth europe achieve sale million estimate prescription demand grow approximately compare partially offset reduction wholesaler inventory level sale growth future impact trend involve overall decrease rate growth demand antipsychotic agent total revenue abilify million compare million total revenue abilify primarily consist alliance revenue represent company share net sale copromotion country otsuka pharmaceutical co ltd otsuka otsukas market exclusivity protection abilify expect expire include grant patent term extension company right copromote abilify european country united kingdom france germany spain act exclusive distributor product rest eu market exclusivity protection abilify expect expire eu extend pende supplemental protection certificate grant company contractual right market abilify expire november puerto rico country eu company exclusive right market abilify june statement exclusivity subject adverse determination occur respect abilify patent reexamination additional information matter item financial statementsnote legal proceeding contingency additional information revenue recognition abilify item financial statementsnote alliance investment sale glucophage franchise decrease million compare decrease million million decrease sale primarily result increase generic competition market exclusivity protection expire march glucophage ir october glucophage xr january glucovance company market product eu japan sales efferalgan formulation acetaminophen pain relief increase include favorable foreign exchange impact million primarily increase sale italy spain result strong flu season sale increase include favorable foreign exchange impact million million estimate prescription prescription growth datum provide include information retail mail order channel reflect information channel hospital institution longterm care estimate prescription prescription growth datum base national prescription audit npa datum provide ims health im supplier market research pharmaceutical industry describe instance basic exclusivity loss date indicate expiration date patent claim active ingredient drug method drug approve indication instance basic exclusivity loss date indicate expiration date datum exclusivity period situation datum exclusivity patent protection competitor seek regulatory approval prior expiration datum exclusivity period submit clinical trial datum obtain marketing approval company assess market exclusivity period product case bycase basis length market exclusivity company product difficult predict certainty complex interaction patent regulatory form exclusivity factor assurance particular product enjoy market exclusivity period time company currently anticipate estimate market exclusivitie report business planning purpose intend reflect company legal opinion strength weakness particular patent legal position discussion market exclusivity protection include chart show net sale key product year basic exclusivity loss occur expect occur eu japan item businessproduct intellectual property product exclusivity estimate endus demand follow table set forth company pharmaceutical product sell pharmaceutical business base annual net sale year end december compare period prior year change report net sale period b estimate total prescription growth retail mail order channel estimate therapeutic category share applicable product calculate company base npa datum provide im c estimate total prescription growth retail mail order channel estimate therapeutic category share applicable product calculate company base nextgeneration prescription service ngps datum provide im year end month end december december change estimate trx total prescription therapeutic category share e change net sale npa datum b ngps datum c npa datum b ngps datum c abilify total revenue avaproavalide cefzil coumadin dovonex erbitux na na na na glucophage franchise paraplatin na na na na plavix pravachol reyataz sustiva tequin videxvidex ec zerit year end month end december december change estimate trx total prescription therapeutic category share e change net sale npa datum b ngps datum c npa datum b ngps datum c abilify total revenue avaproavalide cefzil coumadin dovonex erbitux na na na na glucophage franchise paraplatin na na na na plavix pravachol reyataz sustiva tequin videxvidex ec zerit year end month end december december change estimate trx total prescription therapeutic category share e change net sale npa datum b ngps datum c npa datum b ngps datum c abilify total revenue avaproavalide cefzil coumadin dovonex erbitux na na na na glucophage franchise paraplatin na na na na plavix pravachol reyataz sustiva tequin videxvidex ec zerit reflect percentage change net sale dollar term include change average selling price wholesaler buy pattern b base simple average estimate number prescription retail mail order channel provide ims c base weighted average estimate number prescription unit pill retail mail order channel base datum provide ims erbitux paraplatin specifically parenterally administer oncology product general prescriptionlevel datum physician write prescription product company believe therapeutic category share information provide party product reliable accordingly present e therapeutic category determine company product consider direct competition company product product list compete follow therapeutic category abilify antipsychotic avaproavalide angiotensin receptor blocker cefzil brand oral solid liquid antibiotic coumadin warfarin dovonex anti inflamatoryantipsoriasis glucophage franchise oral antidiabetic plavix antiplatelet agent pravachol hmg coa reductase inhibitor reyataz protease inhibitor sustiva antiretroviral agent tequin brand oral solid antibiotic videxvidex ec nucleoside reverse transcriptase inhibitor zerit nucleoside reverse transcriptase inhibitor excess datum available section omit company historically report estimate total prescription growth estimate therapeutic category share base npa datum ims make available public subscription basis simple average estimate number prescription retail mail order channel quarter company begin disclose estimate total prescription growth estimate therapeutic category share base npa ngps datum ngps datum collect ims new revise methodology release ims limited basis pilot program im publicly announce expect ngps datum available public subscription basis company believe ngps datum provide im provide superior estimate prescription data company product retail mail order channel company calculate estimate total prescription growth estimate therapeutic category share base ngps datum weight average basis reflect fact mail order prescription include great volume product supply compare retail prescription company believe calculation estimate total prescription growth estimate therapeutic category share base ngps datum weight average approach respect retail mail order channel provide superior estimate total prescription demand company use methodology internal demand forecast estimate prescription growth datum estimate therapeutic category share provide include information retail mail order channel reflect information channel hospital institution longterm care datum provide im product imss recordkeeping process estimate base sampling procedure subject inherent limitation estimate base sampling addition ngps datum pilot program refine ims company continuously seeks improve quality estimate prescription growth amount therapeutic category share percentage ultimate patientconsumer demand review methodology process calculation estimate review analysis party datum calculation company expect continue review refine methodology process calculation estimate continue review analyze party datum calculation follow table set forth company key pharmaceutical product sell company international pharmaceutical reporting segment include pharmaceutical product sell company major nonus country base net sale key product sell report segment list percentage change company estimate ultimate patientconsumer demand month december compare month september month september compare month june month june compare month march change demand constant dollar basis december september june vs september vs june vs march international pharmaceutical abilify total revenue avaproavalide bufferin capoten dafalgan efferalgan maxipime monopril paraplatin perfalgan plavix pravachol reyataz sustiva taxol paclitaxel videxvidex ec zerit nutritional enfamil nutramigen health care convatec ostomy wound therapeutic medical imaging cardiolite consumer medicine excedrin na na estimate inventory month hand distribution channel follow table set forth company pharmaceutical product sell company pharmaceutical business base annual net sale pharmaceutical net sale applicable product quarter end september december estimate number month hand applicable product wholesaler distribution channel end quarter december september june net sale month net sale month net sale month dollar millions hand dollar millions hand dollar millions hand abilify total revenue avaproavalide cefzil coumadin dovonex erbitux glucophage franchise paraplatin plavix pravachol reyataz sustiva tequin videxvidex ec zerit march december september net sale month net sale month net sale month dollar millions hand dollar millions hand dollar millions hand abilify total revenue avaproavalide cefzil coumadin dovonex erbitux glucophage franchise paraplatin plavix pravachol reyataz sustiva tequin videxvidex ec zerit month hand december estimate value cefzil inventory wholesaler distribution channel exceed month hand approximately million prescription cefzil antibiotic typically high winter month result company wholesaler build high inventory product fourth quarter meet expect high demand march company work wholesaler inventory level cefzil month hand remain month hand subsequent quarter december estimate value glucophage franchise product inventory glucophage xr glucophage ir glucovance metaglip wholesaler distribution channel exceed month hand approximately million product month hand estimate glucophage franchise product average month hand stockkeepe unit skus product group increase month hand glucophage franchise product end fourth quarter month hand result primarily purchase wholesaler certain sku give effect purchase increase month hand skus month hand increase month hand sku average skus glucophage franchise product aggregate estimate month hand exceed month march estimate value glucophage franchise product inventory wholesaler distribution channel work approximately month hand work remain month hand subsequent quarter october pediatric exclusivity period paraplatin carboplatin expired result entry multiple generic competitor paraplatin lead significant decrease demand paraplatin turn lead month hand product wholesaler distribution channel exceed month september december september estimate value paraplatin inventory wholesaler distribution channel month hand approximately million september million december million september time company continue monitor paraplatin sale intention work wholesaler inventory level month hand december company work wholesaler inventory level paraplatin month hand march september estimate value videxvidex ec inventory wholesaler distribution channel exceed month hand approximately million million respectively result generic competition commence fourth quarter demand videxvidex ec decrease significantly time company continue monitor videxvidex ec sale intention work wholesaler inventory level month hand december company work wholesaler inventory level videxvidex ec month hand product erbitux company determine month hand estimate divide estimate product wholesaler distribution channel estimate outmovement product wholesaler distribution channel period day calculate describe factor influence company estimate include generic competition seasonality product wholesaler purchase light increase wholesaler list price new product launch new warehouse opening wholesaler new customer stocking wholesaler addition estimate calculate party datum represent recordkeeping process reflect estimate company maintain inventory management agreement imas pharmaceutical wholesaler account nearly total gross sale pharmaceutical product current term ima company large wholesaler customer provide company weekly information respect inventory level product hand outmovement product wholesaler currently account total gross sale pharmaceutical product inventory information receive wholesaler exclude inventory hold intermediary sell retailer hospital exclude good transit wholesaler company use information provide wholesaler friday close quarter end calculate inventory hand wholesaler applicable quarter end increase company estimate good transit wholesaler applicable friday reflect weekly datum provide wholesaler company revenue recognition policy sale record substantially risk reward ownership transfer pharmaceutical business generally product ship case good transit wholesaler own applicable wholesaler accordingly reflect calculation inventory wholesaler distribution channel company estimate good transit information provide wholesaler respect open order applicable friday company record sale wholesaler respect open order company determine outmovement product wholesaler period day recent week outmovement product provide wholesaler extrapolate day basis company estimate inventory level hand outmovement pharmaceutical businesss wholesaler customer large wholesaler product base assumption amount bear relationship large wholesaler inventory level outmovement product percentage aggregate sale product wholesaler applicable quarter bear aggregate sale product company large wholesaler quarter finally company consider adjustment necessary extrapolate amount base factor historical sale individual product wholesaler thirdparty market research datum relate prescription trend patient demand addition company receive inventory information wholesaler selective basis certain key product company pharmaceutical business ima discuss arrangement substantially direct wholesaler customer allow company monitor wholesaler inventory level require wholesaler maintain inventory level approximately month demand second quarter company negotiate amendment ima large wholesaler amendment extend original agreement december establish low limit original agreement inventory level company pharmaceutical product hold wholesaler december company reach year ima principle large wholesaler provide low limit wholesaler inventory level m extension previously negotiate help maintain product quality company biologic oncology product erbitux product ship enduser intermediary wholesaler hold later sale company wholesaler provide warehousing packing shipping service erbitux wholesaler hold erbitux inventory consignment company revenue recognition policy company recognize revenue inventory ship wholesaler enduser estimate month hand month end march calculate dividing inventory erbitux hold wholesaler account report wholesaler end quarter company net sale calendar month quarter inventory level report wholesaler product wholesaler recordkeeping process divestiture otn company discontinue consignment arrangement wholesaler erbitux consignment inventory follow divestiture company sell erbitux intermediary specialty oncology distributor ship erbitux directly end user product customer intermediary company recognize revenue shipment consistent revenue recognition policy accordingly subsequent june erbitux inventory hold wholesaler previously disclose company pharmaceutical business outside united states nutritional health care business unit world company significantly direct customer limit information direct customer product level inventory correspond outmovement information reliability party demand information available vary widely accordingly company rely variety method estimate direct customer product level inventory calculate month hand business unit follow table post company website furnish form k set forth company key product sell report segment list net sale applicable product quarter end march december estimate number month hand applicable product direct customer distribution channel reporting segment end quarter estimate month hand key product describe international pharmaceutical reporting segment base datum collect company significant business unit outside united states describe information nonkey product inventory hand direct customer approximately month impact de minimis reporting segment estimate base datum collect united states significant business unit outside united states december september net sale month net sale month dollar millions hand dollar millions hand international pharmaceutical abilify total revenue avaproavalide bufferin capoten dafalgan efferalgan maxipime monopril paraplatin perfalgan plavix pravachol reyataz sustiva taxol paclitaxel videxvidex ec zerit nutritional enfamil nutramigen health care convatec ostomy wound therapeutic medical imaging cardiolite consumer medicine excedrin na na na june march net sale month net sale month dollar millions hand dollar millions hand international pharmaceutical abilify total revenue avaproavalide bufferin capoten dafalgan efferalgan maxipime monopril paraplatin perfalgan plavix pravachol reyataz sustiva taxol paclitaxel videxvidex ec zerit nutritional enfamil nutramigen health care convatec ostomy wound therapeutic medical imaging cardiolite consumer medicine excedrin month hand information represent company estimate aggregate product level inventory hand direct customer divide expect demand applicable product expect demand estimate ultimate patientconsumer demand calculate base estimate endus consumption direct customer outmovement datum recent day period reasonable period factor affect company estimate include generic competition seasonality product direct customer purchase light price increase new product launch new warehouse opening direct customer new customer stocking direct customer expect direct customer purchase governmental bidding situation company rely variety method calculate month hand report segment available company rely information provide party determine estimate aggregate product level inventory hand direct customer expect demand report segment list company limited information direct customer product level inventory endus consumption direct customer outmovement data quality party information available vary widely circumstance case new product seasonal product historical endus consumption outmovement information available applicable case company use estimate prospective demand case direct customer product level inventory ultimate patientconsumer demand outmovement datum exist available company develop variety methodology calculate estimate datum include factor historical sale direct customer party market research datum relate prescription trend endus demand december september march dafalgan analgesic product sell principally europe approximately month inventory hand respectively direct customer level inventory hand primarily private pharmacist purchase dafalgan approximately week seasonality product september efferalgan analgesic product sell principally europe approximately month inventory hand direct customer level inventory hand primarily private pharmacist purchase efferalgan approximately week seasonality product december september nutramigen prosobee infant nutritional product sell principally united states approximately month inventory hand direct customer level inventory hand end december primarily holiday stocking retailer end september primarily impact retailer hold high level inventory response hurricane katrina company plan continue monitor sale nutramigen prosobee intention work wholesaler inventory level month hand june march excedrin analgesic product sell principally approximately month month respectively inventory hand direct customer level inventory hand customary practice direct customer hold warehouse store onehalf month product hand inventory hand percentage change demand datum month september respectively available excedrin include quarter sale company consumer medicine business company continuously seeks improve quality estimate month hand inventory hold direct customer include thorough review methodology process calculation estimate review analysis party datum calculation company expect continue review refine methodology process calculation estimate continue review analyze party data calculation company continue step expedite receipt processing datum non pharmaceuticals business health care group nutritional composition change nutritional sale follow analysis change total change volume price foreign exchange vs vs key nutritional product line sale represent total nutritional sale respectively follow change dollar million infant formula enfamil toddlerchildren nutritional worldwide nutritional sale increase include favorable foreign exchange impact unfavorable impact divestiture adult nutritional business million worldwide nutritional sale million decrease include unfavorable impact divestiture adult nutritional business million quarter company divest adult nutritional business international sale increase include favorable foreign exchange impact unfavorable impact divestiture adult nutritional business million primarily increase sale enfamil enfagrow toddler children nutritional product international sale increase include unfavorable impact divestiture adult nutritional business million million primarily increase sale infant formula children nutritional product sale increase include unfavorable impact divestiture adult nutritional business million primarily increase sale enfamil sale decrease include unfavorable impact divestiture adult nutritional business million million sale enfamil company bestselle infant formula increase include favorable foreign exchange impact million primarily strong sale growth launch enfamil gentlease lipil infant formula august enfamil sale increase include favorable foreign exchange impact million million primarily increase international sale health care health care segment include convatec medical imaging business composition change health care segment sale follow analysis change total change volume price foreign exchange vs vs health care sale business key product year end december follow change dollar millions convatec ostomy wound therapeutic medical imaging cardiolite consumer medicine worldwide convatec sale increase include favorable foreign exchange impact million primarily increase worldwide sale wound therapeutic product sale wound therapeutic product increase include favorable foreign exchange impact million million primarily increase sale aquacel ostomy sale remain constant million include favorable foreign exchange impact convatec sale increase include favorable foreign exchange impact million million primarily increase worldwide sale wound therapeutic product worldwide medical imaging sale increase million sale cardiolite kit preparation technetium tcm sestamibi injection increase million million primarily increase demand medical imaging sale increase include favorable foreign exchange impact million million drive increase sale cardiolite increase partially change time revenue recognition result new distribution agreement enter january geographic area general company product available country world large market united states france japan spain canada italy germany mexico company sale geographic area follow change dollar millions united states total europe middle east africa total western hemisphere total pacific total total sale united states decrease result low sale paraplatin glucophage franchise continue impact early exclusivity loss pravachol low demand result increase competition decrease sale offset increase sale growth driver include plavix abilify erbitux reyataz strong sale growth enfamil sale united states remain constant growth prescription demand key brand include plavix avaproavalide sustiva new product include abilify reyataz erbitux offset low sale product result exclusivity loss monopril paraplatin glucophage franchise sale europe middle east africa decrease include favorable foreign exchange impact result sale decline taxol paclitaxel increase generic competition pravachol exclusivity loss select market include uk netherlands decrease sale partially offset increase sale major european market reyataz abilify launch europe second quarter sale increase include favorable foreign exchange impact result sale decline pravachol exclusivity loss select market include germany uk taxol paclitaxel generic competition majority major european market begin second quarter decrease sale offset increase sale plavix germany spain avaproavalide italy spain sustiva majority major market sale western hemisphere country increase include favorable foreign exchange impact primarily increase sale plavix canada mexico reyataz brazil canada avaproavalide canada sale increase include favorable foreign exchange impact primarily increase sale plavix avaproavalide canada sales pacific region increase result increase sale taxol paclitaxel japan enfagrow enfamil china sale increase include favorable foreign exchange impact result increase sale taxol paclitaxel paraplatin japan plavix avaproavalide australia expense change dollar million cost product sell net sale marketing sell administrative net sale advertising product promotion net sale research development net sale acquire inprocess research development net sale provision restructure net net sale litigation charge net net sale gain sale business net sale equity net income affiliate net sale expense net net sale total expense net net sale change excess cost product sell percentage sale unfavorable impact gross margin result change pharmaceutical sale mix offset million net litigation charge record increase unfavorable impact pharmaceutical sale mix impact generic competition gluchophage franchise paraplatin launch low margin erbitux partially offset sale growth abilify reyataz plavix gross margin negatively impact million net litigation charge higher accelerated depreciation charge compare marketing selling administrative expense percentage sale marketing sell administrative expense increase million primarily high legal cost high pension expense reflect increase amortization unrecognize net loss change actuarial assumption partially offset low sale force expense result focus specialist high value primary care physicians marketing sell administrative expense increase million million primarily increase sale marketing support new product include additional sale representative support abilify addition increase relate cost associate compliance sarbanesoxley act unfavorable foreign exchange drive strengthen euro advertising product promotion expenditure increase million compare primarily increase investment directto consumer marketing campaign plavix abilify increase cost associate prelaunch activity orencia launch baraclude partially offset low spending mature product advertising promotion expense remain relatively constant million compare million increase investment abilify reyataz plavix offset low spending inline nonexclusive product company investment research development total million increase increase percentage sale research development expense compare increase research development expense reflect continue investment latestage compound research development cost include million charge primarily relate milestone payment license agreement million charge consist primarily upfront milestone payment million charge relate upfront payment license agreement research development spending dedicated pharmaceutical product increase pharmaceutical sale compare acquire inprocess research development million relate purchase acordis ukbased company expect strengthen company leadership position wound therapeutic additional information acquisition item financial statement note acquisition divestiture restructure program implement downsize realign streamline operation order increase productivity reduce operating expense rationalize company manufacture network research facility sale marketing organization action restructure program expect complete action restructure program substantially complete december result action company expect future annual benefit earning continue operation minority interest income taxis approximately million million million program respectively additional information restructuring item financial statementsnote restructuring litigation charge net settlement income million compare million million million charge consist increase reserve million liability primarily relate private litigation governmental investigation partially offset insurance recovery million million consist million relate private litigation governmental investigation relate wholesaler inventory issue accounting matters million related platinol litigation settlement million relate pharmaceutical pricing sale practice company establish reserve liabilitie total million comprise million relation wholesaler inventory issue certain accounting matter million relation pharmaceutical pricing sale marketing practice addition company record charge million litigation matter recognize income million million income consist primarily million income patent defense cost reimbursement million litigation settlement income million settlement antitrust litigation involve vitamin manufacturer additional information litigation item financial statementsnote legal proceeding contingency gain sale business million million net tax relate sale canadian consumer medicine business relate asset gain sale business million million net tax relate sale adult nutritional business additional information transaction item financial statementsnote acquisition divestiture equity net income affiliate million compare million million respectively equity net income affiliate principally relate company joint venture sanofi investment imclone million increase equity net income affiliate primarily reflect increase net income sanofi joint venture partially offset net loss investment imclone million increase primarily reflect increase net income sanofi joint venture additional information equity net income affiliate item financial statementsnote alliance investment expense net income million million million respectively expense include net interest expense foreign exchange gain loss income thirdparty contract manufacture royalty income expense defer income debt retirement cost million decrease expense primarily deferred income recognize termination collaborative agreement muraglitazar partially offset debt retirement cost connection repurchase billion note high net foreign exchange loss favorability compare primarily high income thirdparty contract manufacturing low net interest expense low net foreign exchange loss additional information item financial statementsnote expense net year end december company record incomeexpense item affect comparability result period present set forth follow table discussion item item financial statementsnote alliance investment note restructure item note acquisition divestiture note discontinued operation note legal proceeding contingency year end december litigation cost research provision settlement product gain sale expense income dollar million sell development restructure business income expense net total litigation matter private litigation governmental investigation pharmaceutical pricing sale litigation erisa liability matter insurance recovery gain sale equity investment loss sale fix asset accelerate depreciation asset impairment gain sale consumer medicine business upfront milestone payment debt retirement cost downsize streamline worldwide operation termination muraglitazar agreement income taxis item adjustment taxis repatriation foreign earning increase net earning continue operation year end december provision acquire litigation cost inprocess gain restructure settlement product research research sale expense expense dollar million sell development development business item net income net total litigation matter private litigation governmental investigation product liability pharmaceutical pricing sale litigation commercial litigation antitrust litigation product liability insurance recovery gain sale adult nutritional business accelerate depreciation downsize streamline worldwide operation upfront milestone payment acordis iprd writeoff income taxis item defer taxis anticipation repatriation foreign earning tax adjustment reduction net earning continue operation year end december provision litigation cost restructure settlement product research expense dollar million sell development item net income total litigation matter private litigation governmental investigation product liability pharmaceutical pricing sale litigation litigation settlement income upfront payment license agreement accelerate depreciation asset impairment charge termination benefit exit cost relocation retention change estimate income taxis item reduction net earning continue operation earning minority interest income taxis earning continue operation minority interest income taxis change dollar million pharmaceutical nutritional health care total segment corporateother total earning continue operation minority interest income taxis increase million million increase primarily result growth nutritional segment net impact item affect comparability result discuss partially offset low sale gross margin pharmaceutical product primarily exclusivity loss increase spending research development primarily latestage pharmaceutical compound earning continue operation minority interest income taxis decrease million million contribute decrease increase cost product sell result change product mix product lose exclusivity increase investment research development net impact item affect comparability result discuss partially offset growth health care segment high international sale pharmaceutical earning minority interest income tax million decrease primarily low sale gross margin primarily exclusivity loss high advertising product promotion investment growth driver increase spending research development earning minority interest income taxis million decrease million primarily drive gross margin erosion generic competition product mix additional sale representative support abilify increase spending research development high nonclinical grant litigation settlement income partially offset high sale health care group nutritional earning minority interest income tax million increase primarily increase worldwide sale infant formula product international sale toddler children nutritional product partially offset increase investment advertising product promotion research development program earning minority interest income taxis increase million million primarily increase global infant formula sale price increase infant formula line favorable manufacturing variance tight operate expense management health care earning minority interest income tax million decrease primarily sale canadian consumer medicine business relate asset quarter high spending research development partially offset sale growth convatec medical imaging business earning minority interest income taxis health care segment increase million million primarily sale growth convatec medical imaging business addition favorable pricing product mix corporateother earningsloss minority interest income taxis loss million decrease primarily increase gain sale businessesproduct line defer income recognize termination collaborative agreement muraglitazar reduction litigation charge net earningsloss minority interest income taxis increase million million primarily increase litigation charge net unfavorable foreign exchange drive strengthen euro high pension expense reflect increase amortization unrecognize net loss change actuarial assumption increase downsize streamline worldwide operation acquire inprocess research development charge increase partially offset increase gain sale businessesproduct line income taxis effective income tax rate earning continue operation minority interest income taxis compare low effective tax rate primarily charge approximately million estimate deferred income taxis relate repatriation approximately billion special dividend company nonus subsidiary pursuant american job creation act ajca charge relate establishment valuation allowance certain charitable contribution tax benefit associate release certain tax contingency reserve result settlement examination internal revenue service irs year change estimate relate reduction aforementione ajca defer income tax charge partially offset lower estimate foreign tax credit increase effective tax rate effective tax rate primarily attributable aforementioned ajca defer tax charge million aforementioned establishment valuation allowance certain charitable contribution increase estimate contingent tax matter partially offset favorable resolution certain tax refund claim increase foreign tax credit effect certain litigation reserve non deductible fourth quarter company disclose anticipate repatriate approximately billion special dividend record million provision defer income taxis pursuant ajca enact pende matter company repatriate approximately billion foreign subsidiary quarter repatriate remain balance approximately billion fourth quarter company expect approximately billion repatriate qualify special dividend subject finalization federal income tax return relate tax examination irs company expect continue use special dividend accordance requirement establish ajca treasury department second quarter treasury department issue ajca related guidance clarify gross foreign taxis associate special dividend qualify tax rate establish ajca result guidance company reduce million provision recording benefit approximately million tax provision earning associate special dividend discuss income taxis provide balance unremitte earning nonus subsidiary company invest expect invest earning permanently offshore company record significant defer tax asset relate foreign tax credit carryforward approximately million research tax credit carryforward approximately million expire vary amount begin realization foreign tax credit research tax credit carryforward dependent generating sufficient domesticsource taxable income prior expiration realization assure management believe likely defer tax asset realize company anticipate increase level domestic profitability time undertaking action increase biologic manufacturing capacity increase domestic profitability likely cause company effective tax rate increase enhance company ability utilize foreign tax credit research tax credit carryforward foreign tax credit research tax credit carryforward consider realizable reduce near term outcome plavix litigation unfavorable andor time generic competition plavix accelerate event occur company need record significant additional valuation allowance defer tax asset additional information plavix litigation item risk factor item financial statementsnote legal proceeding contingency discontinue operation company complete sale otn equity partner llc cash proceed million include impact preliminary work capital adjustment company record pretax gain million million net tax present gain sale discontinue operation consolidated statement earning otn previously present separate segment discussion otn item financial statementsnote discontinue operation follow amount related otn business segregate continue operation reflect discontinue operation period present year end december dollar million net sale lossearning income taxis net lossearning discontinue operation development march fda approve erbitux use treatment squamous cell carcinoma head neck result fda approval company pay million milestone payment imclone march february fda approve emsam transdermal patch treatment adult major depressive disorder use dietary modification low dose mg hour january fda accept review supplemental new drug application snda plavix treatment patient acute stsegment elevation myocardial infarction stemi fda designate filing priority review sanofiaventis company submit filing emea stemi indication european union january company gilead sciences inc gilead announce obtain datum support bioequivalence new formulation fixeddose combination company sustiva gileads truvada emtricitabine tenofovir disoproxil fumarate component new combination new fixeddose regimen intend treatment hiv infection adult gilead company anticipate submit nda fda second quarter december company complete submission fda nda dasatinib treat chronic myelogenous leukemia cml chronic accelerate blast phase philadelphia chromosomepositive ph acute lymphoblastic leukemia nda seek approval dasatinib investigational multitargete kinase inhibitor treat adult chronic myelogenous leukemia march nda accept grant priority review accelerate approval january company submit maa dasatinib emea december fda approve orencia commercially available february january company complete submission sbla fda licensure thirdparty manufacturing facility support increase production capacity orencia december exelixis inc exelixis company enter collaboration agreement discover develop commercialize novel therapy target liver x receptor lxr nuclear hormone receptor implicate variety cardiovascular metabolic disorder collaboration company jointly identify drug candidate ready investigational new drug applicationenabling study company undertake preclinical development responsible clinical development regulatory manufacturing salesmarketing activity compound term agreement include upfront payment company approximately million exelixis provide research development funding approximately million year initial period year exelixis receive prespecifie development regulatory milestone total approximately million product product collaboration sale milestone royalty sale product commercialize collaboration agreement receive statutory clearance effective january october fda issue approvable letter muraglitazar request additional information ongoing clinical trial fully address cardiovascular safety profile product company continue discussion fda determine likely initiate additional new trial gain regulatory approval consider range option include conduct additional study terminate development muraglitazar additional study approximately year complete december company merck terminate collaboration agreement muraglitazar right return company december result termination agreement company recognize million defer income fourth quarter record expense net company composition matter patent expire united states quarter company complete sale canadian consumer medicine business relate asset consumer medicine novartis ag novartis term agreement novartis acquire trademark patent intellectual property right consumer medicine million cash million attributable postclose supply arrangement company novartis relate asset include right consumer medicine brand latin america europe middle east africa result transaction company record pretax gain million million net tax quarter subject certain postclosing adjustment june company complete manufacturing agreement celltrion inc manufacture biologic product develop company april manufacturers atypical antipsychotic include company receive request fda add boxed warn drug labeling note increase risk death elderly patient dementiarelate psychosis compare placebo patient dementiarelate psychosis company change drug labeling abilify response fda request abilify approve treatment elderly patient dementiarelate psychosis march fda approve abilify tablet oral solution maintain efficacy patient bipolar disorder recent manic mixed episode stabilize maintain week late fda approval base positive result trial design compare maintenance efficacy abilify versus placebo measure time relapse march company receive approval fda baraclude oral antiviral agent treatment chronic hepatitis b drug available april composition matter patent covering baraclude expire october eligible statutory patent term extension date second half company receive approval baraclude international authority include china mexico brazil indonesia argentina financial position liquidity capital resource cash cash equivalent marketable security total approximately billion december compare billion december company continue maintain sufficient level work capital approximately billion december increase billion december future period company expect cash generate operation exist cash borrowing capital market sufficiently cover cash need work capital capital expenditure company expect include substantial investment facility increase maintain company capacity provide biologic commercial scale milestone payment dividend pay united states cash cash equivalent marketable security conversion workingcapital item borrowing expect fund nearterm operation fourth quarter company disclose anticipate repatriate approximately billion special dividend record million provision defer income taxis pursuant ajca enact pende matter company repatriate approximately billion foreign subsidiary quarter repatriate remain balance approximately billion fourth quarter company expect approximately billion repatriate qualify special dividend subject finalization federal income tax return relate tax examination irs company expect continue use special dividend accordance requirement establish ajca treasury department second quarter treasury department issue ajca related guidance clarify gross foreign taxis associate special dividend qualify tax rate establish ajca result guidance company reduce million provision recording benefit approximately million tax provision earning associate special dividend discuss income taxis provide balance unremitte earning nonus subsidiary company invest expect invest earning permanently offshore cash cash equivalent december primarily consist dollar denominate bank deposit original maturity month marketable security december primarily consist dollar denominate float rate instrument aaaaaa credit rating nature instrument company consider reasonable expect fair market value significantly impact change interest rate liquidate cash short notice average interest yield cash cash equivalent december respectively interest yield marketable security average respectively shortterm borrowing end million million respectively reduction borrowing primarily retirement commercial paper company maintain cash balance shortterm investment excess shortterm borrowing longterm debt december denominate primarily dollar include japanese yen debt million longterm debt billion december compare billion december august whollyowne subsidiary company enter new billion term loan facility syndicate lender borrowing facility guarantee company subsidiary borrower certain european subsidiary company facility contain fiveyear tranche billion twoyear tranche million company subject substantially covenant include december revolve credit facility company subject restriction include certain financial covenant prior borrowing proceed facility company obtain waiver lender covenant default facility onetime intercompany distribution december facility fully draw company compliance covenant second quarter company repurchase outstanding billion aggregate principal note incur aggregate pretax loss approximately million connection early redemption note termination relate interest rate swap december company replace prior billion revolving credit facility new billion year revolve credit facility syndicate lender extendable anniversary date consent lender availability facility subject company ability time borrowing meet certain condition include financial covenant net debt capital exceed facility contain material adverse change representation company business condition borrowing borrowing outstanding revolve credit facility december company compliance covenant inception new facility december company ratio consolidate net debt consolidate capital change public credit rating affect availability credit facility company unused shortterm line credit foreign bank million million december respectively majority company debt fix rate company enter fixed float interest rate swap billion longterm debt interest expense net interest swap gain million million million respectively increase interest expense primarily high interest rate increase primarily increase shortterm borrowing high interest rate moodys investor service moodys longterm shortterm credit rating company currently prime respectively company longterm debt rating review downgrade moodys february moodys affirm longterm rating company prime shortterm rating review longterm rating retain negative outlook standard poor sp longterm shortterm credit rating company currently respectively sps longterm credit rating remain negative outlook fitch rating fitch longterm shortterm credit rating company currently f respectively september fitchs longterm credit rating company change negative stable outlook follow discussion work capital cash flow activity december dollar million work capital year end december dollar million cash flow provide byused operating activity invest activity financing activity increase work capital million primarily reduction income taxis payable result payment relate repatriation special dividend ajca low unrealized loss derivative result weaken euro lower accrue liability product liability rebate return partially offset low receivables result collection foreign withholding taxis low sale volume high reserve litigation matter high inventory increase demand new product exist key brand net cash provide operating activity billion billion billion decrease mainly attributable low earning high usage work capital significant change operate asset liability million decrease income tax payable primarily relate settlement examination internal revenue service year benefit arise resolution certain tax contingency million decrease account payable accrue expense primarily vendor payment prior sale otn business low accrue rebate return million decrease litigation settlement payment compare million insurance recovery million increase inventory growth new product anticipation new product launch million decrease liability primarily milestone receipt muraglitazar compound million decrease receivables primarily low sale volume foreign withholding taxis significant change operate asset liability million decrease defer revenue workdown consignment inventory million increase inventory primarily introduction new product include reyataz erbitux high demand key brand include plavix avaproavalide sustiva million decrease account payable accrue expense include advertising promotion defer revenue abilifyand milestone payment net cash provide investing activity billion compare net cash billion billion million increase attributable sale marketable security proceed sale consumer medicine business million time million milestone payment imclone decrease net cash investing activity mainly attributable low purchase marketable security million cash proceed sale company adult nutritional business million low capital spending partially offset milestone payment million imclone million payment acordis acquisition increase purchase trademark patent license net cash financing activitie billion billion billion million increase mainly attributable retirement commercial paper repurchase company outstanding billion aggregate principal note partially offset billion borrowing new term loan facility decrease mainly attributable increase shortterm borrowing partially offset proceed receive issuance convertible debt cash provide operation borrowing primarily past year pay dividend approximately billion company invest approximately billion past year capital expansion improve plant efficiency maintain superior research facility past year company repurchase common stock total share acquire share repurchase program inception million share share repurchase program authorize company purchase common stock time time open market private transaction market condition permit program intend reduce increase share outstanding option exercise obtain share general corporate purpose dividend declare common share december company declare quarterly dividend common share indicate dividend year share dividend decision quarterly basis company board director companys financial condition liquidity affect obligation milestone onetime payment outcome pende litigation investigation include challenge plavix patent information item businessstrategic alliance arrangement item financial statementsnote alliance investment note legal proceeding contingency contractual obligation payment period company contractual obligation december follow obligation expire period dollar million total later year shortterm borrowing longterm debt operating lease purchase obligation standby letter creditperformance guarantee pension liability total longterm debt obligation include shortterm borrowing company consolidated balance sheet december balance approximate outstanding nominal longterm debt value contractual obligation table exclude interest payment obligation company convertible debenture include payment contain feature addition company commit potential future milestone payment thirdpartie inlicense development program payment agreement generally payable achievement certain developmental regulatory andor commercial milestone achievement milestone probable reasonably estimable contingency record company consolidate balance sheet discussion contractual obligation reference item financial statementsnote shortterm borrowing longterm debt note financial instrument note lease note pension postretirement benefit plan sec consent order defer prosecution agreement previously disclose august company enter final settlement sec concluding investigation concern certain wholesaler inventory accounting matter settlement reach consent order consent copy attach exhibit company quarterly report form q period end september term consent company agree subject certain define exception limit sale product sell direct customer include wholesaler distributor hospital retail outlet pharmacie government purchaser base expect demand amount exceed approximately month inventory hand make timely public disclosure change practice company agree consent certain measure implement include establish formal review certification process annual quarterly report file sec b establish business risk disclosure group c retain outside consultant comprehensively study help reengineer company account financial reporting process publicly disclose sale incentive offer direct customer purpose induce purchase product excess expect demand e ensure company budget process give appropriate weight input come come adequately document process company agree consent retain independent adviser date company year end file sec independent adviser continue serve independent monitor defer prosecution agreement dpa discuss consent define certain power responsibilitie independent adviser consent include process independent adviser recommendation company compliance applicable federal security law corporate obligation company agree consent adopt independent adviser recommendation compliance applicable federal security law corporate obligation previously disclose june company enter dpa united states attorney office usao district new jersey resolve investigation usao company relate wholesaler inventory accounting matter cover company settlement sec pursuant dpa usao file criminal complaint company allege conspiracy commit security fraud defer prosecution company dismiss complaint year company satisfie requirement dpa copy dpa file exhibit form k file company june incorporate reference hereto exhibit w dpa thing company agree include form q k file sec annual report shareholder follow information estimate wholesalerdirect customer inventory level product sell pharmaceutical business b major nonus country estimate aggregate wholesalerdirectcustomer inventory level pharmaceutical product sell country take measure aggregate annual sale country c arrangement policy concern wholesalerdirect customer distributor product include effort company control monitor wholesalerdistributor inventory level datum concern prescription measure endus demand product pursuant dpa company include filing report information acquisition divestiture restructuring reserve policy activity rebate accrual policy activity company agree implement remedial measure undertake mandate consent settlement derivative litigation federal security class action relate wholesaler inventory accounting matter addition company agree undertake additional remedial action corporate reform action include appoint additional nonexecutive director acceptable usao b establish maintain training education program topic include corporate citizenship financial reporting obligation c make additional million payment shareholder compensation fund establish connection consent engage attempt engage criminal conduct term define dpa e continue cooperate usao include respect ongoing investigation individual current employee company f retain irdependent monitor dpa board director separate role chairman chief executive officer company june elect nonexecutive chairman independent monitor serve independent adviser pursuant consent define power responsibility dpa include responsibility oversee april company compliance term dpa consent settlement derivative action federal security class action monitor authority require company step believe necessary comply term dpa company require adopt recommendation monitor company object recommendation usao agree adoption recommendation require addition independent monitor report usao quarterly basis company compliance dpa implementation effectiveness internal control financial reporting disclosure process relate compliance function company company establish companywide policy limit sale direct customer purpose comply consent policy include adoption procedure monitor limit sale direct customer accordance term consent procedure include governance process escalate appropriate management level potential question concern compliance policy timely resolution question concern addition compliance policy monitor regular basis company maintain inventory management agreement imas pharmaceutical wholesaler account nearly total gross sale pharmaceutical product current term ima company large wholesaler customer provide company weekly information respect month hand product level inventory outmovement product wholesaler currently account total gross sale pharmaceutical product inventory information receive wholesaler company internal information estimate month hand product level inventory wholesaler company estimate month hand product inventory level pharmaceutical businesss wholesaler customer large wholesaler extrapolate month hand calculate large wholesaler company consider adjustment necessary extrapolate amount base factor historical sale individual product wholesaler thirdparty market research datum relate prescription trend patient demand contrast company pharmaceutical business outside united states nutritional health care business unit world company significantly direct customer limit information direct customer product level inventory correspond outmovement information reliability party demand information available vary widely accordingly company rely variety method estimate month hand product level inventory business unit company disclose pharmaceutical product sell pharmaceutical business base net sale net sale estimate number month hand wholesaler distribution channel end immediately precede quarter end applicable quarter quarterly annual report form q k company disclose correspond information pharmaceutical product sell major nonus country describe business unit company continue disclose quarterly basis key product level inventory information require estimate month hand product level inventory direct customer distribution nonus pharmaceutical business available prior file quarterly report form q applicable quarter accordingly company disclose information website approximately day end applicable quarter company form q follow quarter addition forego quarterly disclosure company include forego information business unit quarter annual report nonkey product inventory direct customer exceed approximately month hand company disclose estimate month hand product impact company de minimis company enhance continue enhance method estimate month hand product inventory level pharmaceutical business nonus pharmaceutical business world take account complexity describe company take continue step expedite receipt processing datum nonus pharmaceutical business company believe abovedescribe procedure provide reasonable basis ensure compliance consent order dpa provide sufficient information comply disclosure requirement recently issue accounting standard financial accounting standard board fasb issue statement financial accounting standard sfas accounting change error correction replace accounting principle board apb opinion accounting change sfas report accounting change interim financial statement pronouncement apply voluntary change account principle revise requirement accounting reporting change accounting principle sfas require retrospective application prior period financial statement voluntary change accounting principle impracticable pronouncement require change method depreciation amortization depletion longlive nonfinancial asset account change accounting estimate effect change accounting principle sfas effective accounting change correction error fiscal year begin december statement change transition provision exist accounting pronouncement include transition phase effective date sfas adoption accounting pronouncement expect material effect consolidated financial statement march fasb issue fasb interpretation accounting conditional asset retirement obligation fin fin clarifie entity record liability conditional asset retirement obligation fair value obligation reasonably estimate asset retirement obligation cover fin entity legal obligation perform asset retirement activity time method settling obligation conditional future event control entity fin clarifie entity sufficient information reasonably estimate fair value asset retirement obligation fin effective later end fiscal year end december adoption accounting pronouncement material effect consolidated financial statement december fasb issue revise sfas sfas r sharebase payment standard eliminate ability account share base compensation transaction intrinsic valuebase method apb opinion accounting stock issue employee require instead transaction account fairvaluebase method april sec delay effective date sfas r financial statement issue annual period begin june company adopt sfas r january prospective transition method result provision sfas r staff accounting bulletin sab company estimate compensation charge relate sharebased compensation pretax basis million million include million million stock option expense adoption standard tax basis compensation charge relate sharebased compensation estimate million million stock option expense adoption standard include tax amount million million assessment estimate compensation charge affect company stock price number complex subjective variable relate tax impact variable include limited volatility company stock price employee stock exercise behavior item financial statementsnote accounting policy stock compensation plan december fasb issue final staff position fsp application sfas accounting income taxis tax deduction qualified production activity provide american job creation act fsp provide deduction qualified production activity treat special deduction describe sfas accounting income taxis accordingly tax effect deduction report component company current tax provision effect defer tax asset liabilities department treasury recently issue propose tax regulation respect deduction qualified production activity company evaluate impact propose tax regulation fsp income tax provision result operation item financial statementsnote accounting policiesincome taxis december fasb issue sfas exchange nonmonetary asset provision statement effective nonmonetary asset exchange occur fiscal period begin june apply prospectively statement eliminate exception fair value measurement nonmonetary exchange similar productive asset paragraph b apb opinion accounting nonmonetary transaction replace exception exchange commercial substance adoption account pronouncement material effect consolidated financial statement november fasb issue sfas inventory cost amendment arb chapter standard require abnormal amount idle facility relate expense recognize current period charge require allocation fix production overhead cost conversion base normal capacity production facility sfas effective inventory cost incur fiscal year begin june adoption accounting pronouncement expect material effect consolidated financial statement june fasb issue fsp accounting disclosure requirement relate medicare prescription drug improvement modernization act medicare act medicare act introduce prescription drug benefit medicare federal subsidy sponsor retiree health care benefit plan provide benefit actuarially equivalent medicare fsp require effect new law account sfas employer account postretirement benefit pension company adopt fsp quarter retroactive january reduction net periodic benefit cost benefit million base remeasurement accumulate postretirement benefit obligation january effect adoption fsp material company consolidate financial statement item financial statementsnote pension postretirement benefit plan march emerge issue task force eitf reach consensus issue participate security twoclass method fas require use twoclass method compute earning share enterprise participate security multiple class common stock consensus effective fiscal period begin march adoption eitf material effect consolidated financial statement december fasb revised interpretation consolidation variable interest entity fin fin require variable interest entity consolidated company company subject majority risk loss variable interest entitys activity entitle receive majority entitys residual return fin require disclosure variable interest entity company require consolidate significant variable interest consolidation requirement fin revise apply immediately variable interest entity create january exist entity fiscal year interim period end march certain disclosure requirement apply financial statement issue january regardless variable interest entity establish adoption account pronouncement material effect consolidated financial statement critical accounting policy company prepare financial statement conformity accounting principle generally accept united states preparation financial statement conformity generally accept accounting principle gaap require use estimate assumption affect report amount asset liability include disclosure contingent asset contingent liability date financial statement report amount revenue expense report period company critical accounting policy important company financial condition result operation require difficult subjective complex judgment management application result need estimate effect matter inherently uncertain uncertainty factor surround estimate judgment preparation consolidated financial statement actual result vary estimate company believe follow discussion represent critical accounting policy management company independent register public accounting firm discuss company critical accounting policy audit committee board director revenue recognition company recognize revenue accordance sab revenue recognition financial statement amend sab revenue recognition company accounting policy revenue recognition substantial impact report result rely certain estimate require difficult subjective complex judgment management company recognize revenue substantially risk reward ownership transfer customer generally occur date shipment exception describe previous year certain transaction companys pharmaceutical wholesaler account consignment model case sale wholesaler result incentive excess wholesaler ordinary course business inventory level time understand agreement course deal consistent business practice company extend incentive base level excess inventory connection future purchase time incentive cover substantially vary directly wholesaler cost carry inventory excess wholesaler ordinary course business inventory level substantially risk reward ownership transfer shipment accordingly sale account consignment model determination sale wholesaler meet forego criterion involve evaluation variety factor number complex judgment consignment model company recognize revenue shipment product shipment product company invoice wholesaler record defer revenue gross invoice sale price classifie inventory hold wholesaler consignment inventory company cost inventory company recognize revenue net gross net sale adjustment discuss involve significant estimate judgment consignment inventory long subject incentive arrangement later inventory sell wholesaler customer firstin firstout fifo basis case new product product introduction extension exist line product company determine product similar therapeutic category company determine new product dissimilar characteristic exist product company reliably estimate expect return new product company defer recognition revenue right return long exist company develop sufficient historical experience estimate sale return discussion revenue recognition item financial statementsnote accounting policiesrevenue recognition sale rebate return accrual gross net sale adjustment company follow significant category gross net sale adjustment impact company reportable segment prime vendor chargeback wic rebate manage health care rebate contract discount medicaid rebate cash discount sale return adjustment involve significant estimate judgment require company use information external source company account gross net sale adjustment accordance eitf issue accounting consideration give vendor customer include reseller vendor product sfas revenue recognition right return exist applicable net sale section reconciliation companys gross sale net sale significant category grosstonet sale adjustment prime vendor chargeback company business participate prime vendor program government entity significant department defense department veteran affair party pricing product extend wholesaler list price participate entity entity purchase product wholesaler low prime vendor price wholesaler charge difference acquisition cost low prime vendor price company company account prime vendor chargeback reduce account receivable equal company estimate chargeback claim attributable sale company determines estimate prime vendor chargeback primarily base historical experience prime vendor chargeback current contract price prime vendor program company consider prime vendor payment level inventory distribution channel company claim processing time lag adjust reduction account receivable periodically quarter reflect actual experience wic rebate company nutritional business participate competitive bidding basis nutrition program sponsor state tribal government commonwealth puerto rico territory woman infant child wic program company reimburse entity difference wholesaler list price contract price eligible product company account wic rebate establish accrual equal company estimate wic rebate claim attributable sale company determines estimate wic rebate accrual primarily base historical experience wic rebate current contract price wic program company consider level inventory distribution channel new wic contract terminate wic contract change exist wic contract wic participation adjust accrual periodically quarter reflect actual experience manage health care rebate contract discount company offer rebate discount manage health care organization globally contract counterpartie hospital group purchasing organization company account manage health care rebate contract discount establish accrual equal company estimate manage health care rebate contract discount attributable sale company determine estimate manage health care rebate contract discount accrual primarily base historical experience rebate discount current contract price company consider sale performance product subject manage health care rebate contract discount level inventory distribution channel adjust accrual periodically quarter reflect actual experience medicaid rebate company business participate state governmentmanage medicaid program certain qualify federal state government program discount rebate provide participate state local government entity discount rebate provide program include company medicaid rebate accrual consider medicaid rebate purpose discussion company account medicaid rebate establish accrual equal company estimate medicaid rebate claim attributable sale company determines estimate medicaid rebate accrual primarily base historical experience medicaid rebate expansion prospective basis participation nonmandatory aspect qualify federal state government program legal interpretation applicable law relate medicaid qualify federal state government program new information change medicaid program regulation guideline impact rebate company consider outstanding medicaid claims medicaid payment level inventory distribution channel adjust accrual periodically quarter reflect actual experience cash discount certain country company offer cash discount generally approximately sale price incentive prompt payment company account cash discount reduce account receivable discount company consider payment performance adjust accrual reflect actual experience sale return company account sale return accordance sfas establish accrual equal company estimate sale record related product expect return provision sale return million million million respectively respectively gross sale return establish product company determine estimate sale return accrual primarily base historical experience sale return consider factor impact sale return factor include level inventory distribution channel estimate shelf life product recall product discontinuance price change competitive product introduction generic product introduction competitive new product company consider factor adjust accrual periodically quarter reflect actual experience company consider level inventory distribution channel determine believe adjustment sale return accrual appropriate example level inventory distribution channel increase company analyze reason increase reason indicate sale return large expect company adjust sale return accrual take account historical experience company return good policy shelf life company product ranges average approximately month situation company aware product distribution channel near expiration date company analyze situation analysis indicate sale return large expect company adjust sale return accrual take account historical experience company return good policy level inventory distribution channel event product recall product discontinuance company consider reason impact action adjust sale return accrual appropriate taking account historical experience level inventory distribution channel product discontinuance estimate continue demand company consider price change competitive product introduction generic product introduction competitive new product company generally believe factor impact sale return base historical experience company return good policy return new product significantly difficult company assess company determine estimate sale return accrual primarily base historical sale return experience similar product line product similar therapeutic category limit circumstance new product extension exist line product company historical experience product similar therapeutic category company reliably estimate expect return new product company defer recognition revenue right return long exist company develop sufficient historical experience estimate sale return company consider shelf life new product determine believe adjustment sale return accrual appropriate shelf life connection new product tend short shelf life establish product company develop optimal manufacturing process new product lengthen shelf life launch quantity manufacture advance launch date ensure sufficient supply exist satisfy market demand case company assess reduce shelf life level inventory distribution channel project demand determine believe adjustment sale return accrual appropriate adjustment addition significant gross net sale adjustment describe company make gross net sale adjustment example company offer sale discount significantly nonus business offer consumer coupon rebate significantly nutritional pharmaceutical business addition number country outside include major european country company provide rebate government entity company generally account gross net adjustment establish accrual equal company estimate adjustment attributable sale company generally determine estimate accrual gross net sale adjustment primarily base historical experience performance commitment government entity relevant factor include level inventory distribution channel case adjust accrual periodically quarter reflect actual experience use information external source company use information external source estimate significant gross net sale adjustment company estimate inventory wholesaler defer revenue consign inventory base project prescription demandbase sale product historical inventory experience company analysis thirdparty information include write oral information obtain certain wholesaler respect inventory level sellthrough customer thirdparty market research datum companys internal information inventory information receive wholesaler product recordkeeping process exclude inventory hold intermediary sell retailer hospital company receive information ims health im supplier market research pharmaceutical industry use project prescription demand base sale pharmaceutical product company historically report estimate total prescription growth estimate therapeutic category share base national prescription audit npa datum ims make available public subscription basis simple average estimate number prescription retail mail order channel quarter company begin disclose estimate total prescription growth estimate therapeutic category share base npa nextgeneration prescription service ngps datum ngps datum collect ims new revise methodology release ims limited basis pilot program im publicly announce expect ngps datum available public subscription basis company believe ngps datum provide im provide superior estimate prescription data company product retail mail order channel company calculate estimate total prescription growth estimate therapeutic category share base ngps datum weight average basis reflect fact mail order prescription include great volume product supply compare retail prescription company believe calculation estimate total prescription growth estimate therapeutic category share base ngps datum weight average approach respect retail mail order channel provide superior estimate total prescription demand company use methodology internal demand forecast company use information external source identify prescription trend patient demand average selling price company estimate subject inherent limitation estimate rely thirdparty information certain thirdparty information form estimate reflect limitation include lags date thirdparty information generate date company receive thirdparty information retirement benefit company pension plan postretirement benefit plan account actuarial valuation require sfas employer account pension sfas employer account postretirement benefit pension company consider accounting retirement plan critical management require significant subjective judgment number actuarial assumption include discount rate salary growth longterm return plan asset retirement turnover health care cost trend rate mortality rate depend assumption estimate pension postretirement benefit expense vary range outcome material effect report earning addition assumption materially affect accumulate benefit obligation future cash funding plan description company certain subsidiary define benefit pension plan define contribution plan termination indemnity plan regular time employee principal define benefit pension plan bristolmyers squibb retirement income plan principal define contribution plan bristolmyer squibb saving investment program approximately total company define benefit pension plan asset liability hold plan asset plan hold single trust common asset allocation specify reference section total company plan ie plan international plan benefit company define benefit pension plan base primarily year credit service participant compensation asset company define benefit plan consist primarily equity fixedincome security december fair market value plan asset company define benefit plan increase million million december plan asset allocate equity security compare end fix income security compare end private equity investment compare end bristolmyer squibb common stock represent asset plan end company provide comprehensive medical group life benefit substantially retiree elect participate company comprehensive medical group life plan asset allocation postretirement plan identical asset allocation describe define benefit pension plan accrual account significant assumption consistent requirement sfas employer accounting pension company account pension benefit accrual method recognize pension expense payment benefit retiree accrual method accounting pension benefit necessarily require actuarial assumption concern future event determine timing benefit payment company key assumption calculate cost pension benefit discount rate rate compensation increase expect longterm rate return plan asset company consultation actuary evaluate key actuarial assumption assumption calculate cost pension benefit retirement turnover mortality rate base expectation actual experience appropriate determine assumption december year calculate liability information date pension expense follow year depend assumption pension expense vary range outcome material effect report earning addition assumption materially affect accumulate benefit obligation future cash fund actual result give year differ estimate economic factor determine discount rate company use yield high quality corporate bond coincide cash flow plan estimate payout citigroup median yield curve determine discount rate plan assume rate compensation increase company determine future pension obligation reflect estimate change actual future compensation level general price level productivity seniority factor net pension expense company define benefit pension plan include earning minority interest income taxis million compare million plan pension expense determine assumed discount rate assume rate compensation increase present value benefit obligation december plan determine rate assume discount rate determine plan pension expense reduce expense increase approximately million assumed rate compensation increase determine plan pension expense reduce expense decrease approximately million assumed discount rate determine accumulate benefit obligation december reduce accumulate benefit obligation increase million plan pension expense determine expect longterm rate return plan asset expect longterm rate return plan asset determine plan pension expense reduce expense increase million actual rate return earn plan asset year follow year return year return discuss gaap provide difference expect actual return recognize average future service employee december company maintain assume discount rate plan maintain assume rate compensation increase compensation assume increase scale different rate different age rate disclose december single rate age produce present value benefit obligation company reduce expect rate return plan asset company expect net pension expense define benefit pension plan include earning minority interest income taxis approximately million low million reflect primarily positive delay impact favorable investment return company assume discount rate expect longterm rate return plan asset calculate cost pension benefit cost postretirement benefit plan case discount rate december rate pension benefit versus postretirement benefit reflect short duration postretirement liabilitie health care cost retiree population assume increase trend expect increase year actual cost higher assume likely significant upward pressure company expense retiree health care december president bush sign law medicare prescription drug improvement modernization act effect medicare act reflect net periodic postretirement benefit cost reduction million accumulate postretirement benefit obligation december reduction million delay recognition actuarial gain loss december unrecognize net actuarial loss company define benefit plan million million respectively base fair market value plan asset unrecognize net actuarial loss reflect large steady reduction weightedaverage discount rate year sfas provide delay recognition actuarial gain loss include amount arise change estimate plan benefit obligation change assume discount rate difference actual expect return plan asset assumption change sfas require unrecognized net actuarial gain loss determine base marketrelated value plan asset differ fair market value calculate value recognize change fair value systematic rational manner year amortize pension income expense year extent unrecognize net actuarial loss gain exceed great project benefit obligation marketrelated value plan asset begin year net gain loss recognize pension income expense prospectively period approximate average remain service period active employee expect receive benefit plan approximately year extent offset loss gain subsequent year december unrecognize net actuarial loss determine base marketrelated value plan asset million exceed great project benefit obligation market relate value plan asset million offset future unrecognized gain high discount rate higher expect return plan asset amortization unrecognized loss expect increase pension expense follow year approximately million year december unrecognize net actuarial loss determine base marketrelated value plan asset million exceed great project benefit obligation market relate value plan asset million event fair market value pension plan asset particular plan accumulate benefit obligation plan yearend gaap require additional minimum liability circumstance reduction stockholder equity establishment intangible asset december fair market value company define benefit pension plan asset million relate accumulate benefit obligation million company recognize reduction million additional minimum liability cumulatively million december offset million increase comprehensive income include stockholder equity million reduction intangible asset december fair market value company define benefit pension plan asset million relate accumulate benefit obligation million company recognize additional minimum liability million cumulatively million december offset million charge comprehensive income include stockholder equity million reduction intangible asset plan funding company fund policy define benefit plan contribute amount provide current service fund past service liability company contribute million million define benefit plan respectively discussion retirement benefit item financial statementsnote pension postretirement benefit plan acquire inprocess research development fair value inprocess research development acquire business combination determine independent appraisal base present value research project project cash flow income approach utilize consistent guidance practice aid issue american institute certify public accountant asset acquire business combination research development activity focus software electronic device pharmaceutical industry future cash flow predominately base net income forecast project consistent historical pricing margin expense level similar product revenue estimate base relevant market size growth factor expect industry trend individual project life cycle life research project underlie patent determine fair value research project expect revenue adjust technical risk completion result cash flow discount rate approximating company weight average cost capital acquire inprocess research development expense incurred underlying product receive regulatory approval future alternative use addition cost nonrefundable relate acquisition licensing product receive regulatory approval market alternative future use charge earning incur discussion acquire inprocess research development item financial statementsnote accounting policiesacquire inprocess research development impairment longlive asset accordance sfas accounting impairment disposal longlive asset company periodically evaluate current fact circumstance indicate carry value depreciable asset hold recoverable circumstance determine exist estimate undiscounted future cash flow produce longlived asset appropriate grouping asset compare carry value determine impairment exist asset determine impair loss measure base difference asset fair value carry value estimate asset fair value base quote market price active market available quote market price available estimate fair value base valuation technique include discount value estimate future cash flow company report asset dispose low carrying value estimate net realizable value accordance sfas goodwill intangible asset goodwill tested annually impairment twostep process step identify potential impairment second step measure impairment loss goodwill deem impaired carrying reporting unit goodwill exceed estimate fair value sfas require indefinitelive intangible asset test impairment onestep process consist comparison fair value carry value intangible asset intangible asset deem impaired net book value exceed estimate fair value intangible asset evaluate impairment accordance sfas describe estimate future cash flow base reasonable supportable assumption projection require management judgment change key assumption company business prospect change market condition result impairment charge discussion impairment longlive asset item financial statementsnote accounting policiesimpairment longlive asset goodwill intangible asset equity investment company review equity investment impairment base determination decline market value investment company carry value temporary making determination company consider apb opinion equity method accounting investment common stock relate interpretation set forth factor evaluate determine loss value recognize include company ability hold investment market price market price fluctuation investment publicly trade share inability investee sustain earning capacity justify carry investment company investment imclone subject accounting item financial statementsnote alliance investment discussion company investment imclone discussion equity investment item financial statementsnote accounting policiesinvestment note alliance investment restructure downsize streamline operation rationalize manufacture facility company periodically record restructuring charge result company estimate judgment future plan include future termination benefit exit cost incurred restructuring action place actual result vary estimate result adjustment earning discussion restructure item financial statementsnote accounting policiesrestructuring note restructure item contingency normal course business company subject contingency legal proceeding claim arise business cover wide range matter include government investigation shareholder lawsuit product environmental liability tax matter accordance sfas accounting contingency company record accrual contingency probable liability incur loss reasonably estimate discussion contingency item financial statementsnote accounting policiesincome taxis contingency note income taxis note legal proceeding contingency income taxis defer taxis company evaluate need defer tax asset valuation allowance assess likely realize defer tax asset future assessment valuation allowance require require significant judgment include longrange forecast future taxable income evaluation tax planning strategy adjustment defer tax valuation allowance earning period assessment company record defer tax asset relate foreign tax credit carryforward approximately million research tax credit carryforward approximately million expire vary amount begin realization foreign tax credit research tax credit carryforward dependent generating sufficient domesticsource taxable income prior expiration realization assure management believe likely defer tax asset realize company anticipate increase level domestic profitability time undertaking action increase biologic manufacturing capacity increase domestic profitability likely cause company effective tax rate increase enhance company ability utilize foreign tax credit research tax credit carryforward foreign tax credit research tax credit carryforward consider realizable reduce near term outcome plavix litigation unfavorable andor time generic competition plavix accelerate event occur company need record significant additional valuation allowance defer tax asset additional information plavix litigation item risk factor item financial statementsnote legal proceeding contingency tax contingency company conduct business country world subject tax numerous jurisdiction result business activity company file significant number tax return subject examination tax authority tax examination complex tax authority disagree treatment item report company require year resolve company establish liability possible assessment tax authority amount represent reasonable provision taxis ultimately expect pay need adjusted time information know undistributed earning foreign subsidiary december company approximately billion undistributed earning foreign subsidiary taxis provide company invest expect invest undistributed earning permanently offshore future earning repatriate united states company determine earning remit foreseeable future additional tax provision require complexity tax law assumption practicable estimate amount income taxis provide discussion income taxis item financial statementsnote accounting policiesincome taxis note income taxis outlook previously disclose anticipated sale decline continued exclusivity loss expect offset growth net sale company growth driver potential new product period additionally gross margin expect stabilize relatively high margin realize sale growth driver certain new product offset lose margin old product lose expect lose exclusivity earning adversely affect company investment support introduction new product loss revenue relate sale product asset impact adoption expense stock option new accounting guideline development additional new compound addition previously disclose company experience substantial revenue loss year expiration market exclusivity protection certain product company estimate reduction net sale range billion level represent continue decline revenue product decline revenue certain additional product lose continue lose market exclusivity protection product year lose lose exclusivity protection include glucophageirglucovanceglucophagexr united states taxol paclitaxel europe japan pravachol united states europe cefzil united states revenue reduction exclusivity loss anticipate begin moderate level major new exclusivity loss expect timing amount sale reduction exclusivity loss realization particular period eventual level remain sale revenue uncertain dependent level sale time exclusivity protection end time degree development generic competition speed approval market entry impact factor company expectation future sale growth include substantial expect increase sale plavix net sale billion currently company large product rank net sale composition matter patent plavix expire currently subject litigation united states trial schedule begin june similar proceeding involve plavix ongoing canada enforcement proceeding outside canada company continue believe patent valid infringe alliance partner patent holder sanofi vigorously pursue case possible time reasonably assess outcome litigation adverse determination litigation time potential generic competition plavix apotex inc apotex corporation apotex announce january receive final approval anda clopidogrel bisulfate fda accordingly apotex decide launch generic product risk time generic competition likely result substantial decrease sale plavix united states company add product line realign focus year company expect devote substantial resource excess historical level meet heighten processing standard require sterile newly introduce product biologic biologic important company product portfolio company continue arrangement party manufacturer expect substantial investment increase internal capacity produce biologic commercial scale march example board director approve capital expenditure million construction expandable largescale multiproduct bulk biologic manufacturing facility facility modular design order accomodate future expansion future period company expect cash generate operation exist cash borrowing capital market sufficiently cover cach need work capital capital expenditure include substantial investment facility increase maintain company capacity provide biologic commercial scale note milestone payment dividend pay united states company subsidiary subject number significant pende lawsuit claim proceeding investigation assurance increase scope matter future lawsuit claim proceeding material company addition increase trend foreign government scrutinize sale marketing activity pharmaceutical company assurance investigation investigation material possible time reasonably assess final outcome investigation litigation management continue believe previously disclose year aggregate impact current reserve legal matter affect company reasonably likely material company result operation cash flow material financial condition liquidity company expectation year describe reflect potential impact litigation company result operation special note forwardlooke statement annual report include document incorporate reference write oral statement company make time time contain certain forwardlooking statement meaning section security act section e securities exchange act identify forwardlooke statement fact use word expect anticipate estimate target project guidance intend plan believe word term similar meaning expression connection discussion future operate financial performance identify forwardlooke statement fact relate strictly historical current fact forwardlooke statement base current expectation involve inherent risk uncertainty include factor delay divert change cause actual outcome differ materially current expectation statement likely relate thing company goal plan projection financial position result operation cash flow market position product development product approval sale effort expense performance result current anticipate product outcome contingency legal proceeding financial result base current expectation involve inherent risk uncertainty include internal external factor delay divert change year company include important factor cautionary statement include annual report particularly item risk factor company believe cause actual result differ materially forwardlooke statement company believe prudent plan assumption assurance give goal plan set forth forwardlooke statement achieve reader caution place undue reliance statement speak date company undertake obligation release publicly revision forwardlooke statement result new information future event item quantitative qualitative disclosure market risk company expose market risk change currency exchange rate interest rate reduce risk company enter certain derivative financial instrument available costeffective basis hedge underlie economic exposure instrument manage consolidated basis efficiently net exposure advantage natural offset derivative financial instrument speculative purpose gain loss hedge transaction offset gain loss underlying exposure hedge ineffective portion hedge report earning occur company primary foreign currency exposure anticipate transaction primarily intercompany inventory purchase expect occur year euro canadian dollar japanese yen mexican peso chinese yuan company utilize foreign currency forward contract hedge exposure certain foreign currency designate derivative instrument cash flow hedge table summarize company outstanding foreign exchange forward contract december fair value foreign exchange forward contract base yearend currency rate fair value foreign exchange forward contract view relation fair value underlie hedged transaction overall reduction exposure adverse fluctuation foreign currency exchange rate weight average notional fair dollar million currency rate strike price value maturity foreign exchange forward australian dollar brazilian real canadian dollar euro polish zloty swiss franc total contract december company hold foreign exchange forward contract maturity date december company hold option contract notional amount fair value foreign exchange forward contract maturity date express table notional fair value year maturity dollar million dollar million december company hold foreign exchange forward contract aggregate notional million fair value foreign exchange forward contract million million record noncurrent asset million record current liability contract primarily relate exposure euro canadian dollar australian dollar company estimate appreciation depreciation underlie currency hedge level dollar december variable hold constant decrease increase respectively million fair value foreign exchange forward contract hold december company obligate settle foreign exchange forward contract base specify contract rate december balance defer net aftertax gain foreign exchange forward contract include accumulate comprehensive income million million estimate reclassify earning month december company hold option foreign exchange forward contract aggregate notional fair value million million liability respectively contract primarily relate exposure euro canadian dollar australian dollar swiss franc british pound company reclassify deferred loss million comprehensive income earning majority classify cost product sell year end december impact hedge ineffectiveness earning significant additionally company use foreign exchange forward contract offset exposure certain currency asset liability foreign exchange forward contract designate hedge change fair value derivative recognize earning occur amount recognize earning relate foreign exchange forward contract qualify hedge accounting treatment significant company use foreign exchange forward contract hedge foreign currency denominate monetary asset liability primary objective foreign exchange forward contract protect dollar value foreign currency denominate monetary asset liability effect volatility foreign exchange rate occur prior receipt settlement dollar foreign currency denominate monetary asset liability primarily denominate japanese yen euro foreign exchange forward contract designate hedge mark market incomeexpense notional fair value purchase foreign exchange forward contract million million liability respectively december million million liability respectively december notional fair value sell foreign exchange forward contract million million asset respectively december million million asset respectively december addition foreign exchange forward contract note company use non dollar borrowing less extent foreign exchange forward contract hedge foreign currency exposure company net investment certain foreign affiliate non dollar borrowing foreign exchange forward contract designate hedge net investment effective portion foreign exchange gain loss hedge record foreign currency translation component comprehensive income december million tax gain million tax loss respectively record foreign currency translation component comprehensive income company use derivative instrument interest rate risk management stratergy derivative instrument include interest rate swap subject fairvalue hedge accounting treatment company execute fix float interest rate swap convert billion company fix rate debt pay variable rate debt year end december company recognize net reduction interest expense million reflect benefit lower float rate obtain swap agreement april connection early redemption billion note company terminate billion notional fixedtofloate interest rate swap agreement incur pretax loss million june company terminate million notional fixedtofloate interest rate swap agreement relate billion note incur pretax loss million loss amortize interest expense remain life note million recognize september company terminate million notional fixedtofloate interest rate swap agreement relate million debenture result gain million gain recognize interest expense remain life debenture approximately million recognize sfas require revaluation fair value swap contract underlie debt hedge swap contract underlie debt revalue result increase noncurrent asset million current liability million reduction longterm debt million increase noncurrent asset million current liability million longterm debt million december respectively swap contract generally hold maturity speculative purpose follow table summarize interest rate swap outstanding december notional variable rate interest rate contract underlie debt receive maturity fair value dollar million swap associate month note libor swap associate month note libor swap associate month note libor swap associate month note libor december company hold interest rate swap contract notional value million fair value million estimate increase decrease basis point shortterm longterm interest rate material impact company consolidate financial position result operation cash flow company million million longterm debt outstanding december respectively item financial statement note shortterm borrowing longterm debt note financial instrument additional information company maintain cash cash equivalent marketable security financial institution order limit exposure financial institution financial institution headquarter primarily north america europe bristolmyers squibb company consolidate statement earning dollar share million share datum item financial statement supplementary datum year end december earning net sale cost product sell marketing sell administrative advertising product promotion research development acquire inprocess research development provision restructure net litigation charge net gain sale business equity net income affiliate expense net total expense earning continue operation minority interest income taxis provision income taxis minority interest net taxis earning continue operation discontinue operation net earning net gain disposal net earning earning common share basic earning continue operation discontinue operation net earning net gain disposal net earning dilute earning continue operation discontinue operation net earning net gain disposal net earning average common share outstanding basic dilute dividend declare common share accompany note integral financial statement bristolmyers squibb company consolidate statement comprehensive income retain earning dollar millions comprehensive income net earning comprehensive income foreign currency translation net tax liability tax benefit defer gainslosse derivative qualify hedge net tax liability tax benefit minimum pension liability adjustment net tax benefit available sale security net tax benefit zero net tax liability total comprehensive income comprehensive income retain earning retain earning january net earning cash dividend declare retain earning december accompany note integral financial statement bristolmyers squibb company consolidated balance sheet dollar million december asset current asset cash cash equivalent marketable security receivables net allowance inventory include consignment inventory defer income taxis net valuation allowance prepaid expense total current asset property plant equipment net goodwill intangible asset net deferred income taxis net valuation allowance prepay pension asset total asset liability current liability shortterm borrowing account payable accrue expense accrue rebate return foreign income taxis payable dividend payable accrue litigation liability defer revenue consign inventory total current liability pension post retirement liability defer income liability longterm debt total liability commitment contingency note stockholder equity prefer stock convertible series authorize million share issue outstanding liquidation value share common stock par value share authorize billion share million issue million issue capital excess par value stock restrict stock accumulate comprehensive loss retain earning cost treasury stock million common share million total stockholder equity total liability stockholder equity accompany note integral financial statement bristolmyers squibb company consolidate statement cash flow dollar million year end december cash flow operating activity net earning adjustment reconcile net earning net cash provide operating activity depreciation amortization defer income tax benefit litigation settlement expense net recovery provision restructure gain sale business defer income recognize acquire inprocess research development impairment charge asset writeoff lossgain disposal property plant equipment investment company undistribute loss affiliate net unfunded pension expense change operate asset liability receivables inventory prepaid expense asset defer revenue consign inventory litigation settlement payment net insurance recovery account payable accrue expense product liability foreign income taxis payable liability net cash provide operating activity cash flow invest activity purchase net sale maturity marketable security addition property plant equipment capitalize software proceed disposal property plant equipment investment company proceed sale businessesproduct line purchase acordis speciality fibre imclone milestone payment purchase trademark patent license business divestiture acquisition cost investment company net cash provide byused investing activity cash flow financing activity shortterm repaymentsborrowing longterm debt borrowing longterm debt repayment issuance common stock stock plan dividend pay net cash financing activity effect exchange rate cash cash equivalent decreaseincrease cash cash equivalent cash cash equivalent begin period cash cash equivalent end period accompany note integral financial statement note accounting policy basis consolidation consolidated financial statement include account bristolmyer squibb company bms company bristolmyers squibb control majorityowned subsidiary intercompany balance transaction eliminate certain prior year amount reclassify conform current year presentation use estimate preparation financial statement conformity generally accept accounting principle gaap require use estimate assumption affect report amount asset liability disclosure contingent asset contingent liability date financial statement report amount revenue expense report period significant assumption employ estimate determine value intangible asset restructuring charge accrual sale rebate return accrual legal contingency tax asset tax liability estimate apply revenue recognition policy accounting retirement postretirement benefit include actuarial assumption actual result differ estimate result revenue recognition company recognize revenue accordance staff accounting bulletin sab revenue recognition financial statement amend sab revenue recognition substantially risk reward ownership transfer customer generally revenue recognize time shipment case certain sale nutritional health care segment certain nonus business pharmaceutical segment revenue recognize date receipt purchaser revenues reduce time recognition reflect expect return estimate base historical experience additionally provision time revenue recognition discount rebate estimate sale allowance base historical experience update change fact circumstance appropriate provision record reduction revenue case sale wholesaler result incentive excess wholesaler ordinary course business inventory level time understand agreement course deal consistent business practice company extend incentive base level excess inventory connection future purchase time incentive cover substantially vary directly wholesaler cost carry inventory excess wholesaler ordinary course business inventory level substantially risk reward ownership transfer shipment accordingly sale account consignment model determination sale wholesaler meet forego criterion involve evaluation variety factor number complex judgment consignment model company recognize revenue shipment product shipment product company invoice wholesaler record defer revenue gross invoice sale price classifie inventory hold wholesaler consignment inventory company cost inventory company recognize revenue consignment inventory long subject incentive arrangement later inventory sell wholesaler customer firstin firstout fifo basis case new product product introduction extension exist line product company determine product similar therapeutic category company determine new product dissimilar characteristic exist product company reliably estimate expect return new product company defer recognition revenue right return long exist company develop sufficient historical experience estimate sale return sale rebate return accrual medicaid rebate accrual million million december respectively woman infant child wic rebate accrual million million respectively manage health care rebate contractual discount accrual million million december respectively rebate accrual establish period relate revenue recognize result reduction sale establishment liability include accrue liability accrual record base estimate proportion record revenue result rebate return prime vendor chargeback accrual establish similar manner record reduction account receivable million million december respectively note accounting policy continue income taxis defer taxis provision income taxis determine asset liability approach accounting income taxis approach defer taxis represent future tax consequence expect occur report amount asset liability recover pay provision income taxis represent income taxis pay payable current year plus change defer taxis year defer taxis result difference financial tax basis company asset liability adjust change tax rate tax law change enact valuation allowance record reduce defer tax asset likely tax benefit realize assessment valuation allowance require require significant judgment include longrange forecast future taxable income evaluation tax planning initiative adjustment defer tax valuation allowance earning period assessment december company net defer tax asset million million respectively net valuation allowance million million respectively company record defer tax asset relate foreign tax credit carryforward research tax credit carryforward expire vary amount begin realization foreign tax credit research tax credit carryforward dependent generating sufficient domesticsource taxable income prior expiration realization assure management believe likely defer tax asset realize company anticipate increase level domestic profitability time undertaking action increase biologic manufacturing capacity increase domestic profitability likely cause company effective tax rate increase enhance company ability utilize foreign tax credit research tax credit carryforward foreign tax credit research tax credit carryforward consider realizable reduce near term outcome plavix litigation unfavorable andor time generic competition plavix accelerate event occur company need record significant additional valuation allowance defer tax asset additional information plavix litigation item risk factor item financial statementsnote legal proceeding contingency tax benefit qualified production activity guidance financial accounting standard board fasb staff position fsp application fasb statement accounting income taxis tax deduction qualified production activity provide american job creation act deduction treat special deduction describe statement financial accounting standard sfas special deduction affect defer tax asset liability exist enactment date impact deduction report period deduction claim company tax return undistribute earning foreign subsidiary december company approximately billion undistributed earning foreign subsidiary taxis provide company invest expect invest undistributed earning permanently offshore future earning repatriate united states company determine earning remit foreseeable future additional tax provision require complexity tax law assumption practicable estimate amount income taxis provide tax contingency company conduct business country world subject tax numerous jurisdiction result business activity company file significant number tax return subject examination tax authority tax examination complex tax authority disagree treatment item report company require year resolve company establish liability possible assessment tax authority result know tax exposure amount represent reasonable provision taxis ultimately expect pay need adjusted time information know cash cash equivalent cash equivalent primarily highly liquid investment original maturity month time purchase record cost approximate fair value note accounting policy continue marketable security company account marketable security accordance sfas account certain investment debt equity security company determine appropriate classification marketable security availableforsale time purchase december company investment marketable security report fair value unrealize gain loss report component accumulate comprehensive income loss stockholder equity amortize cost debt security hold maturity adjust amortization premium accretion discount date purchase maturity amortization include interest income addition deduction coupon interest earn investment company follow investment manager method determine cost basis computing realize gain loss sale availableforsale security average cost method realize gain loss include income expense inventory valuation inventory generally state average cost excess market capital asset depreciation expenditure addition renewal improvement capitalize cost depreciation generally compute straightline method base estimate useful life relate asset estimate useful life major class depreciable asset year building year machinery equipment fixture company periodically evaluate current event circumstance indicate carry value depreciable asset recoverable impairment longlive asset company periodically evaluate current fact circumstance indicate carry value depreciable asset hold recoverable circumstance determine exist estimate undiscounted future cash flow produce longlived asset appropriate grouping asset compare carry value determine impairment exist asset determine impair loss measure base difference asset fair value carry value estimate asset fair value base quote market price active market available quote market price available estimate fair value base valuation technique include discount value estimate future cash flow company report asset dispose low carrying value estimate net realizable value capitalize software certain cost obtain internal use software significant system project capitalize amortize estimate useful life software range year cost obtain software project significant expense incur capitalize software net accumulate amortization include intangible asset million million december respectively amortization expense million million million year end december respectively investment january company adopt fasb interpretation fin interpretation consolidation variable interest entity interpretation arb fin clarifie application accounting research bulletin arb consolidated financial statement certain entity equity investor characteristic control financial interest sufficient equity risk entity finance activity additional subordinate financial support party entity know variable interest entity vie fasb issue revision fin fin r december fin r effective interim period end march new exist vie adoption fin effect company financial statement entity meet definition vie fin company account entity provision arb consolidated financial statement amend sfas consolidation majorityowne subsidiary require company consolidate majority own subsidiary ability exercise control company account own company ability exercise significant influence equity method accounting company share net income loss equity investment include equity net income affiliate consolidate statement earning company review equity investment impairment base determination decline market value investment company carry value temporary making determination company consider accounting principle board apb opinion equity method accounting investment common stock relate interpretation set forth factor evaluate note accounting policy continue determine loss value recognize include company ability hold investment market price market price fluctuation investment publicly trade share inability investee sustain earning capacity justify carry investment longterm investment security comprise marketable equity security security investment market value readily available include asset marketable equity security classify availableforsale report fair value fair value base quote market price end report period security investment market value readily available carry cost unrealize gain loss report net relate tax effect component accumulate comprehensive income loss stockholder equity sell time sale gain loss calculate specific identification method recognize income expense loss recognize income expense decline market value deem temporary goodwill intangible asset goodwill long amortize test impairment annually twostep process step identify potential impairment second step measure impairment loss goodwill deem impaired carrying reporting unit goodwill exceed estimate fair value company complete goodwill impairment assessment indicate impairment goodwill intangible asset consist patent trademark technology license capitalize software amortize straightline basis useful life range year indefinitelive intangible asset test impairment onestep process consist comparison fair value carry value intangible asset intangible asset deem impaired net book value exceed estimate fair value intangible asset evaluate impairment describe impairment longlive asset restructure downsize streamline operation rationalize manufacture facility company periodically record restructuring charge result company estimate judgment future plan include future termination benefit exit cost incurred restructuring action place actual result vary estimate result potential adjustment earning subsequent period product liability accrual product liability include associate legal cost record undiscounted basis probable liability incur liability reasonably estimate base exist information accrual adjust periodically assessment effort progress additional information available receivables relate insurance thirdparty recovery product liability record undiscounted basis probable recovery realize classified reduction litigation charge consolidate statement earning contingency normal course business company subject loss contingency legal proceeding claim arise business cover wide range matter include government investigation shareholder lawsuit product environmental liability tax matter accordance sfas accounting contingency sfas company record accrual loss contingency probable liability incur loss reasonably estimate company accordance sfas recognize gain contingency realize discussion contingency note income taxis note legal proceeding contingency derivative financial instrument derivative financial instrument company principally management interest rate foreign currency exposure company hold issue derivative financial instrument speculative purpose company record derivative instrument balance sheet fair value change derivative fair value recognize earning specific hedge criterion meet derivative designate fair value hedge change fair value derivative hedge item attributable hedge risk recognize consolidated statement earning derivative designate cash flow hedge effective portion change fair value derivative record comprehensive income loss subsequently recognize consolidated statement earning hedge item affect earning cash flow classify consistent underlying hedged item purchase foreign currency note accounting policy continue option entire change fair value include measurement hedge effectiveness cash flow hedge ineffective portion change fair value cash flow hedge recognize charge credit earning company designate assign derivative hedge forecast transaction specific asset specific liability hedge asset liability sell extinguish forecast transaction hedge long expect occur company immediately recognize gain loss designate hedge financial instrument consolidate statement earning shipping handling cost company typically charge customer shipping handle cost shipping handling cost charge include marketing sell administrative expense million million advertising cost advertising cost expense incur advertising expense million million million respectively milestone payment company time time enter strategic alliance party company right develop manufacture market andor sell pharmaceutical product right own party result alliance company obligate payment alliance partner contingent achievement certain predetermine criterion milestone achieve prior marketing approval product payment expense research development product approval additional milestone capitalize amortize cost product sell remain useful life asset capitalize milestone payment test recoverability event change circumstance indicate carrying amount recoverable acquire inprocess research development fair value inprocess research development acquire business combination determine independent appraisal base present value research project project cash flow income approach utilize consistent guidance practice aid issue american institute certify public accountant asset acquire business combination research development activity focus software electronic device pharmaceutical industry future cash flow predominately base net income forecast project consistent historical pricing margin expense level similar product revenue estimate base relevant market size growth factor expect industry trend individual project life cycle life research project underlie patent determine fair value research project expect revenue adjust technical risk completion result cash flow discount rate approximating company weight average cost capital acquire process research development expense incurred underlying product receive regulatory approval future alternative use addition cost nonrefundable relate acquisition licensing product receive regulatory approval market alternative future use charge earning incur earning share basic earning common share compute weightedaverage number share outstanding year dilute earning common share compute weightedaverage number share outstanding year plus incremental share outstanding assume exercise dilutive stock option restrict stock convertible instrument foreign currency translation net asset company foreign subsidiary translate dollar current exchange rate dollar effect arise translate net asset subsidiary change rate record foreign currency translation adjustment account include comprehensive income stock compensation plan december fasb issue revise sfas sfas r sharebase payment standard eliminate ability account share base compensation transaction intrinsic valuebase method apb opinion accounting stock issue employee require instead transaction account fairvaluebase method april sec delay effective date sfas r financial statement issue annual period begin june company adopt sfas r january prospective transition method note accounting policy continue result provision sfas r sab company estimate compensation charge relate sharebased compensation pretax basis million million include million million stock option expense adoption standard tax basis compensation charge relate sharebased compensation estimate million million stock option expense adoption standard include tax amount million million assessment estimate compensation charge affect company stock price number complex subjective variable relate tax impact variable include limited volatility company stock price employee stock exercise behavior respect accounting treatment retirement eligibility provision employee sharebase compensation award company historically follow nominal vest period approach adoption sfas r january company adopt nonsubstantive vest period approach begin recognize compensation cost year period award grant retirement eligible employee year period grant date date retirement eligibility achieve vesting period adoption nonsubstantive vest period approach expect material effect consolidated financial statement conjunction adoption sfas r company change method attributing value sharebase compensation expense accelerate multipleoption approach straightline singleoption approach compensation expense sharebase payment award grant prior adoption continue recognize accelerated multipleoption approach permissible compensation expense sharebase payment award grant subsequent adoption sfas r recognize straightline singleoption approach currently company apply apb opinion relate interpretation accounting stockbase compensation plan disclose pro forma net income relate pro forma income share information accordance sfas accounting stockbase compensation sfas accounting stockbase compensation coststransition disclosure company recognize compensation expense stock option grant plan exercise price option date grant equal fair market value date grant restrict stock company recognize compensation expense straightline basis period restriction expire follow table summarize company result pro forma basis record compensation expense base fair value grant date award plan consistent methodology prescribe sfas dollar million share datum net earning report total stockbase employee compensation expense include report net earning net relate tax effect total stockbase employee compensation expense determine fair value base method award net relate tax effect pro forma basic earning share report pro forma diluted earning share report pro forma option relate discontinued operation impact basic diluted earning share note stockholder equity additional information recently issue accounting standard fasb issue sfas accounting change error correction replace apb opinion accounting change sfas report accounting change interim financial statement pronouncement apply voluntary change account principle revise requirement accounting reporting change accounting principle sfas require retrospective application prior period financial statement voluntary change accounting principle impracticable pronouncement require change method depreciation amortization depletion longlive nonfinancial asset account change accounting estimate note accounting policy continue effect change accounting principle sfas effective accounting change correction error fiscal year begin december statement change transition provision exist accounting pronouncement include transition phase effective date sfas adoption accounting pronouncement expect material effect consolidated financial statement march fasb issue fasb interpretation accounting conditional asset retirement obligation fin fin clarifie entity record liability conditional asset retirement obligation fair value obligation reasonably estimate asset retirement obligation cover fin entity legal obligation perform asset retirement activity time method settling obligation conditional future event control entity fin clarifie entity sufficient information reasonably estimate fair value asset retirement obligation fin effective later end fiscal year end december adoption accounting pronouncement material effect company consolidate financial statement december fasb issue revise sfas sfas r sharebase payment standard eliminate ability account share base compensation transaction intrinsic valuebase method apb opinion accounting stock issue employee require instead transaction account fairvaluebase method stock compensation plan december fasb issue fsp application sfas accounting income taxis tax deduction qualified production activity provide american job creation act fsp provide deduction qualified production activity treat special deduction describe sfas accounting income taxis accordingly tax effect deduction report component company tax provision effect defer tax asset liabilities department treasury recently issue propose tax regulation respect deduction qualified production activity company evaluate impact propose tax regulation fsp income tax provision result operation income taxis december fasb issue sfas exchange nonmonetary asset provision statement effective nonmonetary asset exchange occur fiscal period begin june apply prospectively statement eliminate exception fair value measurement nonmonetary exchange similar productive asset paragraph b apb opinion accounting nonmonetary transaction replace exception exchange commercial substance adoption account pronouncement material effect company consolidate financial statement november fasb issue sfas inventory cost amendment arb chapter standard require abnormal amount idle facility relate expense recognize current period charge require allocation fix production overhead cost conversion base normal capacity production facility sfas effective inventory cost incur fiscal year begin june adoption accounting pronouncement expect material effect consolidated financial statement june fasb issue fsp accounting disclosure requirement relate medicare prescription drug improvement modernization act medicare act medicare act introduce prescription drug benefit medicare federal subsidy sponsor retiree health care benefit plan provide benefit actuarially equivalent medicare fsp require effect new law account sfas employer account postretirement benefit pension company adopt fsp quarter retroactive january reduction net periodic benefit cost benefit million base remeasurement accumulate postretirement benefit obligation january effect adoption fsp material company consolidate financial statement item financial statementsnote pension postretirement benefit plan march emerge issue task force eitf reach consensus issue participate security twoclass method fas require use twoclass method compute earning share enterprise participate security multiple class common stock consensus effective fiscal period begin march adoption eitf material effect consolidated financial statement december fasb revised interpretation consolidation variable interest entity fin fin require variable interest entity consolidated company company subject majority risk loss variable interest entitys activity entitle receive majority entitys residual return fin require note accounting policy continue disclosure variable interest entity company require consolidate significant variable interest consolidation requirement fin revise apply immediately variable interest entity create january exist entity fiscal year interim period end march certain disclosure requirement apply financial statement issue january regardless variable interest entity establish adoption account pronouncement material effect consolidated financial statement note alliance investment sanofiaventis company agreement sanofiaventis sanofi codevelopment cocommercialization avaproavalide irbesartan angiotensin ii receptor antagonist indicate treatment hypertension plavix clopidogrel platelet aggregation inhibitor worldwide alliance operate framework geographic territory america principally united states canada puerto rico latin american countries australia europe asia accordingly territory partnership form manage central expense market research development royalty supply finish product individual country general country level agreement copromote partnership form party sell brand comarket party operate sell brand independently place agreement expire later respect plavix respect avaproavalide americas australia europe asia ii expiration patent exclusivity right applicable territory company act operating partner territory cover americas australia own majority control interest territory sanofis ownership interest territory company consolidate country partnership result territory record sanofis share result minority interest net taxis million million million company record sale territory comarkete country outside territory germany italy spain greece million million million cash flow operating activity partnership territory cover americas australia record operating activity company consolidate statement cash flow distribution partnership profit sanofi sanofis fund ongoing partnership operation occur routine basis record operating activity company consolidate statement cash flow sanofi act operating partner territory cover europe asia own majority financial control interest territory company ownership interest partnership territory company account investment partnership entity territory equity method record share result equity net income affiliate consolidate statement earning company share net income partnership entity tax million million million company routinely receive distribution profit provide fund ongoing operation partnership territory cover europe asia transactions record operating activity company consolidate statement cash flow company sanofi form alliance copromotion irbesartan company contribute irbesartan distribution right united states sanofi pay company total million year end december company account transaction sale interest license defer amortize million income expect useful life license approximately year formation irbesartan copromotion alliance company recognize income million million million respectively unamortize portion defer income record liability section consolidate balance sheet million million december respectively otsuka company worldwide commercialization agreement otsuka pharmaceutical co ltd otsuka codevelop copromote otsuka abilify aripiprazole treatment schizophrenia relate psychiatric disorder japan china taiwan north korea south korea philippines thailand indonesia pakistan egypt company begin copromote product otsuka puerto rico november june company receive marketing approval european commission product currently copromote otsuka united kingdom germany spain abilify currently distribute exclusively company france temporary basis otsuka join copromotion product company record alliance revenue contractual share otsukas net sale copromotion country exclude united kingdom record expense relate product company recognize alliance revenue abilify ship risk reward ownership transfer otsukas customer united kingdom france copromotion otsuka commence company record net sale relate cost product sell company exclusive right sell abilify country europe americas number countries asia country company record net sale relate cost product sell term note alliance investment continue agreement company purchase product otsuka perform finish manufacture sale company customer agreement expire november puerto rico entire european union agreement expire june country company exclusive right sell abilify agreement expire later tenth anniversary commercial sale country expiration applicable patent country company record revenue abilify million million million total milestone payment otsuka agreement december million million expense acquire inprocess research development remain million capitalize intangible asset amortize cost product sell remain life agreement range year company amortize cost product sell million million million unamortized capitalize payment balance million million december respectively imclone company commercialization agreement expire september imclone system incorporate imclone biopharmaceutical company focus develop targeted cancer treatment codevelopment copromotion erbitux united state food drug administration fda approve biologics license application bla erbitux use combination irinotecan treatment patient epidermal growth factor receptor egfrexpresse metastatic colorectal cancer refractory irinotecanbase chemotherapy use single agent treatment patient egfrexpresse metastatic colorectal cancer intolerant irinotecanbase chemotherapy company pay million milestone payment initial approval erbitux fda approve imclone chemistry manufacture control supplemental bla sbla licensure bb manufacturing facility march fda approve erbitux use treatment squamous cell carcinoma head neck result fda approval company pay million milestone payment imclone march agreement imclone receive distribution fee base flat rate product revenue north america addition company coexclusive right commercialize erbitux japan imclone previously grant coexclusive right merck kgaa japan december company japanese affiliate bmkk merck kgaa merck ltd imclone execute joint development agreement erbitux japan company account million approval milestone pay additional million milestone expect pay march license acquisition amortize payment cost product sell expect useful life license approximately year company amortize cost product sell million million respectively unamortized portion approval payment record intangible asset million million december respectively company account investment imclone equity method record share result equity net income affiliate consolidate statement earning company record investment imclone common stock december million million respectively company hold million share imclone stock represent approximately imclone share outstanding december share basis carry value imclone investment closing market price imclone share december respectively compare respectively december company determine equity share imclone net income loss eliminate imclone result milestone revenue imclone recognize million preapproval milestone payment company company record million preapproval milestone payment equity investment expense remain million acquire inprocess research development period milestone revenue recognize imclone excess million eliminate company determine equity share imclone result share imclone result operation company record net loss million income million net loss million company record net sale erbitux million million merck april company enter collaboration agreement merck co inc merck worldwide codevelopment copromotion muraglitazar company dual ppar peroxisome proliferator activate receptor agonist currently phase iii clinical development use treat type diabetes term agreement company receive million upfront payment million milestone payment january submission new drug application nda note alliance investment continue december company submit nda fda regulatory approval muraglitazar october fda issue approvable letter muraglitazar request additional information ongoing clinical trial fully address cardiovascular safety profile product company continue discussion fda determine likely initiate additional new trial gain regulatory approval consider range option include conduct additional study terminate development muraglitazar additional study approximately year complete december company merck terminate collaboration agreement muraglitazar right return company december result termination agreement company recognize million defer income fourth quarter record expense net company composition matter patent expire united states summary financial information follow summarize financial information company equity investment imclone joint venture sanofi europe asia dollar millions revenue gross profit net income current asset noncurrent asset current liability noncurrent liability note restructure activity company record pretax charge million relate termination benefit relate cost workforce reduction downsize streamline worldwide operation primarily north america latin america europe africa asia charge million relate employee termination benefit relate expense approximately sell administrative personnel include restructure cardiovascularmetabolic primary care sale organization workforce headcount reduction million relate retention bonus million relate asset impairment charge offset million adjustment reflect change estimate restructure action take prior period follow table present detail charge segment type company expect substantially complete restructuring activity termination relocation asset dollar million employee benefit exit cost retention writedown total pharmaceutical nutritional health care subtotal change estimate restructure reflect statement earning activity company record pretax restructuring charge million relate termination benefit relate cost workforce reduction downsizing streamline worldwide operation primarily europe north america asia latin america charge million primarily relate employee termination benefit relate expense approximately sell administrative manufacturing personnel million relate primarily asset impairment million relate consolidation certain research facility million retention bonus charge partially offset million adjustment reflect change estimate restructure action take prior period million gain sale research facility previously write restructure note restructure continue follow table present detail charge segment type company substantially complete restructuring activity asset relocation termination exit write dollar million employee benefit cost down retention total pharmaceutical health care corporateother subtotal change estimate gain sale research facility restructuring reflect statement earning activity company record pretax charge million relate termination benefit relate cost workforce reduction downsizing streamline worldwide operation primarily europe north america asia latin america charge million relate employee termination benefit relate expense approximately sell administrative manufacturing personnel million relate consolidation certain research facility million retention bonus charge offset million adjustment reflect change estimate restructure action take prior period principally higher anticipate proceed disposal asset reduce separation cost follow table present detail charge segment type company substantially complete restructuring activity asset relocation termination exit write dollar million employee benefit cost down retention total pharmaceutical health care subtotal change estimate restructure reflect statement earning rollforward restructuring charge spend liability associate prior current action follow employee termination exit cost dollar million liability liability total balance december charge spend change estimate balance december charge spend change estimate balance december charge spend change estimate balance december liability include accrue expense consolidate balance sheet note acquisition divestiture january company complete sale inventory trademark patent intellectual property right relate dovonex treatment psoriasis united states warner chilcott company inc million cash addition company receive royalty base net sale dovonex end result transaction company expect recognize pretax gain approximately million million net tax quarter subject certain postclosing adjustment quarter company complete sale canadian consumer medicine business relate asset consumer medicine novartis ag novartis term agreement novartis acquire trademark patent intellectual property right consumer medicine million cash include impact work capital adjustment million attributable postclose supply arrangement company novartis relate asset include right consumer medicine brand latin america europe middle east africa result operation consumer medicine include company consolidated statement earning date disposal result transaction company record pretax gain million million net tax quarter subject certain postclosing adjustment april company complete acquisition acordis speciality fibre acordis company purchase stock acordis million incur million acquisition cost connection transaction additional million payment contingent achievement future production volume purchase price acquisition allocate tangible identifiable intangible asset acquire liability assume base estimate fair value acquisition date million million allocate inprocess research development immediately expense million assign identifiable intangible asset predominantly patent excess purchase price estimate fair value net asset acquire record goodwill acquisition account purchase method accordingly result operation include accompany consolidated financial statement date acquisition february company complete divestiture adult nutritional business novartis million include million contingent achievement contractual requirement satisfy million upfront payment supply agreement company record total pretax gain million million net tax include million contingent payment million reduction company goodwill associated mead johnson product line note discontinued operation company complete sale oncology therapeutic network otn equity partner llc cash proceed million include impact preliminary work capital adjustment company record pretax gain million million net tax present gain sale discontinue operation consolidated statement earning otn previously present separate segment follow amount related otn business segregate continue operation report discontinue operation date disposition reflect cost certain service provide otn company cost allocate company otn service include legal counsel insurance external audit fee payroll process certain human resource service information technology system support year end december dollar million net sale lossearning income taxis net lossearning discontinue operation consolidated balance sheet december include otn net asset expect sell include million asset primarily consist receivables million liability primarily consist account payable addition goodwill relate otn december million writtenoff gain sale second quarter consolidated statement cash flow include otn business period present date disposition company use centralized approach cash management financing operation accordingly debt allocate business cash flow operating activity discontinue operation consist outflow million year end december cash inflow million million year end december respectively cash flow investing activity discontinue operation million year end december investing activity year end december note earning share numerator basic earning share net earning available common stockholder numerator diluted earning share net earning available common stockholder interest expense add assume conversion convertible debt common stock denominator basic earning share weight average number common stock outstanding period denominator diluted earning share weight average share outstanding adjusted effect dilutive stock option assume conversion convertible debt common stock computation basic diluted earning common share follow year end december amount million share datum basic earning continue operation discontinue operation net earning net gain disposal net earning basic earning share average common share outstanding earning continue operation discontinue operation net earning net gain disposal net earning common share dilute earning continue operation interest expense conversion convertible debt bond net tax discontinue operation net earning net gain disposal net earning dilute earning share average common share outstanding conversion convertible debt bond incremental share outstanding assume exercise dilutive stock option earning continue operation discontinue operation net earning net gain disposal net earning common share weightedaverage share issuable exercise stock option include diluted earning share calculation dilutive million million million note expense net component expense net year end december dollar million interest expense interest income foreign exchange transaction loss net expense net interest expense reduce net interest swap gain million million million respectively interest income relate primarily cash cash equivalent investment marketable security net include income thirdparty contract manufacture royalty income expense defer income recognize termination collaborative agreement muraglitazar gain loss disposal investment property plant equipment debt retirement cost note income taxis component earning loss continue operation minority interest income taxis year end december dollar million nonus amount categorize base location tax authority provisionbenefit income taxis attributable continue operation consist year end december dollar millions current nonus defer nonus company provision income taxis different compute apply statutory federal income tax rate earning continue operation minority interest income taxis result follow earning minority interest income taxis dollar million earning continue operation minority interest income tax statutory rate effect operation ireland puerto rico switzerland state local taxis net valuation allowance change estimate contingent tax matter nondeductible reserve anticipate dividend repatriation ajca federal foreign valuation allowance foreign note income taxis continue effective income tax rate earning continue operation minority interest income taxis compare low effective tax rate primarily charge approximately million estimate deferred income taxis relate repatriation approximately billion special dividend company nonus subsidiary pursuant american job creation act ajca charge relate establishment valuation allowance certain charitable contribution tax benefit associate release certain tax contingency reserve result settlement examination internal revenue service irs year change estimate relate reduction aforementione ajca defer tax charge partially offset lower estimate foreign tax credit increase effective tax rate effective tax rate primarily attributable aforementioned ajca defer tax charge million aforementioned establishment valuation allowance certain charitable contribution increase estimate contingent tax matter partially offset favorable resolution certain tax refund claim increase foreign tax credit effect certain litigation reserve non deductible fourth quarter company disclose anticipate repatriate approximately billion special dividend record million provision defer taxis pursuant ajca enact pende matter company repatriate approximately billion foreign subsidiary quarter repatriate remain balance approximately billion fourth quarter company expect approximately billion repatriate qualify special dividend subject finalization federal income tax return relate tax examination irs company expect continue use special dividend accordance requirement establish ajca treasury department second quarter treasury department issue ajca related guidance clarify grossup foreign taxis associate special dividend qualify tax rate establish ajca result guidance company reduce million provision recording benefit approximately million tax provision component current noncurrent defer income tax asset liability december dollar millions acquire inprocess research development intercompany profit inventory item foreign tax credit carryforward defer income alternative minimum tax research development credit carryforward charitable contribution carryforward state tax net operating loss carryforward foreign defer tax asset postretirement pension benefit depreciation defer foreign currency gainloss anticipate dividend repatriation ajca legal settlement net valuation allowance defer tax asset net recognize deferred income taxis current deferred income taxis noncurrent foreign income taxis payable liability noncurrent total valuation allowance million december relate million foreign state net defer tax asset million foreign state net operating loss tax credit carryforward million charitable contribution carryforward company currently believe likely realize note income taxis continue company record defer tax asset relate foreign tax credit carryforward approximately million research tax credit carryforward approximately million expire vary amount begin realization foreign tax credit research tax credit carryforward dependent generating sufficient domesticsource taxable income prior expiration realization assure management believe likely defer tax asset realize company anticipate increase level domestic profitability time undertaking action increase biologic manufacturing capacity increase domestic profitability likely cause company effective tax rate increase enhance company ability utilize foreign tax credit research tax credit carryforward foreign tax credit research tax credit carryforward consider realizable reduce near term outcome plavix litigation unfavorable andor time generic competition plavix accelerate event occur company need record significant additional valuation allowance defer tax asset additional information plavix litigation item risk factor item financial statementsnote legal proceeding contingency income taxis pay year million million million respectively current tax benefit realize exercise stock option charge capital excess par value stock amount million million million respectively december company approximately billion undistributed earning foreign subsidiary taxis provide company invest expect invest undistributed earning permanently offshore future earning repatriate united states company determine earning remit foreseeable future additional tax provision require complexity tax law assumption practicable estimate amount income taxis provide company settle federal income tax return internal revenue service irs company federal income tax return currently examination irs company conduct business state municipality foreign country subsidiary company state local foreign tax authority routinely examine company income tax return company establish liability possible assessment tax authority result know tax exposure include limited transfer price certain tax credit deductibility certain expense state local foreign tax matter amount represent reasonable provision taxis ultimately expect pay need adjusted time information know effect change estimate related contingent tax matter include effective tax rate reconciliation company recognize income tax benefit approximately million settlement company federal income tax return year company reorganize structure ownership nonus subsidiary principal purpose reorganization facilitate company ability efficiently deploy financial resource outside united states company believe reorganization transaction generally taxfree inside outside united states possible tax authority particular jurisdiction assert tax liability arise reorganization transaction operation reorganize subsidiary reasonably possible predict tax authority assert tax liability reasonably estimate possible loss range loss respect assert tax liability company vigorously challenge assertion believe prevail assurance result company prevail final non appealable determination possible impact material note receivables major category receivables follow december dollar million trade receivables miscellaneous receivable allowance receivables net note inventory major category inventory follow december dollar million finish good work process raw packaging material inventory net company finish good inventory impair determined inventory rework commercialization december carry value inventory million allowance provide note property plant equipment major category property plant equipment follow december dollar million land building machinery equipment fixture construction progress accumulate depreciation property plant equipment net capitalize interest include category property plant equipment show company capitalize interest million million million year end december respectively note goodwill change carry goodwill year end december follow pharmaceutical nutritional health care discontinue dollar million segment segment segment operation total balance december purchase accounting adjustment reduction sale adult nutritional business purchase price allocation adjustment balance december purchase accounting adjustment reduction sale otn reduction sale consumer medicine purchase price allocation adjustment balance december note intangible asset december intangible asset consist follow december dollar million patentstrademark accumulate amortization patentstrademark net license accumulate amortization license net technology accumulate amortization technology net capitalize software accumulate amortization capitalize software net total intangible asset net company record impairment charge million result actual estimate future sale decline tequin amortization expense intangible asset year end december million million million respectively expect amortization expense relate current net carrying intangible asset follow year end december dollar million later year note shortterm borrowing longterm debt shortterm borrowing end million million respectively reduction borrowing primarily retirement commercial paper august whollyowne subsidiary company enter new billion term facility syndicate bank lender borrowings facility guarantee company subsidiary borrower certain european subsidiary company facility contain fiveyear tranche billion twoyear tranche million interest pay periodic basis agree lender annual rate equal applicable libor plus company subject substantially covenant include december revolve credit facility company subject restriction include certain financial covenant prior borrowing proceed facility company obtain waiver lender covenant default facility onetime intercompany distribution december facility fully draw company compliance covenant second quarter company repurchase outstanding billion aggregate principal note incur aggregate pretax loss approximately million connection early redemption note termination relate interest rate swap december company replace prior billion revolving credit facility new billion year revolve credit facility syndicate lender extendable anniversary date consent lender facility contain financial covenant ratio consolidated debt consolidated capital exceed company compliance covenant inception new facility borrowing outstanding revolve credit facility december company unused shortterm line credit foreign bank million million december respectively note shortterm borrowing longterm debt continue component longterm debt follow december dollar million note note float rate bank term facility float rate convertible debenture note float rate bank term facility note debenture debenture debenture yen note industrial revenue bond yen note yen note variable rate industrial revenue bond company outstanding billion convertible debenture pay interest quarterly annual rate equal month libor reset quarterly minus yield zero final maturity september debenture callable par time september issuer holder redeem debenture par september fundamental change ownership company occur bond initial conversion price conversion rate share adjustable depend average closing price applicable period maximum conversion rate share company enter fixed float interest rate swap billion longterm debt company execute fix float interest rate swap convert billion company fix rate debt pay variable rate debt year end december company recognize net reduction interest expense million reflect benefit lower float rate obtain swap agreement april connection early redemption billion note company terminate billion notional fixedtofloate interest rate swap agreement incur pretax loss million june company terminate million notional fixedtofloate interest rate swap agreement relate billion note incur pretax loss million loss amortize interest expense remain life note million recognize september company terminate million notional fixedtofloate interest rate swap agreement relate million debenture receive gain million gain recognize interest expense remain life debenture approximately million recognize cash payment interest include payment interest rate swap million million million respectively company cash receipt interest rate swap million million million respectively exclude cash payment interest payment period dollar million total later year longterm debt obligation include shortterm borrowing company consolidated balance sheet december balance approximate outstanding nominal longterm debt value company convertible debenture include payment contain feature describe december company provide financial guarantee form standby letter credit performance bond majority standby letter credit insurance company support thirdparty liability program performance bond relate sale company product foreign ministry health middle east company believe significant majority guarantee expire funded amount obligation present follow table note shortterm borrowing longterm debt continue expiration period great dollar million total year year year standby letter credit performance bond guarantee total commercial commitment note stockholder equity change common share treasury stock capital excess par value stock restrict stock capital excess common share treasury cost treasury par value restrict dollar share million issue share stock stock stock balance december issue pursuant stock plan option amortization restrict stock lapse forfeiture restrict stock balance december issue pursuant stock plan option amortization restrict stock lapse forfeiture restrict stock balance december issue pursuant stock plan option amortization restrict stock lapse forfeiture restrict stock balance december share company prefer stock convertible share common stock callable company option reduction number issue share prefer stock conversion share common stock dividend declare common share accumulate balance relate component comprehensive incomeloss follows defer accumulate foreign currency incomeloss minimum pension available sale comprehensive dollar million translation effective hedge liability adjustment security incomeloss balance december comprehensive incomeloss balance december comprehensive incomeloss balance december comprehensive incomeloss balance december stock compensation plan companys stock incentive plan executive officer key employee grant option purchase company common stock market price date option grant option generally exercisable installment year fourth anniversary grant date maximum term year additionally plan provide grant stock appreciation right grantee surrender exercisable right receive common stock andor cash measure excess market price common stock option exercise price term stock incentive plan authorize share include outstanding share year number share tender prior year pay purchase price option number share previously utilize satisfy withholding tax obligation exercise share available grant prior year grant year share cancel forfeit expire available future grant note stockholder equity continue stock incentive plan provide grant common stock key employee subject restriction continuous employment restriction generally expire fiveyear period date grant compensation expense recognize restrict period december million million share restrict stock outstanding plan respectively million share restrict stock grant fair value common share stock incentive plan incorporate company longterm performance awards award deliver form target number performance share threeyear cycle award base cumulative ep cumulative sale ultimate payout modify company total stockholder return versus company proxy peer group threshold target meet performance period payment longterm performance award plan maximum performance measure result maximum payout target december million million performance share outstanding plan respectively million performance share grant fair value common share teamshare stock option plan fulltime employee exclude key executive grant option purchase company common stock market price date option grant company authorize million share issuance plan individual grant generally exercisable evenly fourth fifth anniversary grant date maximum term year option million share exercise plan december fair value option grant estimate common share common share common share respectively date grant blackschole optionprice model follow assumption dividend yield volatility riskfree interest rate expect life year stock option transaction share common stock weight average available issue exercise price share million option award plan share balance december authorize grant exercise lapsed balance december authorize grant exercise lapsed balance december authorize grant exercise lapsed balance december note stockholder equity continue follow table summarize information concern company stock compensation plan currently outstanding exercisable option number security remain available future issuance equity compensation number security issue weight average exercise plan exclude exercise outstanding price outstanding security reflect option right option right column share millions b c plan category equity compensation plan approve security holder equity compensation plan approve security holder share million option outstanding option exercisable weight average range exercise remain contractual weight average number weight average price number outstanding life exercise price exercisable exercise price average contractual life remain year december million share common stock reserve issuance pursuant stock plan option conversion prefer stock option relate discontinued operation include amount material note financial instrument company expose market risk change currency exchange rate interest rate reduce risk company enter certain derivative financial instrument available costeffective basis hedge underlie economic exposure instrument manage consolidated basis efficiently net exposure advantage natural offset derivative financial instrument speculative purpose company primary foreign currency exposure anticipate transaction primarily intercompany inventory purchase expect occur year euro canadian dollar japanese yen mexican peso chinese yuan company utilize foreign currency forward contract hedge exposure certain foreign currency designate derivative instrument cash flow hedge notional amount company foreign exchange derivative contract december million million respectively derivative majority qualify hedge future anticipate cash flow effective portion change fair value temporarily defer comprehensive income oci recognize earning hedge item affect earning sfas require company perform periodic assessment hedge effectiveness assessment determine derivative designate qualifying hedge continue highly effective offset change cash flow hedge item ineffective portion fair value long defer oci include current period earning year end december hedge ineffectiveness earning significant additionally company use foreign exchange forward contract offset exposure certain currency asset liability foreign exchange forward contract designate hedge change fair value derivative recognize earning note financial instrument continue occur amount recognize earning relate foreign exchange forward contract qualify hedge accounting treatment significant fair value option forward contract asset million liability million december respectively record asset accrue liability december respectively fair value foreign exchange contract base yearend currency rate blackschole model case option contract company exposure net foreign currency denominate asset liability approximately million million december respectively primarily europe japan mexico australia canada addition foreign exchange hedge contract note company utilize forward contract hedge foreign currency denominate monetary asset liability primary objective forward contract protect dollar value foreign currency denominate monetary asset liability effect volatility foreign exchange rate occur prior receipt settlement dollar foreign currency denominate monetary asset liability primarily denominate japanese yen euro forward contract designate hedge mark market incomeexpense notional fair value purchase foreign exchange forward contract million million liability respectively december million million liability respectively december notional fair value sell foreign exchange forward contract million million asset respectively december million million asset respectively december company use non dollar borrowing less extent forward contract hedge foreign currency exposure company net investment certain foreign affiliate non dollar borrowing forward contract designate hedge net investment effective portion foreign exchange gain loss hedge record foreign currency translation component comprehensive income december million tax gain million tax loss respectively record foreign currency translation component comprehensive income company use derivative instrument interest rate risk management strategy derivative instrument comprise principally fix float rate interest rate swap subject fairvalue hedge accounting treatment company execute fixedto float interest rate swap contract financial institution convert billion company fix rate debt pay variable rate debt notional amount swap billion billion december respectively accordance sfas accounting derivative instrument hedging activity company recognize net reduction interest expense million million million respectively reflect benefit lower float rate obtain swap compare fix rate underlie debt april connection early redemption billion note company terminate billion notional fixedtofloate interest rate swap agreement incur pretax loss million june company terminate million notional fixedtofloate interest rate swap agreement relate billion note incur pretax loss million loss amortize interest expense remain life note million recognize september company terminate million notional fixedtofloate interest rate swap agreement relate million debenture result gain million gain recognize interest expense remain life debenture approximately million recognize swap contract underlie debt hedge record fair value result increase noncurrent asset million current liability million reduction longterm debt million increase noncurrent asset million current liability million longterm debt million december respectively swap contract generally hold maturity company use derivative financial instrument speculative purpose company reclassify deferred loss million million million respectively oci earning majority classify cost product sell carry company financial instrument include cash cash equivalent marketable security account receivable account payable approximate fair value december longterm debt difference fair value carry value material note segment information company organize reportable segmentspharmaceutical nutritional health care pharmaceutical segment comprise global pharmaceutical international consumer medicine business nutritional segment consist mead johnson primarily infant formula business children nutritional business health care segment consist convatec medical imaging consumer medicine united states canada quarter company complete sale consumer medicine business additional information sale consumer medicine note acquisition divestiture company product sell principally wholesale retail trade nationally internationally certain product sell drug manufacturer hospital clinic government agency medical profession wholesaler account approximately respectively company total net sale sale wholesaler account respectively company total net sale wholesaler account approximately respectively company total net sale sale concentrate pharmaceutical segment business segment earning minority interest net sale income taxis yearend asset dollar million pharmaceutical nutritional health care total segment corporateother total corporateother consist principally interest income interest expense certain administrative expense allocation business segment certain corporate program gain sale consumer medicine business corporateother asset include cash cash equivalent marketable security goodwill asset otn hold available sale december sell certain asset capital expenditure depreciation dollar million pharmaceutical nutritional health care total segment corporateother total geographic area net sale yearend asset dollar millions united states europe middle east africa western hemisphere pacific total change yearend assets united states western hemisphere primarily relate cash repatriation company nonus subsidiary pursuant ajca note lease minimum rental commitment noncancelable operating lease primarily real estate motor vehicle effect december year end december dollar million later year total minimum payment total minimum sublease rental net minimum rental commitment operate lease rental expense net sublease rental income million million million million million million note pension postretirement benefit plan company certain subsidiary define benefit pension plan define contribution plan termination indemnity plan regular time employee principal pension plan bristolmyers squibb retirement income plan fund policy contribute amount provide current service fund past service liability plan benefit base primarily participant year credit service compensation plan asset consist principally equity fixedincome security company provide comprehensive medical group life benefit substantially retiree elect participate comprehensive medical group life plan medical plan contributory contribution adjust periodically vary date retirement original retire company life insurance plan noncontributory plan asset consist principally equity fixedincome security similar plan exist employee certain country outside united states cost company defer benefit postretirement benefit plan include follow component pension benefit benefit dollar million service costbenefit earn year interest cost project benefit obligation expect return plan asset net amortization deferral net periodic benefit cost curtailment settlement total net periodic benefit cost company recognize impact medicare prescription drug improvement modernization act accordance fsp record million million respectively reduction net periodic benefit cost note pension postretirement benefit plan continue change benefit obligation plan asset december company define benefit postretirement benefit plan pension benefit benefit dollar million benefit obligation begin year service costbenefit earn year interest cost project benefit obligation plan participant contribution curtailment settlement actuarial lossesgain plan amendment benefit pay exchange rate gainslosse benefit obligation end year fair value plan asset begin year actual return plan asset employer contribution plan participant contribution settlement transfer inout benefit pay exchange rate lossesgain fair value plan asset end year fund status unamortized net obligation adoption unrecognize prior service cost unrecognized net actuarial loss net recognize amount recognize balance sheet consist prepay benefit cost accrue benefit cost intangible asset accumulate comprehensive loss net recognize plan underfunde accrue benefit obligation exceed accrue benefit liability december additional minimum liability establish increase accrue benefit liability value underfunde accrue benefit obligation additional minimum liability total million million december respectively unfunded benefit equalization plan international plan additional minimum liability offset intangible asset million million charge comprehensive income include stockholder equity million million december respectively accumulate benefit obligation define benefit pension plan million million december respectively information pension plan accumulate benefit obligation excess plan asset december dollar millions project benefit obligation accumulate benefit obligation fair value plan asset note pension postretirement benefit plan continue attributable primarily unfunded benefit equalization plan plan international market unfunde benefit equalization plan provide pension benefit employee compensation irs limit fund taxadvantage manner additional information pertaining company pension postretirement plan pension benefit benefit dollar million decreaseincrease minimum liability include impact foreign currency fluctuation include comprehensive income weightedaverage assumption determine benefit obligation december pension benefit benefit discount rate rate compensation increase weightedaverage actuarial assumption determine net periodic benefit cost year end december pension benefit benefit discount rate expect longterm return plan asset rate compensation increase december company expect longterm rate return pension plan asset target asset allocation public equity international private equity fix income approximate apply expect return public equity private equity fix income target allocation actual historical return relevant annualize return period end december year year year pension plan asset represent approximately total company pension plan asset december disclose total company expect return asset pension plan impact international pension plan typically employ aggressive asset allocation expect return disclose benefit relevant asset invest manner pension plan asset international plan asset assume health care cost trend rate december health care cost trend rate assume year rate cost trend rate assume decline ultimate trend rate year rate reach ultimate trend rate assume health care cost trend rate effect amount report health care plan onepercentagepoint change assume health care cost trend rate follow effect percentage percentagepoint point increase decrease dollar million effect total service interest cost effect postretirement benefit obligation note pension postretirement benefit plan continue company asset allocation pension postretirement benefit december pension benefit benefit public equity security debt security include cash private equity total company investment strategy emphasize equity order achieve high expect return long run low expense low require cash contribution pension plan target asset allocation public equity international private equity fix income maintain cash flow ie cash contribution benefit payment rebalance target necessary investment diversify major asset category equity passively manage investment actively manage investment strategy international pension plan typically similar asset allocation usually conservative bristolmyer squibb company common stock represent plan asset december asset postretirement benefit commingle pension plan asset investment strategy identical describe pension plan contribution minimum contribution require company plan cash contribution pension plan contribution pension plan company taxdeductible contribution h account retiree medical benefit equal portion pension normal cost contribution international pension plan expect million range estimate future benefit payment follow benefit payment mainly pension plan reflect expect future service appropriate expect pay benefit dollar million pension benefit gross medicare subsidy net year saving plan principal define contribution plan bristolmyer squibb saving investment program company contribution base employee contribution level company match company contribution plan million million million termination indemnity plan company operate certain jurisdiction primarily europe require record statutory termination obligation obligation assess accordance eitf determination vested benefit obligation define benefit pension plan total liability record obligation million december million december note legal proceeding contingency lawsuit claim proceeding investigation pende company certain subsidiary accordance sfas accounting contingency company record accrual contingency probable liability incur loss reasonably estimate matter involve antitrust security patent infringement pricing sale marketing practice environmental health safety matter product liability insurance coverage significant matter describe assurance increase scope matter future lawsuit claim proceeding investigation material management continue believe previously disclose year aggregate impact current reserve legal matter affect company reasonably likely material company result operation cash flow material financial condition liquidity company decision obtain insurance coverage dependent market condition include cost availability exist time decision result external factor availability insurance restrictive cost increase significantly company evaluate risk determine cost obtain insurance outweighs benefit coverage protection loss self insure product liability effective july company continue evaluate risk benefit determine insurance need future intellectual property plavix litigation plavix currently company large product rank net sale net sale plavix approximately billion year end december plavix patent subject number challenge united states canada describe currently company expect plavix market exclusivity united states apotex announce january receive final approval anda clopidogrel bisulfate fda accordingly apotex decide launch generic product risk time generic competition likely result substantial decrease sale plavix united states company expect final approval andas defendant subject potential day semiexclusivity apotex united states company territory partnership alliance sanofi plaintiff pende patent infringement lawsuit institute district court southern district new york entitle sanofisynthelabo sanofisynthelabo inc bristolmyers squibb sanofi pharmaceutical hold partnership v apotex inc apotex corp apotex cv shs sanofisynthelabo sanofisynthelabo inc bristolmyers squibb sanofi pharmaceutical hold partnership v dr reddys laboratories ltd dr reddys laboratories inc cv shs sanofisynthelabo sanofisynthelabo inc bristolmyers squibb sanofi pharmaceutical hold partnership v teva pharmaceuticals usa inc teva pharmaceuticals industries ltd cv sanofiaventis sanofisynthelabo inc bristolmyers squibb sanofi pharmaceutical hold partnership v cobalt pharmaceuticals inc cv shs teva pharmaceuticals industries ltd dismiss case proceeding involve plavix progress canada suit file march september september respectively base patent composition matter patent disclose claim thing hydrogen sulfate salt clopidogrel market plavix suit base patent disclose claim thing use clopidogrel prevent secondary ischemic event plaintiff later withdraw patent lawsuit plaintiff infringement position base defendant file abbreviate new drug application anda fda seek approval sell generic clopidogrel bisulfate prior expiration composition matter patent defendant respond allege patent invalid andor unenforceable apotex add antitrust counterclaim case consolidate discovery fact discovery close october expert discovery complete november joint pretrial order apotex case submit court approve court schedule trial apotex matter begin june apotex case try jury plaintiff file motion consolidate dr reddys case apotex case trial motion pende court stipulation approve district court southern district new york april party patent infringement litigation teva agree teva litigation stay pende resolution apotex dr note legal proceeding contingency continue reddys litigation party teva litigation bind outcome litigation district court apotex dr reddys april court deny moot pende motion consolidate teva litigation litigation apotex dr reddys result court approval stipulation party submit similar stipulation court cobalt case october court approve case cobalt stay april apotex file complaint declaratory judgment sanofiaventis sanofiaventis inc bristolmyers squibb sanofi pharmaceutical hold partnership complaint seek declaratory judgment patent unenforceable alleged inequitable conduct commit prosecution patent defendant respond submit motion dismiss court grant september apotex file appeal united states court appeal federal circuit company territory partnership alliance sanofi plaintiff pende patent infringement lawsuit institute district court district new jersey entitle sanofisynthelabo sanofisynthelabo inc bristolmyers squibb sanofi pharmaceutical hold partnership v watson pharmaceuticals inc watson laboratories inc cv suit file october base patent disclose claim particular crystalline polymorph form hydrogen sulfate salt clopidogrel market plavix case discovery phase december court permit watson pursue declaratory judgment counterclaim respect patent january court approve party stipulation stay case pende outcome trial apotex matter case officially stay canada sanofisynthelabo sanofisynthelabo canada inc institute prohibition action federal court canada apotex inc apotex minister health response notice allegation noa apotex direct canadian patent cover clopidogrel bisulfate apotexs notice allegation indicated file abbreviate new drug submission ands clopidogrel bisulfate tablet seek approval notice compliance and expiration canadian patent expire august apotexs noa allege patent invalid infringe hear hold february february march canadian federal court ottawa reject apotexs challenge canadian plavix patent hold asserted claim novel obvious infringe grant sanofis application order prohibition minister health apotex inc order prohibition preclude approval apotexs ands patent expire federal court decision reverse appeal apotex file appeal sanofisynthelabo sanofisynthelabo canada inc institute prohibition action federal court canada apotex minister health response noa direct canadian patent cover form polymorph clopidogrel bisulfate apotex seek approval and expiration patent apotex allege noa infringe patent invalid action discontinue sanofiaventis sanofisynthelabo canada inc institute prohibition action federal court canada novopharm limited novopharm minister health response notice allegation novopharm direct canadian patent cover clopidogrel bisulfate novopharm noa indicate file ands clopidogrel bisulfate tablet seek approval notice compliance and expiration canadian patent expire august novopharm noa allege patent invalid novopharm withdraw noa agree bind result apotex proceed prohibition action discontinue sanofiaventis sanofisynthelabo canada institute prohibition action federal court canada cobalt pharmaceuticals inc minister health response notice allegation cobalt direct canadian patent cobalt noa indicate file ands clopidogrel bisulfate tablet seek notice compliance and expiration patent cobalt allege patent invalid patent invalid infringe case stay pende outcome apotex appeal plaintiff intend vigorously pursue enforcement patent right plavix possible time reasonably assess outcome lawsuit company prevail lawsuit apotex final approval anda enter market generic product risk time potential generic competition plavix possible reasonably estimate impact lawsuit company note legal proceeding contingency continue loss market exclusivity plavix subsequent development generic competition material company sale plavix result operation cash flow material financial condition liquidity note income taxis additional information intellectual property litigation tequin company kyorin pharmaceuticals co ltd kyorin commence patent infringement action march teva usa teva industries united states district court southern district new york relate antibiotic gatifloxacin kyorin hold composition matter patent company sell tequin teva industry dismiss case action relate tevas file anda generic version gatifloxacin tablets certification composition matter patent expire december grant patent term extension december invalid infringe filing suit place stay approval tevas generic product june court decision adverse company kyorin date trial matter schedule begin tequin injectable form company kyorin commence patent infringement action march apotex inc apotex corp sicor pharmaceuticals inc sicor inc sicor pharmaceuticals sales inc teva pharmaceuticals usa inc teva pharmaceutical industries ltd united states district court southern district new york relate injectable form antibiotic gatifloxacin kyorin hold composition matter patent company sell tequin action relate apotexs sicor file andas generic version injectable gatifloxacin piv certification composition matter patent expire december grant patent term extension december invalid filing lawsuit place stay approval apotexs sicor generic product julyaugust court decision adverse company kyorin date sicor case consolidated proceeding stipulation approve district court southern district new york august party agree apotex case stay pende resolution teva sicor case party bind outcome litigation erbitux october complaint file yeda research development company ltd yeda imclone aventis pharmaceuticals inc district court southern district new york action allege seek individual associate yeda name coinventor patent cover therapeutic combination egfrspecific monoclonal antibody antineoplastic agent chemotherapeutic agent use treatment cancer yeda action successful yeda position practice license practice invention result product competition erbitux occur company party action unable predict outcome stage proceeding repligen corporation repligen massachusetts institute technology mit file lawsuit united states district court district massachusetts imclone claim imclone manufacture sale erbitux infringe patent generally cover process protein production mammalian cell repligen mit seek damage base sale erbitux commence february patent expire repligen mit seek extension patent company party action unable predict outcome stage proceeding orencia january repligen corporation repligen regent university michigan file complaint company united states district court eastern district texas marshall division complaint allege company anticipate sale orencia infringe patent abilify august otsuka file united states patent trademark office uspto request reexamination composition matter patent cover abilify antipsychotic agent treatment schizophrenia relate psychiatric disorder patent number patent expire include grant supplemental protection extension otsuka determine original patent application contain error description prior art reference identify wrong patent number addition otsuka take opportunity bring information attention uspto uspto grant request reexamination reexamination proceed ongoing reexamination proceeding allow uspto consider patentability patent claim light correct patent number newly cite information uspto expect final decision reexamination end company right commercialize product expire november note legal proceeding contingency continue company otsuka believe invention claim patent patentable prior art expect uspto reconfirm reexamination guarantee outcome patentability patent reconfirm follow reexamination soon expect loss market exclusivity abilify subsequent development generic competition material operating result company security litigation vanlev litigation april june company chairman board chief executive officer charle heimbold jr chief scientific officer peter ringrose phd name defendant number class action lawsuit allege violation federal security law regulation action consolidate action district court district new jersey plaintiff claim defendant disseminate materially false misleading statement andor fail disclose material information concern safety efficacy commercial viability vanlev drug development period november april number relate class action make essentially allegation file district court southern district new york action transfer district court district new jersey court certify separate class class relate period november april class period class relate period march march second class period class period involve claim relate vanlevs efficacy safety andor potential blockbuster drug second class period involve claim relate vanlevs potential blockbuster drug class certification prejudice defendant right fully contest merit plaintiff claim plaintiff seek compensatory damage cost expense behalf shareholder respect class period december company defendant motion summary judgment plaintiff claim august court grant deny summary judgment motion dismiss individual defendant peter r dolan peter ringrose case february court grant preliminary approval settlement agreement party company pay million settlement fund agree certain nonmonetary term settlement subject certain condition include final approval fairness hearing schedule accordingly company establish reserve fourth quarter million pay settlement fund february securities matter company certain current officer pricewaterhousecooper name defendant number security class action derivative suit united states district court southern district new york lawsuit allege violation federal security law regulation connection sale incentive wholesaler inventory level breach fiduciary duty connection company conduct concern thing safety efficacy commercial viability vanlev discuss company sale incentive certain wholesaler inventory level wholesaler company investment relation imclone imclone product erbitux allege anticompetitive behavior connection buspar taxol paclitaxel suit settle respect company current officer director september certain company current officer name purport class action starkman v bristolmyers squibb et al file new york state supreme court allege factual claim similar resolve federal class action southern district new york note assert common law fraud breach fiduciary duty claim behalf stockholder purchase company stock october hold stock march october company remove case united states district court southern district new york case currently stay november class action complaint file united states district court eastern district missouri company dk health care resources inc dk current dk director officer behalf purchaser dk stock august september complaint allege company participate fraudulently inflate value dk stock allegedly engage improper channelstuffe agreement dk company file motion dismiss case january motion consideration court private security litigation reform act discovery automatically stay pende outcome motion dismiss plaintiff move partially lift automatic stay court consider motion note legal proceeding contingency continue case note preliminary stage company unable assess outcome reasonably estimate possible loss range loss respect case august company enter final settlement sec concluding investigation concern certain wholesaler inventory accounting matter company agree admit deny liability violate certain provision security law company establish million fund distribute certain company shareholder plan distribution establish sec settlement resolve ongoing investigation sec activity certain current member company management connection wholesaler inventory issue accounting matter company continue cooperate investigation june united states attorney office district new jersey office file criminal complaint charge company conspiracy commit security fraud connection previously disclose investigation office concern inventory accounting matter cover company settlement sec connection filing complaint company office enter deferred prosecution agreement pursuant agreement company agree maintain continue implement remedial measure pursuant settlement sec certain additional remedial action appoint independent monitor continue cooperate office include respect ongoing investigation individual current employee company additional payment million fund shareholder establish pursuant company settlement sec company fulfill obligation defer prosecution agreement office dismiss criminal complaint year date filing pricing sale promotional practice litigation investigation company number pharmaceutical manufacturer defendant private class action suit bring attorney general state numerous new york counties city new york pende federal state court relate pricing company product federal case consolidate pretrial purpose caption pharmaceutical industry average wholesale price litigation mdl district court district massachusetts awp mdl pleading private class action amend course awp mdl response court ruling class certification merit issue october plaintiff file amend master consolidated class action complaint tamcc allege company pharmaceutical manufacturer report price certain prescription drug product list drug company case effect falsely overstate average wholesale price awp publish industry compendia turn improperly inflate reimbursement pay medical provider prescribe administer product tamcc assert claim federal rico statute state consumer protection fair trade statute court prior ruling rico claim dismiss continue include tamcc primarily appeal purpose addition opinion date august court decline certify propose class company drug selfadministere patient ie pill liquid purchase pharmacy express willingness certify class involve drug administer physician eg injectable oncology drug january court hear argument certification class person entity pay reimburse seven company physicianadministere drug certify follow class nationwide class individual medicare b beneficiaries ii massachusetts class medigap insurers iii massachusetts class entity person private commerce pay reimburse drug base awp fact discovery plaintiff company close private awp mdl proceeding case progress issue expert discovery january court issue case management order schedule summary judgment motion file march set trial date company november certain state attorney general action suit new york counties new york city proceed awp mdl specifically company defendant complaint montana illinois kentucky california attorney general master consolidated complaint new york counties new york city complaint nassau county new york attorney general suit proceed company drug manufacturer state court pennsylvania nevada wisconsin alabama mississippi company defendant remove federal court recent state court case file arizona attorney general defendant seek transfer case awp mdl finally company defendant case commence erie county new york proceeding state court allegation state attorney general new york county new york city case similar note legal proceeding contingency continue private class action awp mdl follow respect allege company manufacturer cause awps inflate injure entity person reimburse prescription drug base awps primary difference awp mdl states county sue behalf payor drug state medicaid program behalf corporate individual citizen state pay reimburse drug base awps b states county limit cite great number drug contend awps inflate c certain states new york county allege company defendant underpaid rebate owe medicaid rebate statute rebate agreement federal government finally company defendant private class action pende arizona state court contain allegation similar awp mdl class certify case stay pende resolution class motion awp mdl company defendant putative class action involve price section b public health service act require prescription drug manufacturer offer discount qualified medical provider generally disproportionately service poor people case pende alabama federal court plaintiff medical provider claim provider country receive discount price entitle case pende california federal court county santa clara california contend county cities california provide finance local hospital necessary company defendant provide appropriate discount alabama court deny defendant motion dismiss february motion dismiss california action grant court grant plaintiff leave amend plaintiff file amend complaint case preliminary stage company unable assess outcome possible effect business profitability reasonably estimate possible loss range loss respect case company prevail final nonappealable determination litigation impact material company number pharmaceutical manufacturer receive subpoenas document request government agency seek record relate pricing sale marketing practice good price report drug cover medicare andor medicaid public health service act b program request record come attorney office district massachusetts eastern district pennsylvania northern district texas civil division department justice offices inspector general department health human service office personnel management conjunction civil division department justice office pharmacy assistance health resource services administration hrsa state addition request information come house committee energy commerce senate finance committee connection investigation committee currently conduct medicaid good price issue use educational grant pharmaceutical company previously disclose mid company initiate internal review certain sale marketing practice focus practice comply applicable antikickback law analyze practice respect compliance good price reporting rebate requirement medicaid program certain governmental programs reference medicaid rebate program applicable fda requirement company meet representative attorney office district massachusetts discuss review receive related subpoena attorney office include subpoena receive document relate possible label promotion abilify company internal review expect continue resolution pende governmental investigation relate matter company produce document actively cooperate investigation result assertion civil andor criminal claim company reserve liabilitie relation pharmaceutical pricing sale marketing practice million possible time reasonably assess final outcome matter accordance gaap company determine represent minimum expect probable loss respect matter loss include imposition fine penalty administrative remedy andor liability additional rebate amount eventual loss relate matter exceed reserve impact material company believe end range loss estimate company prevail final nonappealable determination investigation impact material previously disclose company undertake analysis method process calculate price report governmental rebate pricing program relate pharmaceutical business analysis complete early base analysis company identify need revision methodology process calculate report pricing relate rebate amount implement revise methodology process begin report federal government agency primary responsibility rebate price reporting obligation center medicare medicaid services cms quarter addition revise methodology process company recalculate good price average manufacturer price require report note legal proceeding contingency continue company federal medicaid rebate agreement certain state agreement correspond revise rebate liability amount program threeyear period completion analysis early company determine estimate rebate liability program threeyear period actually rebate pay company period accordingly fourth quarter company record reduction rebate liability estimate overpayment company submit propose revision update estimate cms review recently notify government submit update estimate correct recently identify programming error department justice doj inform company review submission conjunction previously disclose subpoena receive company doj relate thing good price report drug cover medicaid discuss detail request company provide additional information propose revision estimate agency position revision company methodology calculation require company believe base current information recalculation period likely result material rebate liability uncertainty surround recoverability company estimate overpayment arise review process describe company record reserve equal estimate overpayment general commercial litigation company number pharmaceutical manufacturer name defendant action file california state superior court oakland james clayworth et al v bristolmyers squibb company et al allege defendant conspire fix price pharmaceutical agree charge drug united states charge outside united states particularly canada assert claim california cartwright act unfair competition law plaintiff seek treble damage damage sustain restitution profit obtain defendant charge artificially high price plaintiff injunction bar defendant charge plaintiff high price offer customer award reasonable attorney fee cost relief court deem proper case preliminary stage company unable assess outcome possible effect business profitability reasonably estimate possible loss range loss respect case company prevail final nonappealable determination litigation impact material company name defendant pharmaceutical company action bring utility consumer action network consumer advocacy organization focus privacy issue lawsuit file california state superior court san diego county entitle utility consumer action network behalf privacy right clearinghouse et al v bristolmyers squibb co et al originally direct retail drug store amend july add company pharmaceutical company defendant lawsuit rowan klein representative action behalf similarly situate person consume public v walgreen et al file february california state superior court san diego county retail pharmacy company pharmaceutical company substantially utility consumer action network lawsuit jointly refer complaint complaint seek equitable relief monetary damage attorney fee base allegedly unfair business practice untrue misleading advertising california statute include california confidentiality medical information act specifically complaint allege drug marketing program retail store sell consumer confidential medical information company complaint allege company consumer medical information direct marketing increase sale target drug january company pharmaceutical defendant seek dismiss utility consumer action network case klein case ground californias proposition require plaintiff injure party order stand bring suit company contend plaintiff case personally injure october court enter stay case pende california supreme courts decision review intermediate appellate decision discuss applicability proposition pende case case preliminary stage company unable assess outcome possible effect business profitability reasonably estimate possible loss range loss respect case company prevail final nonappealable determination lawsuit impact material product liability litigation company party product liability lawsuit involve allegation injury cause company pharmaceutical overthecounter medication lawsuit involve certain overthecounter medication contain phenylpropanolamine ppa involve hormone replacement therapy hrt product polyurethanecovere breast implant smoothwalle breast implant company serzone stadol n prescription drug addition lawsuit company face unfiled claim involve product note legal proceeding contingency continue serzone serzone nefazodone hydrochloride antidepressant launch company canada march united states december company add black box warn serzone label warn potential risk severe hepatic event include possible liver failure need transplantation risk death month black box warning add package insert serzone number lawsuit include class action file company plaintiff allege company know know hepatic risk pose serzone failed adequately warn physician user risk seek compensatory punitive damage medical monitoring refund cost purchase serzone august federal case transfer district court southern district west virginia serzone product liability litigation mdl addition case file united states national class action file canada company announce follow evaluation commercial potential product generic entry marketplace rapidly decline brand sale decide discontinue manufacture sale product effective june admit wrongdoe liability october company enter settlement agreement respect claim united states territory serzone pursuant term propose settlement claim dismiss litigation terminate defendant receive release company commit pay million fund class member class counsel petitioned court award reasonable attorney fee expense fee pay company reduce money pay class member settlement company terminate settlement base number claim submit number purport class member opt participate settlement instead pursue individual claim november district court conditionally certify temporary settlement class preliminarily approve settlement optout period end april fairness hearing occur june september court issue opinion grant final approval settlement order approve settlement enter september company reserve liabilitie lawsuit million include reasonable attorney fee expense possible time reasonably assess final outcome lawsuit number contingency affect settlement accordance gaap company determine amount represent minimum expect probable loss respect lawsuit eventual loss relate lawsuit exceed reserve impact material company believe topend range loss estimate hormone replacement therapy hrt litigation national institutes health nih launch womens health initiative whi clinical trial involve approximately healthy postmenopausal woman participant give prempro estrogen progestin premarin estrogen manufacture wyeth july article journal american medical association report prempro subject increase risk breast cancer heart attack blood clot stroke decrease risk hip fracture colorectal cancer prempro phase study stop july premarin phase continue stop march nih informed study participant stop study medication trial conjugate equine estrogen premarin estrogenalone versus placebo woman continue follow year include ascertainment outcome mammogram report legal complaint file wyeth shortly whi halt july july company serve hrt lawsuit plaintiff allege thing hormone therapy product cause breast cancer stroke blood clot cardiac injury woman defendant aware risk fail warn consumer company product involve litigation estrace estrogenonly tablet estradiol generic estrogenonly tablet delestrogen injectable estrogen ovcon oral contraceptive contain estrogen progestin federal case transfer district court eastern district arkansas prempro wyeth product liability litigation mdl february company defendant lawsuit involve abovementione product file behalf approximately plaintiff federal state court united states lawsuit involve multiple defendant company expect dismiss case product company hormone therapy product sell company january august company maintain estrace anda continue manufacture product supply agreement possible time reasonably assess final outcome litigation reasonably estimate possible loss range loss respect litigation note legal proceeding contingency continue environmental proceeding october company commence voluntary environmental audit mead johnson facility mt vernon indiana determine compliance epa new source performance standard nsps applicable operation incinerator december company disclose possible violation nsps requirement currently process modify operation fall exemption requirement date epa indiana department environmental management pursue penalty potential violation company potentially subject civil penalty past noncompliance nsp environmental protection agency epa investigate industrial commercial facility use refrigeration equipment contain ozonedeplete substance od enforce compliance regulation govern prevention service repair leak od requirement company perform voluntary corporatewide audit facility puerto rico use odscontaine refrigeration equipment company submit audit report epa november identify potential violation od requirement facility addition matter cover company audit report letter epa epa previously send company wholly own subsidiary mead johnson request information compliance od requirement facility evansville indiana company respond request june result identify potential violation evansville facility company currently discussion epa resolve potential violation discover audit identify result epa request information evansville facility epa determine evansville facility facility violation applicable od requirement company subject penalty andor require convert replace refrigeration equipment use nonod approve substitute march company commence voluntary environmental audit barceloneta humacao puerto rico facility determine compliance epa regulation maximum achievable control technology requirement emission hazardous air pollutant pharmaceutical production pharmaceutical mact company submit epa audit report humacao facility june barceloneta facility july disclose potential violation pharmaceutical mact requirement facility date epa discuss potential violation company company undertaking action correct potential violation epa determine barceloneta humacao facilities violate pharmaceutical mact requirement company subject civil penalty andor require investment facility ensure compliance pharmaceutical mact october company contact north brunswick nj board education boe discovery industrial waste material allegedly include material er squibb son expansion project north brunswick township high school number neighbor residential property adjacent public park area january new jersey department environmental protection njdep send company information request letter possible waste disposal site company respond march school board township current owner school property park conduct jointly finance soil remediation work work plan approve njdep evaluate need conduct response action remediate contain potentially impact ground water financial constraint boe ask company contribute fund interim basis assure uninterrupted performance necessary site work company actively monitor cleanup project include cost offer negotiate boe township term cooperative funding agreement allocation process municipal record indicate township operate landfill site company actively investigate historic use site include company possible connection date boe township assert claim company september njdep issue administrative enforcement directive notice new jersey spill compensation control act require company approximately company perform assessment natural resource damage nrd implement unspecified interim remedial measure restore condition low passaic river directive allege company liable historically send bulk waste inland chemical company facility newark nj own mckesson corp reprocessing release hazardous substance facility migrate newark bay continue adverse impact low passaic river watershe subsequently epa issue notice letter comprehensive environmental response compensation liability act cercla numerous partiesbut include companyseeke cooperation study condition substantially stretch passaic river subject njdep directive group party enter consent agreement epa finance portion study epa initially estimate study cost million recent epa internal estimate peg number twice consent agreement private party group commit pay roughly half million estimate subject revision future negotiation study lead cleanup action direct epa army corps engineer company work cooperatively note legal proceeding contingency continue group party receive njdep directive andor epa notice explore potential resolution directive address risk collateral claim company believe caused contribute contamination low passaic river watershe company inform njdep willing discuss njdeps allegation company private party group continue discuss federal agency designate trustee natural resource affect contamination passaic river watershe possibility funding cooperative nrd study presumably dovetail ongoing epa study ideally join njdep coordinate action njdep seek directive late njdep issue supplemental directive file suit site party seek compel implementation interim measure unclear njdep additional action site party andor litigation arise response new claim extent liability company face njdep epa respect future claim federal trustee mckesson responsible party determined december company njdep enter administrative consent order aco concern allege violation new jersey air pollution control act implement regulation company new brunswick facility pursuant aco company agree submit permit application create facilitywide emission cap pay small administrative fine obligation satisfy early subsequently february aco amend provide company install new cogeneration turbine new brunswick facility december obtain applicable air permit december company obtain applicable permit purchase new cogeneration turbine cost approximately million company defendant include major pharmaceutical company purport class action suit file superior court puerto rico february resident ward municipality barceloneta allege air emission government own operate wastewater treatment facility municipality cause respiratory ailment violate local air rule adversely impact property value company believe wastewater discharge treatment facility material compliance term company permit september party stipulate dismissal prejudice claim property damage personal injury leave claim relate nuisance remain case court schedule hearing class certification motion september hearing adjourn settlement discussion party continue november december successful february new judge appoint potential conflict interest involve prior judge case status conference schedule april company believe litigation resolve immaterial bring matter resolution event adverse judgment company ultimate financial liability great anticipate company responsible state federal foreign law include cercla certain cost investigate andor remediate contamination result past industrial activity company current site waste disposal reprocess facility operate party company typically estimate cost base information obtain epa counterpart state agency andor study prepare independent consultant include total estimate cost site expect costshare potentially responsible party company accrue liability probable reasonably estimable december company estimate share total future cost site approximately million record liability represent sum good estimate simple estimate reasonably estimate minimal probable range cost take account potential recovery party currently expect company pay million exclude legal fee year investigation remediation matter include liability cercla onsite remedial obligation possible predict certainty outcome environmental proceeding ultimate cost remediation company believe reasonably possible expenditure company incur excess exist reserve material adverse effect business financial position result operation matter october sec notify company conduct informal inquiry activity certain company german pharmaceutical subsidiary employee andor agent sec informal inquiry encompass matter currently investigation german prosecutor munich germany company understand inquiry investigation concern potential violation foreign corrupt practice act german law company cooperate sec german authority company establish accrual represent minimum expect probable loss respect investigation german prosecutor note legal proceeding contingency continue january company notify prosecutor bari region italy prosecutor company investigation result activitie employee region investigation involve company number doctor pharmacist pharmaceutical company sale representative main allegation party engage plan defraud national health service prosecutor allege company lack appropriate compliance control andor process procedure control activity sale representative hear schedule march prosecutor request close operation pharmaceutical company investigation appoint judicial administrator preliminary measure company believe request unwarranted indemnification officer director companys corporate bylaw require extent permit law company shall indemnify officer director judgment fine penalty amount pay settlement include legal fee appeal incur connection civil criminal action proceeding relate service company subsidiary bylaw provide limit indemnification indemnification permit case willful misconduct know violation criminal law improper personal benefit permit law state delaware company year purchase director officer insurance coverage cover claim director officer amount type coverage varied period period dictate market condition litigation matter regulatory action describe involve certain company current director officer cover aforementioned indemnity applicable certain prior period insurance policy certain indemnification payment cover company director officer insurance coverage company predict certainty extent company recover insurer indemnification payment connection litigation matter regulatory action describe note subsequent event january company complete sale inventory trademark patent intellectual property right relate dovonex treatment psoriasis united states warner chilcott company inc million cash addition company receive royalty base net sale dovonex end result transaction company expect recognize pretax gain approximately million million net tax quarter subject certain postclosing adjustment note select quarterly financial datum unaudite second fourth dollar million share datum quarter quarter quarter quarter year net sale gross margin earning continue operation discontinue operation net net earning earning common share basic earning continue operation discontinue operation net net earning dilute earning continue operation discontinue operation net net earning dividend declare common share cash cash equivalent marketable security net sale gross margin earning continue operation discontinue operation net net earning earning common share basic earning continue operation discontinue operation net net earning dilute earning continue operation discontinue operation net net earning dividend declare common share cash cash equivalent marketable security note earning share quarter add amount year period compute discrete basis include litigation charge million million million second fourth quarter respectively second quarter include litigation insurance recovery million million respectively second fourth quarter include restructure item million million million million respectively fourth quarter include upfront payment license agreement million million respectively second quarter include million million respectively gain sale equity investment second quarter include million million million respectively loss sale fix asset second quarter include debt retirement cost million fourth quarter include million defer income net cost result termination collaborative agreement merck muraglitazar quarter include gain sale consumer medicine business million include litigation charge million million million second fourth quarter respectively second quarter include litigation settlement income million second fourth quarter include gain sale adult nutritional business million million million million respectively second fourth quarter include provision restructure item million million million million respectively second fourth quarter include upfront payment license agreement million million million million respectively second quarter include writeoff acquire inprocess research development million million respectively common equivalent share exclude computation dilute earning share effect anti dilutive follow million second fourth quarter quarter quarter quarter year report independent register public accounting firm board director stockholder bristolmyers squibb company complete integrate audits bristolmyer squibb company consolidate financial statement internal control financial reporting december audit december consolidated financial statement accordance standard public company accounting oversight board united states opinion base audit present consolidated financial statement financial statement schedule opinion consolidated financial statement list index appear item present fairly material respect financial position bristolmyer squibb company subsidiary december result operation cash flow year period end december conformity accounting principle generally accept united states america addition opinion financial statement schedule list index appear item present fairly material respect information set forth read conjunction relate consolidated financial statement financial statement financial statement schedule responsibility company management responsibility express opinion financial statement financial statement schedule base audit conduct audits statement accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance financial statement free material misstatement audit financial statement include examine test basis evidence support amount disclosure financial statement assess accounting principle significant estimate management evaluate overall financial statement presentation believe audits provide reasonable basis opinion internal control financial reporting opinion management assessment include management report internal control financial reporting appear item company maintain effective internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission coso fairly state material respect base criterion furthermore opinion company maintain material respect effective internal control financial reporting december base criterion establish internal control integrate framework issue coso company management responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting responsibility express opinion management assessment effectiveness company internal control financial reporting base audit conduct audit internal control financial reporting accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance effective internal control financial reporting maintain material respect audit internal control financial reporting include obtain understand internal control financial reporting evaluate management assessment testing evaluate design operating effectiveness internal control perform procedure consider necessary circumstance believe audit provide reasonable basis opinion company internal control financial reporting process design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition assets company ii provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company iii provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate pricewaterhousecooper llp pricewaterhousecooper llp philadelphia pa march item change disagreement accountant account financial disclosure item control procedure evaluation disclosure control procedure december management carry evaluation supervision participation chief executive officer chief financial officer effectiveness design operation disclosure control procedure term define exchange act rule e base evaluation management conclude december disclosure control procedure effective provide reasonable assurance company record process summarize report information company disclose report company file submit securities exchange act amend time period specify sec rule form management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting supervision participation management include chief executive officer chief financial officer management assess effectiveness internal control financial reporting december base framework internal controlintegrate framework issue committee sponsor organization treadway commission base assessment management conclude company internal control financial reporting effective december provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance united states generally accept accounting principle inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate pricewaterhousecooper llp pwc independent register public accounting firm audit company financial statement include report issue report management assessment effectiveness company internal control financial reporting december include change internal control financial reporting change companys internal control financial reporting quarter end december materially affect reasonably likely materially affect company internal control financial reporting item b information iii item director executive officer registrant reference proxy statement file march respect director registrant incorporate reference hereof response information require item b information require item respect executive officer registrant include ia reliance general instruction g instruction item b regulation sk item executive compensation reference proxy statement file march respect executive compensation incorporate reference hereof response information require item item security ownership certain beneficial owner management relate stockholder matter reference proxy statement file march respect security ownership certain beneficial owner management incorporate reference hereof response information require item item certain relationship relate transaction reference proxy statement file march respect certain relationship relate transaction incorporate reference hereof response information require item item auditor fee reference proxy statement file march respect auditor fee incorporate reference hereof response information require item iv item